

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
4 December 2003 (04.12.2003)

PCT

(10) International Publication Number
WO 03/099787 A1(51) International Patent Classification⁷: C07D 211/46, 211/58, 211/62, 211/54, 211/74, 401/04, 401/12, 401/14, 405/12, 409/12, 417/04, 417/12, 473/34, A61K 31/451, 31/454, 31/4545, 31/4709, 31/497, 31/513

Sarushima-gun, Ibaraki 306-0231 (JP). ISHII, Takeshi [JP/JP]; 26-8-303, Ohsugi 5-chome, Edogawa-ku, Tokyo 132-0022 (JP). KONO, Rikako [JP/JP]; Towa City Coop 401, 180-1, Sakuragi-cho 4-chome, Omiya-ku, Saitama-shi, Saitama 330-0854 (JP).

(21) International Application Number: PCT/JP03/06720

(74) Agent: TSUKUNI, Hajime; SVAX TS Bldg., 22-12, Toranomon 1-chome, Minato-ku, Tokyo 105-0001 (JP).

(22) International Filing Date: 29 May 2003 (29.05.2003)

(25) Filing Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GII, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:

2002-155744	29 May 2002 (29.05.2002)	JP
60/395,342	12 July 2002 (12.07.2002)	US
2002-248755	28 August 2002 (28.08.2002)	JP
60/409,595	11 September 2002 (11.09.2002)	US

(71) Applicant (for all designated States except US): TAN-ABE SEIYAKU CO., LTD. [JP/JP]; 2-10, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8505 (JP).

Published:


— with international search report

(72) Inventors; and


(75) Inventors/Applicants (for US only): TAKAHASHI, Masami [JP/JP]; 1-9-207, Hoshidanishi 4-chome, Katano-shi, Osaka 576-0015 (JP). MIYAKE, Tsumoru [JP/JP]; 8-59-601, Motoyamaminami-machi 9-chome, Higashinada-ku, Kobe-shi, Hyogo 658-0015 (JP). MORITANI, Yasunori [JP/JP]; 19-13, Kitakibougaoka, Kawachinagano-shi, Osaka 586-0091 (JP). ASAII, Hidetoshi [JP/JP]; 1474-2, Kotsutsumi, Sowa-cho,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL PIPERIDINE COMPOUND



(57) Abstract: The present invention provides a novel piperidine compound of the formula [I]: wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R₁ represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, etc., or a group of the formula: (a) wherein R₁₁ and R₁₂ are the same or different, and each represents hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group, etc., R₂ represents hydrogen atom, etc., Z represents oxygen atom or a group represented by -N(R₃)-, R₃ represents hydrogen atom or an alkyl group, etc., R₄ represents hydrogen atom or an alkyl group, etc., or a pharmaceutically acceptable salt thereof.



WO 03/099787 A1

DESCRIPTION

NOVEL PIPERIDINE COMPOUND

5 Technical field

The present invention relates to a novel piperidine compound having excellent tachykinin receptor antagonistic action.

10 Background art

Tachykinin is a general name for a group of neuropeptides, and there have been known substance P (hereinafter referred to as SP), neurokinin-A, and neurokinin-B in mammals. These peptides are known to exhibit 15 a various kinds of biological activities by binding their corresponding receptors which exist in vivo (neurokinin-1, neurokinin-2, neurokinin-3). Among them, SP is one of those which have the longest history in the neuropeptides, and have been studied in detail. Its existence was confirmed in an 20 extract of horse intestinal tube in 1931, and it was a peptide comprising 11 amino acids, whose structure was determined in 1971.

SP exists widely in peripheral nervous system, and it has physiological activities such as vasodilation action, 25 vascular permeability promoting action, smooth muscle contracting action, hypertarachia (neuronal excitement) action, salivation action, diuretic action, immunological action, etc., as well as a function of neurotransmitter of the primary sensory neuron. Specifically, it is known that 30 SP released from the terminus of posterior horn of spinal cord upon pain impulse transfers pain information to the secondary neuron, and that SP released from the peripheral terminus induces an inflammatory reaction in the receptor. From these facts, SP is considered to be involved in various 35 diseases (for example, pain, inflammation, allergy, thamuria, incontinence of urine, respiratory disease, mental illness,


depression, uneasiness, emesis, etc.), and also, SP is considered to be involved in Alzheimer type dementia [Review: Physiological Reviews, vol.73, pp.229-308 (1993), Journal of Autonomic Pharmacology, vol.13, pp.23-93 (1993)].

5 Currently, as a therapeutic agent for the above-mentioned various diseases (especially for emesis, depression, urination disorder, etc.), there have not been discovered yet any compound having an excellent tachykinin receptor antagonistic action (specifically, SP receptor antagonistic action), and at the same time, having sufficiently satisfying safety, sustainability (metabolism, dynamics in vivo, and absorption), etc. Therefore, a compound has been sought for which has an excellent tachykinin receptor antagonistic action, and has sufficiently satisfying clinical effect as 10 15 the therapeutic agent.

Accordingly, an object of the present invention is to provide a compound having excellent tachykinin receptor antagonistic action, and having a clinical satisfying effect in terms of safety, sustainability (metabolism, dynamics in 20 vivo and absorption), etc.

Summary of the invention


The present invention relates to a piperidine compound represented by the formula [I]:



25

wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R¹ represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, a substituted thiol group, a substituted carbonyl group, a substituted sulfinyl 30

group, a substituted sulfonyl group, or a group represented by the formula:




wherein R^{11} and R^{12} are the same or different and each is hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, or R^{11} and R^{12} are taken together, with an adjacent nitrogen atom, to form a heterocyclic group selected from piperidino group, azacycloheptyl group, pyrrolidino group, imidazolidinyl group, hexahdropyrimidinyl group, thiazolidyl group, morpholino group, triazolyl group, tetrazolyl group and purinyl group, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, R^2 represents hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, Z represents oxygen atom or a group represented by $-N(R^3)-$, wherein R^3 represents hydrogen atom or an optionally substituted alkyl group, R^4 represents hydrogen atom or an optionally substituted alkyl group, or a pharmaceutically acceptable salt thereof.

In the present invention, Ring A represents an optionally substituted benzene ring, and a substituent of the benzene ring is exemplified by an alkyl group, a halogen atom, cyano group, optionally protected hydroxyl or alkoxy group. Ring A may have 1 to 3 of these substituent(s) which is (are)


the same or different.

In the present invention, Ring B represents an optionally substituted benzene ring, and a substituent of the benzene ring is exemplified by a trihalogenoalkyl group, a halogen atom, a cyano group, a phenyl group, a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom, an alkyl group, an optionally protected hydroxyl or an alkoxy group. Ring B may have 1 to 3 of these substituent(s) which are the same or different.

A preferred example of Ring A and Ring B in the compound of the present invention is exemplified by a compound wherein Ring A is a benzene ring of the formula:



and Ring B is a benzene ring of the formula:




wherein A¹, A² and A³ are the same or different, and each is hydrogen atom, a halogen atom, an alkyl group, an optionally protected hydroxyl or alkoxy group,

B¹, B² and B³ are the same or different, and each is hydrogen atom, a trihalogenoalkyl group, a halogen atom, a cyano group, a phenyl group, a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom, an alkyl group, an optionally protected hydroxyl or an alkoxy group. The trihalogenoalkyl group is exemplified by a trifluoromethyl group or a trichloromethyl group, etc. The heterocyclic group is exemplified by a tetrazolyl group, etc.

In the present invention, a protecting group of the optionally protected hydroxyl group is exemplified by a

conventional protection group such as an optionally substituted arylalkyl group, an optionally substituted silyl group and an acyl group. In the above, preferred are an arylalkyl group such as benzyl group and phenethyl group, a 5 substituted silyl group such as tert-butyldimethylsilyl group and tert-butyldiphenylsilyl group, and an acyl group such as formyl group, acetyl group, propionyl group, malonyl group, acryloyl group and benzoyl group.


In the present invention, R¹ is an optionally 10 substituted alkyl group, an optionally substituted hydroxyl group, a substituted thiol group, a substituted carbonyl group, a substituted sulfinyl group, a substituted sulfonyl group, or a group represented by the formula:



15 wherein R¹¹ and R¹² are the same or different, and each is hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and 20 sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, or R¹¹ and R¹² are taken together, with an adjacent nitrogen atom, to form a heterocyclic group 25 selected from piperidino group, azacycloheptyl group, pyrrolidino group, imidazolidinyl group, hexahdropyrimidinyl group, thiazolidyl group, morpholino group, triazolyl group, tetrazolyl group and purinyl group, wherein the heterocyclic group is 30 optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized.


In the above, R¹ is preferably an optionally substituted alkyl group, an optionally substituted hydroxyl group, a substituted thiol group, a substituted carbonyl

group, a substituted sulfinyl group, a substituted sulfonyl group, or a group represented by the formula:



wherein R¹¹ and R¹² are the same or different, and each
 5 is hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally
 10 oxidized,

further preferably is an optionally substituted alkyl group, an optionally substituted hydroxyl group, a substituted thiol group, a substituted carbonyl group, a substituted sulfinyl group, a substituted sulfonyl group, or a group represented
 15 by the formula:



wherein R¹¹ is a substituted carbonyl group, a substituted sulfonyl group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group
 20 is optionally oxidized, and R¹² is hydrogen atom, an optionally substituted alkyl group, a substituted carbonyl group, a substituted sulfonyl group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is
 25 optionally substituted, and the nitrogen atom contained in the heterocyclic group is
 30 optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized.

In the present invention, the substituent of the optionally substituted alkyl group of R¹ is exemplified by an alkoxy carbonyl group, a morpholinocarbonyl group, a pyridylaminocarbonyl group, a morpholinoaminocarbonyl group, 5 a piperidinocarbonyl group substituted by an alkoxyphenyl group, a dialkylaminocarbonyl group, hydroxyl group, a hydroxyalkylaminocarbonyloxy group or an alkylpiperazinocarbonyl group.

In the present invention, the substituent of the 10 optionally substituted hydroxyl group of R¹ is exemplified by (1) a substituted carbonyl group, (2) a substituted sulfinyl group, (3) a substituted sulfonyl group or (4) an optionally substituted alkyl group.

15 The substituent of the substituted carbonyl group in the above (1) is exemplified by an optionally substituted alkyl group, an optionally substituted alkoxy group, a substituted amino group, a monocyclic heterocyclic group having 1 to 2 atom(s) selected from nitrogen atom and oxygen 20 atom as a hetero atom (the monocyclic heterocyclic group is optionally substituted). The substituent of the optionally substituted alkyl group is exemplified by hydroxyl group. The substituent of the optionally substituted alkoxy group is exemplified by an alkoxy group, hydroxyl group or a halogen 25 atom. The substituent of the substituted amino group is exemplified by an alkyl group substituted by a group selected from a halogen atom, a dialkylamino group, piperidinyl group, morpholino group, a carboxyl group, a morpholinocarbonyl group, a dialkylaminocarbonyl group, an alkylaminocarbonyl 30 group, an alkanoylamino group, an alkylthio group, an alkoxy group, an alkylsulfonyl group, an alkanoyloxy group and hydroxyl group; piperidinyl group substituted by a hydroxyalkanoyl group or an alkoxyalkanoyl group; or a dialkylamionsulfonyl group. The monocyclic heterocyclic group 35 is exemplified by morpholino group, piperazinyl group, imidazolyl group, thiomorpholino group, piperidino group,

furyl group, tetrahydrothiazolinyl group or pirrolidinyl group. The substituent of the monocyclic heterocyclic group is exemplified by an alkyl group which may be substituted by hydroxyl group, an alkoxycarbonyl group, a carboxyl group, 5 hydroxyalkylaminocarbonyl group, alkoxyalkylaminocarbonyl group, alkylthioalkylaminocarbonyl group, alkylsulfinylalkylaminocarbonyl group, an alkylsulfonylalkylaminocarbonyl group or morpholino group, an oxo group or hydroxyl group.

10 The substituent of the substituted sulfinyl group in the above (2) is exemplified by an alkyl group or thienyl group.

15 The substituent of the substituted sulfonyl group in the above (3) is exemplified by an alkyl group or thienyl group.

20 The substituent of the optionally substituted alkyl group in the above (4) is exemplified by an optionally substituted hydroxyl group, a dialkylamino group or a monocyclic heterocyclic group having 1 to 4 atom(s) selected from sulfur atom, nitrogen atom and oxygen atom as a hetero atom (the monocyclic heterocyclic group is optionally substituted). The substituent of the optionally substituted hydroxyl group is exemplified by an alkyl group, an alkylsulfonyl group or tetrahydropyranyl group. The 25 monocyclic heterocyclic group is exemplified by pyridyl group, piperidinyl group, morpholino group, isoxazolyl group, triazolyl group, tetrazolyl group or pirrolidinyl group. The substituent of the monocyclic heterocyclic group is exemplified by an alkyl group or a phenyl group.

30 In the present invention, the substituent of the substituted thiol group of R^1 is exemplified by a substituted phenyl group, a substituted carbonyl group or an optionally substituted alkyl group. The substituent of the substituted phenyl group is exemplified by hydroxyl group. The 35 substituent of a substituted carbonyl group is exemplified by an alkyl group. The substituent of the optionally substituted


alkyl group is exemplified by an alkylaminocarbonyl group, a dialkylaminocarbonyl group an alkoxy carbonylamino group, hydroxyalkanoylamino group, a morpholinocarbonylamino group, a hydroxyalkylaminocarbonylamino group, an alkanoyloxy group 5 or hydroxyl group.

In the present invention, the substituent of the substituted carbonyl group of R¹ is exemplified by hydroxyl group, an alkoxy group, an optionally substituted amino group or a monocyclic heterocyclic group having 1 to 4 atom(s), 10 selected from sulfur atom, nitrogen atom and oxygen atom as a hetero atom(s) (the monocyclic heterocyclic group is optionally substituted). The substituent of the optionally substituted amino group is exemplified by (a) group(s) selected from pyridyl group optionally substituted by 15 hydroxyl group(s), pyrimidyl group, an alkylpyrido group, pyrazinyl group, and an alkyl group optionally substituted by hydroxyl group or cyano group. The monocyclic heterocyclic group is exemplified by piperidino group, piperazino group, morpholino group, thiomorpholino group or pyrrolidino group. 20 The substituent of the monocyclic heterocyclic group is exemplified by an alkyl group, hydroxyl group, an oxo group, pyrimidyl group, pyrazinyl group, an alkylsulfonyl group, an alkanoyl group or hydroxyalkyl group.

In the present invention, the substituent of the substituted sulfinyl group of R¹ is exemplified by hydroxyl group or an optionally substituted alkyl group. The substituent of the optionally substituted alkyl group is exemplified by hydroxyl group. 25

In the present invention, the substituent of the substituted sulfonyl group of R¹ is exemplified by an optionally substituted alkyl group. The substituent of the optionally substituted alkyl group is exemplified by hydroxyl group or an alkanoyloxy group. 30

In the present invention, when R¹ is a group of the formula: 35



(1) the substituent of the substituted carbonyl of R^{11} and R^{12} is exemplified by an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted aryl group, a substituted amino group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized. The substituent of the optionally substituted alkyl group is exemplified by an alkylaminocarbonyl group, a dialkylaminocarbonyl group wherein the alkyl moiety thereof is optionally substituted by hydroxyl group, an aminocarbonyl group, an alkoxy carbonyl amino group, an alkanoylamino group, an amino group substituted by an alkoxy carbonyl group and an alkyl group, an amino group substituted by an alkanoyl group and an alkyl group, an alkoxy group, a halogen atom, tetrazolyl group, pyridyl group, furyl group, hydroxyl group, an alkylthio group, 2-oxopyrrolidino group, 2-aminothiazolyl group, 2-thiol-4-alkylthiazolyl group, 2,2-dialkyl-1,3-dioxolanyl group, a cycloalkyl group, an alkylsulfinyl group, an alkylsulfonyl group, thienyl group, 5-methyl-2,4(1H,3H)pyrimidinedione group, an amino group or a dialkylamino group. The substituent of the optionally substituted aryl group is exemplified by nitro group or an amino group, and the aryl group is exemplified by phenyl group, naphthyl group, phenanthryl group or anthracenyl group. The substituent of the substituted amino group is exemplified by an alkyl group optionally substituted by a group selected from a halogen atom, an alkoxy group and hydroxyl group, and the amino group is mono-substituted or di-substituted. The heterocyclic group is exemplified by a saturated or unsaturated monocyclic or bicyclic aromatic heterocyclic

group, such as thienyl group, furyl group, tetrahydrofuryl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group,

5 pyridazinyl group, pirrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group,

10 indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl group, quinoxalinyl group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl

15 group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, indolinyl group, isoindolinyl group, tetrahydroisoquinolyl group, tetrahydroquinoxalinyl group, dihydropthalazinyl group, etc. Among these heterocyclic

20 groups, pyridyl group, pirrolidinyl group, piperazinyl group, quinolyl group, piperidinyl group, pyrimidyl group, thiazolyl group, pyrazinyl group, morpholino group, thiomorpholino group, indolyl group, cinnolinyl group, furyl group, tetrahydrofuryl group, thienyl group, etc. are preferably

25 used. The substituent of the heterocyclic group is exemplified by a dialkylamino group, an alkoxy carbonyl group, morpholino alkyl group, a hydroxy alkyl group, an alkyl group, benzyloxy group, an alkoxy carbonyl group, an alkanoyl group, hydroxyl group, an oxo group or formyl group.

30 (2) The substituent of the substituted sulfonyl group of R^{11} and R^{12} is exemplified by an optionally substituted alkyl group, cyanophenyl group, a dialkylamino group, or alkenyl group. The substituent of the the optionally substituted alkyl group is exemplified by a halogen atom, hydroxyl group,

35 a dialkylamino group optionally substituted by hydroxyl group, morpholino group, piperidino group or 4-methylpiperazino

group.

(3) The substituent of the optionally substituted alkyl group of R^{11} and R^{12} is exemplified by a dialkylaminocarbonyl group, an alkoxy group, a dialkylamino group, cyano group, 5 morpholino group, pyridyl group or a halogen atom.

(4) The heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom of R^{11} and R^{12} is exemplified by a saturated or unsaturated monocyclic or bicyclic aromatic heterocyclic 10 group, such as thienyl group, furyl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, pirrolidinyl group, pyrrolinyl group, imidazolidinyl group, 15 imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidyl group, piperazinyl group, morpholinyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl 20 group, quinoxaliny group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, 25 indolinyl group, isoindolinyl group, tetrahydroquinolyl group, tetrahydroisoquinolyl group, tetrahydroquinoxaliny group, dihydropthalazinyl group. Of these heterocyclic groups, pyridyl group, pyrrolyl group, piperazinyl group, quinolyl group, piperidinyl group, pyrimidyl group, thiazolyl group, 30 pyrazinyl group, morpholino group, indolyl group, cinnolinyl group, furyl group, thienyl group, etc. are preferably used. The substituent of the heterocyclic group is exemplified by a dialkylamino group, an alkoxy carbonyl group, an alkyl group, an alkoxy group, hydroxyl group, a halogen atom etc.

35 Further, when R^{11} and R^{12} form a bond at the termini thereof, to form a heterocyclic group, with an adjacent

nitrogen atom, selected from piperidino group, azacycloheptyl group, pyrrolidino group, imidazolidinyl group,

hexahdropyrimidinyl group, thiazolidyl group, morpholino group, triazolyl group, tetrazolyl group and purinyl group,

5 the substituent of the heterocyclic group is exemplified by an alkyl group substituted by an alkoxy group or hydroxyl group, piperidinyl group, alkoxyphenyl group, an alkanoyl group, hydroxyl group, an oxo group and an amino group.

When the nitrogen atom of the heterocyclic group is
10 oxidized, the oxidized nitrogen atom means a state where the nitrogen atom is cationized, which is exemplified by N-oxomorpholino group or N-alkylmorpholinio group.

In the present invention, R² represents hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom.

In the present invention, the substituent of the optionally substituted hydroxyl group of R² is exemplified by an alkyl group.

20 In the present invention, the substituent of the optionally substituted amino group of R² is exemplified by an alkyl group.

In the present invention, the substituent of the optionally substituted alkyl group of R² is exemplified by an
25 alkoxy group.

In the present invention, the substituent of the substituted carbonyl group of R² is exemplified by hydroxyl group, an alkoxy group or alkylamino group.

In the present invention, Z is exemplified by an oxygen atom or a group of -N(R³)-.

In the present invention, R³ is exemplified by hydrogen atom or an optionally substituted alkyl group. The substituent of the optionally substituted alkyl group of R³ is exemplified by hydroxyl group, an alkanoyl group, a
35 halogen atom, an alkoxy group or an alkylamino group.

In the present invention, R⁴ is exemplified by hydrogen

atom or an optionally substituted alkyl group. The substituent of the optionally substituted alkyl group of R^4 is exemplified by a halogen atom, an alkoxy group or alkylamino group.

5 As the preferred compound of the present invention, a compound where R^1 is an optionally substituted alkyl group is mentioned.

10 The preferred substituent of the optionally substituted alkyl group is dialkylaminocarbonyl group, morpholinocarbonyl group, hydroxyl group, alkoxy carbonyl group or hydroxyalkylaminocarbonyloxy group.

15 As the preferred compound of the present invention, a compound where R^1 is an optionally substituted hydroxyl group is mentioned. Of these, preferred is a compound where R^1 is an optionally substituted alkoxy group. Additionally preferred is a compound where R^1 is an optionally substituted carbonyloxy group.

20 The preferred substituent of the optionally substituted alkoxy group is hydroxyl group, an alkylsulfonyloxy group, tetrahydropyranloxy group, a triazolyl group, tetrazolyl group optionally substituted by alkyl group, or alkoxy group, and more preferred is hydroxyl group or tetrahydropyranloxy group. The preferred substituent of the optionally substituted carbonyoxy group is morpholino group; imidazolyl group; an alkylamino group wherein the alkyl moiety thereof is optionally substituted by hydroxyl group, morpholinocarbonyl group, a dialkylaminocarbonyl group, an alkylaminocarbonyl group, alkanoylamino group, an alkylthio group, an alkoxy group, an alkylsulfonyl group, an alkanoyloxy group or carboxyl group; piperidino group substituted by hydroxyl group, an alkoxy carbonyl group, carboxyl group, a hydroxyalkylaminocarbonyl group, an alkoxyalkylaminocarbonyl group, an alkylthioalkylaminocarbonyl group, an alkylsulfinylalkylaminocarbonyl group, an alkylsulfonylalkylaminocarbonyl group or a hydroxyalkyl

group; piperidinylamino group substituted by a hydroxyalkanoyl group or an alkoxyalkanoyl group; thiomorphorino group wherein the sulfur atom is optionally substituted by oxo group; oxopyrroridinyl group;

5 oxotetrahydrothiazolinyl group; or dialkylaminosulfonylamino group, and more preferred is morpholino group; alkylamino group wherein the alkyl moiety thereof is optionally substituted by hydroxyl group; or thiomorpholino group wherein the sulfur atom is substituted by oxo group.

10 As the preferred compound of the present invention, a compound where R^1 is a substituted thiol group is mentioned.

The preferred substituent of the optionally substituted thiol group is an alkanoyl group; or an alkyl group optionally substituted by hydroxyl group, an

15 alkylaminocarbonyl group, a dialkylaminocarbonyl group, an alkoxy carbonylamino group, a hydroxyalkanoylamino group, morpholinocarbonylamino group, a hydroxyalkylaminocarbonylamino group or an alkanoyloxy group.

20 As the preferred compound of the present invention, a compound where R^1 is a substituted carbonyl group is mentioned.

The preferred substituent of the optionally substituted carbonyl group is an alkoxy group; amino group optionally substituted by pyrimidyl group or an alkylpyrido group; an 25 alkylamino group wherein the alkyl moiety thereof is optionally substituted by hydroxyl group or cyano group; a di(hydroxyalkyl)amino group; a pyridylamino group wherein the pyridyl moiety thereof is optionally substituted by hydroxyl group; piperidino group substituted by hydroxy group or oxo 30 group; piperazino group substituted by oxo group, an alkyl group, an alkylsulfonyl group or alkanoyl group; morpholino group; thiomorpholino group; or pyrrolidino group substituted by an hydroxyalkyl group or hydroxyl group, and more preferred is pyrimidylamino group or hydroxypiperazino group.

35 As the preferred compound of the present invention, a compound where R^1 is a substituted sulfinyl group is


mentioned.

The preferred substituent of the optionally substituted sulfinyl group is an alkyl group optionally substituted by hydroxyl group, or hydroxyl group, and more preferred is an 5 alkyl group optionally substituted by hydroxyl group.

As the preferred compound of the present invention, a compound where R¹ is a substituted sulfonyl group is mentioned.

The preferred substituent of the optionally substituted 10 sulfonyl group is an alkyl group optionally substituted by hydroxyl group or an alkanoyloxy group, and more preferred is an alkyl group optionally substituted by hydroxyl group.

As the preferred compound of the present invention, a compound where R¹ is the group of the formula:



wherein R¹¹ and R¹² are the same or different and each is hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, or R¹¹ and R¹² are taken together, with an 20 adjacent nitrogen atom, to form a heterocyclic group selected from piperidino group, azacycloheptyl group, pyrrolidino group, imidazolidinyl group, hexahdropyrimidinyl group, thiazolidinyl group, morpholino group, triazolyl group, tetrazolyl group and 25 purinyl group, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, 30 is mentioned.

Of these, preferred is a compound wherein R¹¹ is a

substituted carbonyl group and R¹² is hydrogen atom or an alkyl group. Further, each of the compounds wherein R¹¹ is respectively, an optionally substituted alkanoyl group, an optionally substituted aminocarbonyl group,

5 morpholinocarbonyl group, and piperidinylcarbonyl group substituted by an alkanoyl group is respectively preferred. Another preferred example is a compound wherein R¹¹ is a substituted sulfonyl group and R¹² is hydrogen atom or an alkyl group.


10 The preferred substituent of the optionally substituted alkanoyl group is an an alkanoyl group, an alkylaminocarbonyl group, a dialkylaminocarbonyl group, aminocarbonyl group, an alkoxy carbonylamino group, an alkanoylamino group, amino group substituted by an alkoxy carbonyl group and an alkyl group, amino group substituted by an alkanoyl group and alkyl group, an alkoxy group optionally substituted by phenyl group, furyl group, tetrazolyl group, hydroxyl group, an alkylthio group, an alkylsulfinyl group, an alkylsulfonyl group, 2-aminothiazolyl group, 2-oxopyrrolidino group, 2-thiol-4-

15 alkylthiazolydiny group or a cycloalkyl group, and more preferred is an alkoxy group, hydroxyl group or an cycloalkyl group. The preferred substituent of the optionally substituted aminocarbonyl group is halogen atom, hydroxyl group or an alkyl group optionally substituted by alkoxy group, and more preferred is an alkyl group. The preferred substituent of the optionally substituted sulfonyl group is an alkyl group optionally substituted by hydroxyl group or halogen group, an alkenyl group or a dialkylamino group, and more preferred is an alkyl group.


20 The compound of the present invention is exemplified by a compound of the formula [I] wherein Ring A is a benzene ring of the formula:

25

30



and Ring B is a benzene ring of the formula:



wherein A¹ is an alkyl group, hydrogen atom, a halogen atom or an alkoxy group, A² is hydrogen atom or a halogen atom, A³ is hydrogen atom, B¹ is a trihalogenoalkyl group, a halogen atom or an alkyl group, B² is a trihalogenoalkyl group, a halogen atom or an alkyl group, B³ is hydrogen atom,

5 R¹ is hydroxyl group; an alkyl group substituted by a dialkylaminocarbonyl group, a morpholinocarbonyl group, hydroxyl group, an alkoxy carbonyl group, a morpholinoaminocarbonyl group, a hydroxyalkylaminocarbonyloxy group or an alkylpiperazinocarbonyl group; dihydroxyphenylthio group; alkanoylthio group; an alkylthio

10 group optionally substituted by hydroxyl group, an alkylaminocarbonyl group, a dialkylaminocarbonyl group, an alkoxy carbonylamino group, hydroxyalkanoylamino group, a morpholinocarbonylamino group, a hydroxyalkylaminocarbonylamino group or an alkanoyloxy group;

15 20 25 30

15 R¹ is hydroxyl group; an alkyl group substituted by a dialkylthionium group; an alkoxy group optionally substituted by hydroxyl group, an alkylsulfonyloxy group, a tetrahydropyranloxy group, a dialkylamino group, pyridyl group, a triazolyl group, a tetrazolyl group optionally substituted by an alkyl group, piperidino group, morpholino group, pyrrolidino group or an alkoxy group; thienylsulfonyloxy group; morpholinocarbonyloxy group; alkyl piperazinocarbonyloxy group; imidazolylcarbonyloxy group; piperidinoalkylaminocarbonyloxy group; morpholinoalkylaminocarbonyloxy group; an alkylaminocarbonyloxy group wherein the alkyl moiety thereof is optionally substituted by hydroxyl group, a morpholinocarbonyl group, a dialkylaminocarbonyl group, an alkylaminocarbonyl group, an alkanoylamino group, an

alkylthio group, an alkoxy group, an alkylsulfonyl group, an alkanoyloxy group or a carboxyl group; dialkylaminoalkylaminocarbonyloxy group; a piperidino-carbonyloxy group substituted by hydroxyl group, an

5 alkoxy carbonyl group, a carboxyl group, a hydroxyalkylaminocarbonyl group, an alkoxyalkylaminocarbonyl group, an alkylthioalkylaminocarbonyl group, an alkylsulfinylalkylaminocarbonyl group, an alkylsulfonylalkylaminocarbonyl group or hydroxyalkyl group;

10 dialkylaminocarbonyloxy group optionally substituted by hydroxyl group; a piperidinylaminocarbonyloxy group substituted by a hydroxyalkanoyl group or an alkoxyalkanoyl group; a thiomorpholinocarbonyloxy group wherein the sulfur atom is optionally substituted by an oxo group;


15 oxopyrrolidinylcarbonyloxy group; oxotetrahydrothiazolinylcarbonyloxy group; dialkylaminosulfonylaminocarbonyloxy group; a carboxyl group; an alkoxy carbonyl group; an aminocarbonyl group optionally substituted by a pyrimidinyl group or a pyrazinyl group; an

20 alkylaminocarbonyl group wherein the alkyl moiety is optionally substituted by hydroxyl group or a cyano group; a di(hydroxyalkyl)aminocarbonyl group; a pyridylaminocarbonyl group wherein the pyridyl group moiety is optionally substituted by hydroxyl group; an aminocarbonyl group

25 substituted by an alkylpyrido group; a piperidinocarbonyl group substituted by hydroxyl group or an oxo group; a piperazinocarbonyl group substituted by an oxo group, an alkyl group, a pyrimidinyl group, a pyrazinyl group, an alkylsulfonyl group or an alkanoyl group; a

30 morpholinocarbonyl group; thiomorpholinocarbonyl group; a pyrrolidinocarbonyl group substituted by a hydroxyalkyl group or hydroxyl group; an alkylsulfinyl group optionally substituted by hydroxyl group; a hydroxysulfinyl group; an alkylsulfonyl group optionally substituted by hydroxyl group

35 or an alkanoyloxy group; or the group of the formula:



wherein R^{11} is hydrogen atom; a pyridyl group; an alkanoyl group optionally substituted by a group selected from an alkanoyl group, an alkylaminocarbonyl group, a dialkylaminocarbonyl group, an aminocarbonyl group, an amino group, an alkoxy carbonylamino group, an alkanoylamino group, an amino group substituted by an alkoxy carbonyl group and an alkyl group, an amino group substituted by an alkanoyl group and an alkyl group, a halogen atom, a dialkylamino group, an alkoxy group optionally substituted by a phenyl group, a furyl group, a tetrazolyl group, hydroxyl group, an alkylthio group, an alkylsulfinyl group, an alkylsulfonyl group, 2-aminothiazolyl group, 2-oxopyrrolidino group, 2,2-dialkyl-1,3-dioxyranyl group, 2-thiol-4-alkylthiazolinyl group, a cycloalkyl group and a 5-alkyl-2,4(1H,3H)pyrimidinedione group; a phenylcarbonyl group optionally substituted by an amino group or a nitro group; a pyridylcarbonyl group optionally substituted by an alkyl group or hydroxyl group; a furylcarbonyl group optionally substituted by a formyl group, a morpholinoalkyl group or hydroxyalkyl group; a thienylcarbonyl group; quinolylcarbonyl group; an indolylcarbonyl group substituted by an alkyl group; a pyrazinylcarbonyl group optionally substituted by an alkyl group or an alkanoyl group; a morpholinocarbonyl group; a pyrrolidinylcarbonyl group optionally substituted by a benzyloxy group, an alkoxy carbonyl group, an alkanoyl group, hydroxyl group or an oxo group; tetrahydrofurylcarbonyl group; a piperidinylcarbonyl group substituted by an alkoxy carbonyl group or an alkanoyl group; a thiomorpholinocarbonyl group wherein the sulfur atom is optionally substituted by an oxo group; 3-alkyl-

2, 4(1H, 3H)pyrimidinedione carbonyl group; an alkylaminocarbonyl group wherein the alkyl moiety thereof is optionally substituted by a halogen atom, hydroxyl group or an alkoxy group; a

5 dialkylaminocarbonyl group; an alkoxy carbonyl group optionally substituted by an alkoxy group, hydroxyl group or a halogen atom; an alkylsulfonyl group optionally substituted by a group selected from hydroxyl group, morpholino group, an alkylpiperazino group, a dialkylamino group optionally substituted by hydroxyl group and a halogen atom; alkenylsulfonyl group; a dialkylamionsulfonyl group; or an alkyl group optionally substituted by morpholino group, a halogen atom, an alkoxy group, a cyano group, pyridyl group, a

10 dialkylaminocarbonyl group or a dialkylamino group, and R¹² is hydrogen atom; pyridyl group; a pyrazinyl group; or an alkyl group, or

15 -N(R¹¹)(R¹²) is triazolyl group, a tetrazolyl group; an aminopurinyl group, morpholino group, a morpholinio group wherein the nitrogen atom is substituted by an alkyl group, an N-oxomorpholino group, piperidino group optionally substituted by piperidino group, pyrrolidino group optionally substituted by hydroxyl group or an alkoxyalkyl group, an imidazolidinyl group substituted by a hydroxyalkyl group and oxo group, a

20 hexahydropyrimidinyl group substituted by a hydroxyalkyl group and oxo group, a dioxopyrrolidino group, a thiazolidyl group or an azacycloheptyl group,


25 R² is hydrogen atom,

30 Z is an oxygen atom or a group represented by -N(R³)-, R³ is an alkyl group optionally substituted by hydroxyl group or an alkanoyl group,

R⁴ is hydrogen atom or an alkyl group optionally substituted by hydroxyl group.

35 Of these, preferred is a compound wherein R¹ is substituted by hydroxyl group; an alkyl group substituted by a

dialkylaminocarbonyl group, a morpholinocarbonyl group, a morpholinoaminocarbonyl group or an alkylpiperazinocarbonyl group; dihydroxyphenylthio group; alkanoylthio group; an alkylthio group optionally substituted by hydroxyl group; an 5 alkoxy group optionally substituted by hydroxyl group, an alkylsulfonyloxy group, a tetrahydropyranyloxy group, a dialkylamino group, pyridyl group, a triazolyl group, a tetrazolyl group optionally substituted by an alkyl group, piperidino group, morpholino group, pyrrolidino group or an 10 alkoxy group; a morpholinocarbonyloxy group; an alkylpiperazinocarbonyloxy group; an imidazolylcarbonyloxy group; a piperidinoalkylaminocarbonyloxy group; a morpholinoalkylaminocarbonyloxy group; an alkylaminocarbonyloxy group wherein the alkyl moiety thereof 15 is optionally substituted by hydroxyl group, a morpholinocarbonyl group or a carboxyl group; dialkylaminoalkylaminocarbonyloxy group; a piperidino carbonyloxy group optionally substituted by hydroxyl group or hydroxyalkyl group; a dialkylaminocarbonyloxy group 20 optionally substituted by hydroxyl group; a thiomorpholino carbonyloxy group wherein the sulfur atom is optionally substituted by an oxo group; an oxopyrrolidinylcarbonyloxy group; an oxo tetrahydrothiazolinylcarbonyloxy group; a dialkylaminosulfonylaminocarbonyloxy group; an alkoxy carbonyl 25 group; an aminocarbonyl group optionally substituted by a hydroxyalkyl; an alkylsulfinyl group optionally substituted by hydroxyl group; an alkylsulfonyl group optionally substituted by hydroxyl group; or a group of the formula:



30 wherein R^{11} is hydrogen atom ; an alkanoyl group optionally substituted by a group selected from an amino group, a halogen atom, a dialkylamino group, an alkoxy group, furyl group, a tetrazolyl group, hydroxyl group, an alkylthio group, an alkylsulfinyl group, an

alkylsulfonyl group, 2-aminothiazolyl group, 2,2-dialkyl-1,3-dioxyranyl group, 2-thiol-4-alkylthiazolinyl group, a cycloalkyl group and 5-alkyl-2,4(1H,3H)pyrimidinedione group; a phenylcarbonyl group optionally substituted by an amino group or nitro group; a pyridylcarbonyl group; a furylcarbonyl group optionally substituted by a formyl group, morpholinoalkyl group or hydroxyalkyl group; a thienylcarbonyl group; a quinolylcarbonyl group; a pyrazinylcarbonyl group optionally substituted by an alkyl group; a morpholinocarbonyl group; pyrrolidinocarbonyl group; tetrahydrofurylcarbonyl group; a piperidinylcarbonyl group substituted by an alkoxy carbonyl group; an alkylaminocarbonyl group optionally substituted by a halogen atom, hydroxyl group or an alkoxy group; a dialkylaminocarbonyl group; an alkoxy carbonyl group optionally substituted by an alkoxy group, hydroxyl group or a halogen atom; an alkylsulfonyl group optionally substituted by a group selected from hydroxyl group, morpholino group, an alkylpiperazino group, a dialkylamino group optionally substituted by hydroxyl group and a halogen atom; an alkenylsulfonyl group; a dialkylamionsulfonyl group; or an alkyl group optionally substituted by morpholino group, a halogen atom, an alkoxy group, cyano group, pyridyl group, dialkylaminocarbonyl group or a dialkylamino group, and

R¹² is hydrogen atom; pyridyl group; or an alkyl group. Further preferred is a compound wherein R¹ is hydroxyl group; an alkyl group substituted by a dialkylaminocarbonyl group a morpholinocarbonyl group, a morpholinoaminocarbonyl group or an alkylpiperazinocarbonyl group; a dihydroxyphenylthio group; an alkanoylthio group; an alkylthio group optionally substituted by hydroxyl group; an alkoxy group optionally substituted by hydroxyl group, an alkylsulfonyloxy group, a tetrahydropyranloxy group, pyridyl group, a triazolyl group,


a tetrazolyl group optionally substituted by an alkyl group or an alkoxy group; a morpholinocarbonyloxy group; an imidazolylcarbonyloxy group; a piperidinoalkylaminocarbonyloxy group; a

5 morpholinoalkylaminocarbonyloxy group; an alkylaminocarbonyloxy group optionally substituted by hydroxyl group, a morpholinocarbonyl group or a carboxyl group; a dialkylaminoalkylaminocarbonyloxy group; a piperidinocarbonyloxy group optionally substituted by

10 hydroxyl group or hydroxyalkyl group; a dialkylaminocarbonyloxy group optionally substituted by hydroxyl group; a thiomorpholinocarbonyloxy group wherein the sulfur atom is optionally substituted by an oxo group; an oxopyrrolidinylcarbonyloxy group; an oxotetrahydrothiazolinyl

15 carbonyloxy group; a dialkylaminosulfonylaminocarbonyloxy group; an alkoxycarbonyl group; an aminocarbonyl group optionally substituted by a hydroxyalkyl group; an alkylsulfinyl group optionally substituted by hydroxyl group; an alkylsulfonyl group optionally substituted by hydroxyl

20 group; or, a group of the formula:



wherein R^{11} is an alkanoyl group optionally substituted by a group selected from an amino group, a halogen atom, an alkoxy group, a furyl group, a tetrazolyl group,


25 hydroxyl group, an alkylthio group, an alkylsulfinyl group, an alkylsulfonyl group, 2-aminothiazolyl group, 2,2-dialkyl-1,3-dioxyranyl group, 2-thiol-4-alkylthiazolinyl group, a cycloalkyl group and 5-alkyl-2,4(1H,3H)pyrimidinedione group; a phenylcarbonyl group

30 optionally substituted by an amino group or a nitro group; a pyridylcarbonyl group; a furylcarbonyl group optionally substituted by a formyl group or a hydroxyalkyl group; a quinolylcarbonyl group; a morpholinocarbonyl group; a pyrrolidinocarbonyl group;

a tetrahydrofurylcarbonyl group; a piperidinylcarbonyl group substituted by an alkoxycarbonyl group; an alkylaminocarbonyl group optionally substituted by a halogen atom, hydroxyl group or an alkoxy group; a dialkylaminocarbonyl group; an alkoxycarbonyl group optionally substituted by an alkoxy group, hydroxyl group or a halogen atom; an alkylsulfonyl group optionally substituted by hydroxyl group or a halogen atom; an alkenylsulfonyl group; or a thiensulfonyl group, and


10 R¹² is hydrogen atom; pyridyl group; or an alkyl group.

In the compound of the present invention, as a preferred compound there is mentioned a compound wherein Ring A is a benzene ring of the formula:



15

and Ring B is a benzene ring of the formula:




20 wherein A¹ is an alkyl group, hydrogen atom, a halogen atom or an alkoxy group, A² is hydrogen atom or a halogen atom, A³ is hydrogen atom, B¹ is a trihalogenoalkyl group, hydrogen atom or an alkyl group, B² is a trihalogenoalkyl group, hydrogen atom or an alkyl group, B³ is hydrogen atom,

25 R¹ is hydroxyl group; an alkyl group substituted by a dialkylaminocarbonyl group, a morpholinocarbonyl group, hydroxyl group, an alkoxycarbonyl group or a hydroxyalkylaminocarbonyloxy group; dihydroxyphenylthionyl group; alkanoylthio group; an alkylthio group optionally substituted by hydroxyl group, an alkylaminocarbonyl group, a dialkylaminocarbonyl group, an alkoxycarbonylamino group,

30

hydroxyalkanoylamino group, a morpholinocarbonylamino group, a hydroxyalkylaminocarbonylamino group or an alkanoyloxy group; dialkylthionium group; an alkoxy group optionally substituted by hydroxyl group, an alkylsulfonyloxy group, a 5 tetrahydropyranloxy group, a triazolyl group, a tetrazolyl group optionally substituted by an alkyl group, or an alkoxy group; thienylsulfonyloxy group; morpholinocarbonyloxy group; imidazolylcarbonyloxy group; an alkylaminocarbonyloxy group wherein the alkyl moiety thereof is optionally substituted by 10 hydroxyl group, a morpholinocarbonyl group, a dialkylaminocarbonyl group, an alkylaminocarbonyl group, an alkanoylamino group, an alkylthio group, an alkoxy group, an alkylsulfonyl group, an alkanoyloxy group or a carboxyl group; a piperidinocarbonyloxy group substituted by hydroxyl 15 group, an alkoxycarbonyl group, a carboxyl group, a hydroxyalkylaminocarbonyl group, an alkoxyalkylaminocarbonyl group, an alkylthioalkylaminocarbonyl group, an alkylsulfinylalkylaminocarbonyl group, an alkylsulfonylalkylaminocarbonyl group or hydroxyalkyl group; 20 dialkylaminocarbonyloxy group optionally substituted by hydroxyl group; a piperidinylaminocarbonyloxy group substituted by a hydroxyalkanoyl group or an alkoxyalkanoyl group; a thiomorpholinocarbonyloxy group wherein the sulfur atom is optionally substituted by an oxo group; 25 oxopyrrolidinylcarbonyloxy group; oxotetrahydrothiazolinylcarbonyloxy group; dialkylaminosulfonylaminocarbonyloxy group; a carboxyl group; an alkoxycarbonyl group; an aminocarbonyl group optionally substituted by a pyrimidinyl group; an alkylaminocarbonyl 30 group wherein the alkyl moiety is optionally substituted by hydroxyl group or a cyano group; a di(hydroxyalkyl)aminocarbonyl group; a pyridylaminocarbonyl group wherein the pyridyl group moiety is optionally substituted by hydroxyl group; an aminocarbonyl group 35 substituted by an alkylpyrido group; a piperidinocarbonyl group substituted by hydroxyl group or an oxo group; a

5 piperazinocarbonyl group substituted by an oxo group, an alkyl group, an alkylsulfonyl group or an alkanoyl group; a morpholinocarbonyl group; thiomorpholinocarbonyl group; a pyrrolidinocarbonyl group substituted by a hydroxyalkyl group or hydroxyl group; an alkylsulfinyl group optionally substituted by hydroxyl group; a hydroxysulfinyl group; an alkylsulfonyl group optionally substituted by hydroxyl group or an alkanoyloxy group; or the group of the formula:



10 wherein R^{11} is an alkanoyl group optionally substituted by (a) group(s) selected from an alkanoyl group, an alkylaminocarbonyl group, a dialkylaminocarbonyl group, an aminocarbonyl group, an alkoxy carbonylamino group, an alkanoylamino group, an amino group substituted by an alkoxy carbonyl group and an alkyl group, an amino group substituted by an alkanoyl group and an alkyl group, an alkoxy group optionally substituted by a phenyl group, a furyl group, a tetrazolyl group, hydroxyl group, an alkylthio group, an alkylsulfinyl group, an alkylsulfonyl group, 2-aminothiazolyl group, 2-oxopyrrolidino group, 2,2-dialkyl-1,3-dioxyranyl group, 2-thiol-4-alkylthiazolinyl group and a cycloalkyl group; a phenylcarbonyl group optionally substituted by an amino group or a nitro group; a pyridylcarbonyl group optionally substituted by hydroxyl group; a furylcarbonyl group optionally substituted by a formyl group, or hydroxyalkyl group; a thienylcarbonyl group; an indolylcarbonyl group substituted by an alkyl group; a morpholinocarbonyl group; a pyrrolidinylcarbonyl group optionally substituted by a benzyloxy group, an alkoxy carbonyl group, an alkanoyl group, hydroxyl group or an oxo group; tetrahydrofurylcarbonyl group; a piperidinylcarbonyl group substituted by an

alkoxycarbonyl group or an alkanoyl group; a thiomorpholinocarbonyl group wherein the sulfur atom is optionally substituted by an oxo group; 3-alkyl-2,4(1H,3H)pyrimidinedione carbonyl group; an alkylaminocarbonyl group wherein the alkyl moiety thereof is optionally substituted by a halogen atom, hydroxyl group or an alkoxy group; a dialkylaminocarbonyl group; an alkoxycarbonyl group optionally substituted by an alkoxy group, hydroxyl group or a halogen atom; an alkylsulfonyl group optionally substituted by a group selected from hydroxyl group, and a halogen atom; alkenylsulfonyl group; or a dialkylamionsulfonyl group; and


R¹² is hydrogen atom; a pyrazinyl group; or an alkyl group, or

-N(R¹¹)(R¹²) is triazolyl group, a tetrazolyl group, an aminopurinyl group, a morpholinio group wherein the nitrogen atom is substituted by an alkyl group, an N-oxomorpholino group, an imidazolidinyl group substituted by a hydroxyalkyl group and oxo group, a hexahdropyrimidinyl group substituted by a hydroxyalkyl group and oxo group, or a dioxopyrrolidino group,


R² is hydrogen atom,

Z is an oxygen atom or a group represented by -N(R³)-, R³ is an alkyl group optionally substituted by hydroxyl group, R⁴ is hydrogen atom or an alkyl group optionally substituted by hydroxyl group.

Of these, preferred is a compound wherein Ring A is a benzene ring of the formula:



and Ring B is a benzene ring of the formula:




wherein A¹ is an alkyl group, A² is a halogen atom, A³ is hydrogen atom, B¹ is a trihalogenoalkyl group, B² is a trihalogenoalkyl group, B³ is hydrogen atom,

5 R¹ is an alkoxy group substituted by hydroxyl group or tetrahydropyranloxy; an alkylaminocarbonyloxy group wherein the alkyl moiety thereof is optionally substituted by hydroxyl group; a thiomorpholinocarbonyloxy group wherein the sulfur atom is substituted by an oxo group; an alkylthionyl group; an alkanoyl group substituted by hydroxyl group;

10 aminocarbonyl group substituted by (a) group(s) selected from an alkyl group, pyrazinyl group and pyrimidinyl group; piperzinocarbonyl group substituted by an alkanoyl group; piperidinocarbonyl group substituted by hydroxyl group; an alkylsulfinyl group optionally substituted by hydroxyl group;

15 an alkylsulfonyl group optionally substituted by hydroxyl group; or the group the formula:



20 wherein R¹¹ is an alkanoyl group optionally substituted by (a) group(s) selected from an alkoxy group, hydroxyl group and a cycloalkyl group; an alkoxycarbonyl group; a pyridylcarbonyl group substituted by hydroxyl group; a morpholinocarbonyl group; an alkylaminocarbonyl group; or an alkylsulfonyl group; pyrazinyl group, and


25 R¹² is hydrogen atom, or an alkyl group, -N(R¹¹)(R¹²) is triazolyl group, tetrazolyl group or an N-oxomorpholino group,

R² is hydrogen atom,
Z is a group represented by -N(R³)-,
30 R³ is an alkyl group,
R⁴ is hydrogen atom or an alkyl group.

Further more preferred is a compound wherein R¹ is an alkylaminocarbonyloxy group wherein the alkyl moiety thereof is substituted by hydroxyl group; a thiomorpholinocarbonyloxy group wherein the sulfur atom is substituted by an oxo group;

5 an alkanoyl group substituted by hydroxyl group; piperzinocarbonyl group substituted by an alkanoyl group; piperidinocarbonyl group substituted by hydroxyl group; an alkylsulfinyl group substituted by hydroxyl group; an alkylsulfonyl group optionally substituted by hydroxyl group;

10 or the group the formula:



wherein R¹¹ is an alkanoyl group substituted by hydroxyl group, and R¹² is hydrogen atom.

15 In the present invention, particularly preferred compound is a compound selected from the following (A) to (BK) or pharmaceutically acceptable salt thereof.

(A) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-methylpropionylamino)piperidine,

(B) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-morpholino-carbonylaminopiperidine,

(C) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethoxy)piperidine,

(D) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{2-(2-tetrahydropyranloxy)ethoxy}piperidine,

(E) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methoxy-acetylaminopiperidine,

(F) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methoxy-

carbonylaminopiperidine,

(G) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-ethoxycarbonylamino-2-(4-fluoro-2-methylphenyl)piperidine,

5 (H) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-metansulfonylaminopiperidine,

(I) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-

10 hydroxyethoxy)piperidine,

(J) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxy-acetylaminopiperidine,

(K) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(3-

15 hydroxypropoxy)piperidine,

(L) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-(2-cyclopropyl-2-hydroxyacetylamino)-2-(4-fluoro-2-methylphenyl)piperidine,

20 (M) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxy-2-methylpropionylamino)piperidine,

(N) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((S)-3-

25 hydroxybutyrylamo) piperidine,

(O) (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethyl-aminocarbonyloxy)piperidine,

(P) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-

30 methanesulfinylpiperidine,

(Q) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methanesulfonylpiperidine,

35 (R) (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]-aminocarbonyl-4-ethylaminocarbonyloxy-2-(4-fluoro-2-methyl-

phenyl)piperidine,

(S) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-methoxypropionylamino)piperidine,

5 (T) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-methanesulfonyl-N-methylamino)piperidine,

(U) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-

10 hydroxyethylaminocarbonyloxy)piperidine,

(V) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(3-hydroxy-3-methylbutyrylamino)piperidine,

(W) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-

15 aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethane-sulfinyl)piperidine,

(X) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxy-acetylaminopiperidine,

20 (Y) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((S)-2-hydroxypropionylamino)piperidine,

(Z) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((R)-3-

25 hydroxybutyrylamino)piperidine,

(AA) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxy-2-methylpropanesulfonyl)piperidine,

(AB) (2R,4S)-1-[N-{1-(R)-(3,5-

30 bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethanesulfinyl)piperidine,

(AC) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-

fluoro-2-methylphenyl)-4-((S)-((S)-2-

35 hydroxypropane)sulfinyl)piperidine,

(AD) (2R,4S)-1-[N-{1-(R)-(3,5-

bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{(R)-((S)-2-hydroxypropane)sulfinyl}piperidine,
(AE) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-
5 aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxy-2-methylpropanesulfinyl)piperidine,
(AF) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((S)-2-
10 hydroxypropanesulfonyl)piperidine,
(AG) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-methylethanesulfonyl)piperidine,
(AH) (2R,4S)-1-[N-{1-(R)-(3,5-
15 bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxy-2-methylpropanesulfinyl)piperidine,
(AI) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-
aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{(S)-((S)-2-
20 hydroxypropane)sulfinyl}piperidine,
(AJ) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-
aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{(R)-((S)-2-
hydroxypropane)sulfinyl}piperidine,
(AK) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-
25 aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{(R)-((R)-2-
hydroxypropane)sulfinyl}piperidine,
(AL) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-
aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{(S)-((R)-2-
hydroxypropane)sulfinyl}piperidine,
30 (AM) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-
aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((S)-2-hydroxypropanesulfonyl)piperidine,
(AN) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-
aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((S)-3-hydroxy-
35 butyrylamino)piperidine,
(AO) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-

aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(*(R)*-3-hydroxybutyrylamino)piperidine,
(AP) (2*R*,4*S*)-4-(4-acetylR)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine,
(AQ) (2*R*,4*S*)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-methyl-ethanesulfinyl)piperidine,
(AR) (2*R*,4*S*)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-oxothiomorpholinocarbonyloxy)piperidine,
(AS) (2*R*,4*S*)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethanesulfonyl)piperidine,
(AT) (2*R*,4*S*)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-methyl-ethanesulfonyl)piperidine,
(AU) (2*R*,4*S*)-1-[N-{1-(*R*)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(4-hydroxypiperidinocarbonyl)piperidine,
(AV) (2*R*,4*S*)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methanesulfonylpiperidine,
(AW) (2*R*,4*S*)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(*(R)*-2-hydroxypropionyl)piperidine,
(AX) (2*R*,4*S*)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-methyl-N-pyrazin-2-ylaminocarbonyl)piperidine,
(AY) (2*R*,4*S*)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(pyrazin-2-ylamino)piperidine,
(AZ) (2*R*,4*S*)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-methyl-N-pyrazin-2-ylamino)piperidine,

(BA) (2R,4S)-1-[N-{1-(R)-(3,5-
bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-
fluoro-2-methylphenyl)-4-(1-methylethylthionyl)piperidine,
(BB) (2R,4S)-1-[N-{1-(R)-(3,5-
5 bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-
fluoro-2-methylphenyl)-4-(1-triazoryl)piperidine,
(BC) (2R,4S)-1-[N-{1-(R)-(3,5-
bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-
fluoro-2-methylphenyl)-4-(1-tetrazoryl)piperidine,
10 (BD) (2R,4S)-1-[N-{1-(S)-(3,5-
bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-
fluoro-2-methylphenyl)-4-(N-oxo-morphorino)piperidine,
(BE) (2R,4S)-1-[N-{1-(R)-(3,5-
bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-
15 fluoro-2-methylphenyl)-4-(N-oxo-morphorino)piperidine,
(BF) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-
aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-
oxomorphorino)-piperidine,
(BG) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-
20 aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-
hydroxypyridin-5-yl-carbonylamino)piperidine,
(BH) (2R,4S)-1-[N-{1-(R)-(3,5-
bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-
fluoro-2-methylphenyl)-4-(N-pyrimidin-4-
25 ylaminocarbonyl)piperidine,
(BI) (2R,4S)-1-[N-{1-(R)-(3,5-
bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-
fluoro-2-methylphenyl)-4-(N-methyl-N-pyrimidin-4-
ylaminocarbonyl)piperidine,
30 (BJ) (2R,4S)-1-[N-{1-(S)-(3,5-
bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-
fluoro-2-methylphenyl)-4-(2-hydroxyacetylamino)piperidine, or
(BK) (2R,4S)-1-[N-{1-(R)-(3,5-
bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-
35 fluoro-2-methylphenyl)-4-(1-methylethylthio)piperidine.

In the present invention, more particularly preferred

compound is a compound selected from the following (a) to (s) or a pharmaceutically acceptable salt thereof.

(a) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxy-2-methylpropionylamino)piperidine,

(b) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((S)-3-hydroxybutyrylamino)piperidine,

(c) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethyl-aminocarbonyloxy)piperidine,

(d) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(3-hydroxy-3-methylbutyrylamino)piperidine,

(e) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((R)-3-hydroxybutyrylamino)piperidine,

(f) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxy-2-methylpropanesulfonyl)piperidine,

(g) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxy-2-methylpropanesulfinyl)piperidine,

(h) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((S)-2-hydroxypropanesulfonyl)piperidine,

(i) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((S)-3-hydroxybutyrylamino)piperidine,

(j) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((R)-3-hydroxybutyrylamino)piperidine,

(k) (2R,4S)-4-(4-acetylpirerazinocarbonyl)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine,

(l) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-

aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-oxothiomorpholinocarbonyloxy)piperidine,

(m) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxy-5ethanesulfonyl)piperidine,

(n) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-amino- carbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-methyl-ethanesulfonyl)piperidine,

(o) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(4-hydroxypiperidinocarbonyl)piperidine,


(p) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methanesulfonylpiperidine,

(q) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((R)-2-hydroxy-propionyl)piperidine,


(r) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyacetylamo)piperidine, or

(s) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-methylethylthio)piperidine.

In the compound of the present invention, as a preferred compound there is mentioned a compound wherein Ring A is a benzene ring of the formula:



and Ring B is a benzene ring of the formula:




30 wherein A¹ is an alkyl group, A² is a halogen atom, A³

is hydrogen atom, B^1 is a trihalogenoalkyl group or a halogen atom, B^2 is a trihalogenoalkyl group or a halogen atom, B^3 is hydrogen atom,

5 R^1 is hydroxyl group; an alkyl group substituted by a dialkylaminocarbonyl group or a morpholinocarbonyl group, an alkoxy group optionally substituted by hydroxyl group, an alkylsulfonyloxy group, a triazolyl group, or a tetrazolyl group optionally substituted by an alkyl group; morpholino-carbonyloxy group; a hydroxyalkylaminocarbonyloxy group; an

10 imidazolylcarbonyloxy group; an alkylsulfinyl group optionally substituted by hydroxyl group; an alkylsulfonyl group; an alkylaminocarbonyl group substituted by hydroxyl group; a piperidinocarbonyl group substituted by hydroxyl group; or a group of the formula:




15 wherein R^{11} is an alkanoyl group optionally substituted by hydroxyl group or a 5-alkyl-2,4(1H,3H)pyrimidine-dione group; a pyridylcarbonyl group; a furylcarbonyl group; a thienylcarbonyl group; a morpholinocarbonyl group; an alkoxycarbonyl group; or an alkylsulfonyl group;

20 R^{12} is hydrogen atom; or an alkyl group, or $-N(R^{11})(R^{12})$ is triazolyl group, a morpholinio group wherein the nitrogen atom is substituted by an alkyl group, or an N-oxomorpholino group,

25 R^2 is hydrogen atom,
 Z is a group represented by $-N(R^3)-$,
 R^3 is an alkyl group,
 R^4 is hydrogen atom or an alkyl group.


30 Of these, preferred is a compound wherein R^1 is hydroxyl group; an alkyl group substituted by a dialkylaminocarbonyl group or a morpholinocarbonyl group; an alkoxy group optionally substituted by hydroxyl group, alkylsulfonyloxy group, a triazolyl group, or a tetrazolyl group optionally

substituted by an alkyl group; a morpholinocarbonyloxy group; a hydroxyalkylaminocarbonyloxy group; an imidazolylcarbonyloxy group; an alkylsulfinyl group 5 optionally substituted by hydroxyl group; an alkylsulfonyl group; an alkylaminocarbonyl group substituted by hydroxyl group; a piperidinocarbonyl group substituted by hydroxyl group; or a group of the formula:



10 wherein R^{11} is an alkanoyl group optionally substituted by hydroxyl group or 5-alkyl-2,4(1H,3H)pyrimidinedione group; a pyridylcarbonyl group; a furylcarbonyl group; a thienylcarbonyl group; a morpholinocarbonyl group; an alkoxy carbonyl group; an alkylsulfonyl group; R^{12} is hydrogen atom; or an alkyl group.

15 In the compounds of the present invention, more preferred is a compound wherein R^1 is hydroxyl group; an alkoxy group substituted by hydroxyl group, or a triazolyl group; a hydroxyalkylaminocarbonyloxy group; an alkylsulfinyl group optionally substituted by hydroxyl group; an alkylsulfonyl group; an alkylaminocarbonyl group substituted by hydroxyl group; a piperidinocarbonyl group substituted by hydroxyl group; or a group of the formula:



25 wherein R^{11} is an alkanoyl group optionally substituted by hydroxyl group; and

R^{12} is hydrogen atom; or an alkyl group, or $-N(R^{11})(R^{12})$ is a morpholinio group wherein the nitrogen atom is substituted by an alkyl group, a piperazino group substituted by an N-oxomorpholino group, an alkyl group or an alkanoyl group,


30 R^2 is hydrogen atom,

Z is a group represented by $-N(R^3)-$,

R³ is an alkyl group,

R⁴ is hydrogen atom or an alkyl group.


The more preferred is the compound wherein R¹ is hydroxyl group; an alkoxy group substituted by hydroxyl group, 5 or a triazolyl group; a hydroxyalkylaminocarbonyloxy group; an alkylsulfinyl group optionally substituted by hydroxyl group; an alkylsulfonyl group; an alkylaminocarbonyl group substituted by hydroxyl group; a piperidinocarbonyl group substituted by hydroxyl group; or a group of the formula:



wherein R¹¹ is an alkanoyl group optionally substituted by hydroxyl group;

R¹² is hydrogen atom; or an alkyl group.

In the compound of the present invention, other 15 preferred compound is a compound wherein R¹ is hydroxyl group; an alkoxy group optionally substituted by hydroxyl group, an alkylsulfonyloxy group or a tetrazolyl group; a hydroxyalkylaminocarbonyloxy group; an alkylsulfinyl group optionally substituted by hydroxyl group; an alkylsulfonyl group; 20 an alkylaminocarbonyl group substituted by hydroxyl group; a piperidinocarbonyl group substituted by hydroxyl group; or a group of the formula:



wherein R¹¹ is an alkanoyl group optionally substituted by hydroxyl group; a furylcarbonyl group; a 25 morpholinocarbonyl group; an alkoxycarbonyl group; or an alkylsulfonyl group; and

R¹² is hydrogen atom; or an alkyl group, or

-N(R¹¹)(R¹²) is a triazolyl group, or a tetrazolyl group,


30 R² is hydrogen atom,

Z is a group represented by -N(R³)-,


R³ is an alkyl group,

R^4 is hydrogen atom or an alkyl group.

Another preferred compound is exemplified by the compound wherein Ring A is a benzene ring of the formula:




5 and Ring B is a benzene ring of the formula:



wherein A^1 is an alkyl group, A^2 is a halogen atom, A^3 is hydrogen atom, B^1 is a trihalogenoalkyl group, B^2 is a trihalogenoalkyl group, B^3 is hydrogen atom,

10 R^1 is a hydroxyalkylaminocarbonyloxy group; an alkylsulfinyl group optionally substituted by hydroxyl group; an alkylsulfonyl group; an alkylaminocarbonyl group substituted by hydroxyl group; a piperidinocarbonyl group substituted by hydroxyl group; or a group of the formula:



15

wherein R^{11} is an alkanoyl group optionally substituted by hydroxyl group; or an alkoxy carbonyl group; and R^{12} is hydrogen atom; or an alkyl group


R^2 is hydrogen atom,

20 Z is a group represented by $-N(R^3)-$,

R^3 is an alkyl group,


R^4 is hydrogen atom or an alkyl group.

Still another preferred compound is a compound wherein Ring A is a benzene ring of the formula:




25

and Ring B is a benzene ring of the formula:




wherein A¹ is an alkyl group, A² is a halogen atom, A³ is hydrogen atom, B¹ is a trihalogenoalkyl group, B² is a trihalogenoalkyl group, B³ is hydrogen atom,
 5 R¹ is a hydroxyalkylaminocarbonyloxy group; an alkylsulfinyl group optionally substituted by hydroxyl group; an alkylsulfonyl group; an alkylaminocarbonyl group substituted by hydroxyl group; a piperidinocarbonyl group substituted by hydroxyl group; or a group of the formula:
 10



wherein R¹¹ is an alkanoyl group optionally substituted by hydroxyl group, and
 R¹² is hydrogen atom; or an alkyl group, or
 15 -N(R¹¹)(R¹²) is a morpholinio group wherein the nitrogen atom is substituted by an alkyl group, or an N-oxomorpholino group,

R² is hydrogen atom,
 Z is a group represented by -N(R³)-,
 20 R³ is an alkyl group,
 R⁴ is hydrogen atom or an alkyl group.

More preferred is a compound wherein R¹ is a hydroxyalkylaminocarbonyloxy group; an alkylsulfinyl group optionally substituted by hydroxyl group; an alkylsulfonyl group; an alkylaminocarbonyl group substituted by hydroxyl group; a piperidinocarbonyl group substituted by hydroxyl group; or a group of the formula:



wherein R¹¹ is an alkanoyl group optionally substituted

by hydroxyl group, and R¹² is hydrogen atom; or an alkyl group.

The compound [I] of the present invention can be used for a pharmaceutical use either in a free form or in form of a 5 pharmaceutically acceptable salt.

As the pharmaceutically acceptable salt of the compound [I] of the present invention, there may be mentioned, for example, an inorganic acid salt such as hydrochloride, sulfate, phosphate and hydrobromate; and an organic acid salt 10 etc., such as acetate, fumarate, oxalate, citrate, methanesulfonate, benzenesulfonate, tosylate, maleate, succinate and tartarate.

Further, the compound [I] of the present invention or a pharmaceutically acceptable salt thereof includes any of 15 its internal salts, solvate and hydrates, etc.

Although an optical isomer based on an asymmetric carbon can be present in the compound [I] of the present invention, the present invention includes any of these optical isomers and the mixture thereof. In the present 20 invention, among these optical isomers, preferred is a compound having R configuration at 2-position of the piperidine ring (the connecting position of Ring A), and particularly preferred is a compound having R configuration at the second position of the piperidine ring (the connecting 25 position of Ring A) and S configuration at 4-position (the connecting position of R¹).

The compound [I] or a pharmaceutically acceptable salt thereof of the present invention has an excellent tachykinin receptor antagonistic action, particularly an SP receptor 30 antagonistic action, whereby it is useful as a safe medicament for prophylaxis and treatment for inflammation or allergic diseases (for example, atopic dermatitis, dermatitis, herpes, proriasis, asthma, bronchitis, expectoration, rhinitis, rheumatoid arthritis, osteoarthritis, osteoporosis, 35 multiple sclerosis, conjunctivitis, ophthalmia, cystitis, etc.), pain, migraine, neuralgia, itchiness, cough, and

further central nervous system diseases (for example, schizophrenia, Parkinson's disease, depression, uneasiness, psychosomatic disorder, morphine dependence, dementia (for example, Alzheimer's disease, etc.), etc.), digestive organs
5 disease (for example, hypersensitive bowel disease, ulcerative colitis, Crohn's disease, disorder (for example, gastritis, gastric ulcer, etc.) related to urease-positive *Spirillum* (for example, *helicobacter pylori*, etc.), etc.), nausea, emesis, urinary disorder (for example, pollakiurea,
10 urinary incontinence, etc.), circulatory disease (for example, angina pectoris, hypertension, cardiac failure, thrombosis, etc.) and immune disorder, etc. in mammals (for example, mouse, Mongolian gerbil, ferret, rat, hamster, rabbit, cat, dog, bovine, sheep, monkey, human, etc.). Particularly,
15 since compound [I] or a pharmaceutically acceptable salt thereof which is an active ingredient of the present invention is highly transportable in the brain and at the same time has a low toxicity, showing almost no side effect, it is useful as a therapeutic or prophylactic agent for
20 central nerve system disease such as emesis, depression and so forth, or urinary disorder such as pollakiuria, etc.

Measurements on the compound of the present invention or a pharmaceutically acceptable salt thereof can be carried out, according to the method described in European Journal of Pharmacology, vol. 254, pages 221-227 (1994) with respect to a neurokinin-1 receptor binding action, and according to the method described in European Journal of Pharmacology) vol. 265, pages 179-183 (1994) with respect to an action against the neurokinin-1 receptor induction, and according to the
25 method described in British Journal of Pharmacology vol. 119, pages 931-936 (1996) with regard to the effect against emesis, further according to the method described in Journal of Urology, vol. 155, No. 1, pages 355-360 (1996) with regard to an inhibitory action on pollakiuria.

30 35 The compound [I] or a pharmaceutically acceptable salt thereof of the present invention can be administered orally


or parenterally, and it can be formulated into a suitable preparation, using a conventionally used pharmaceutical carrier for an oral or parenteral administration. As such a pharmaceutical carrier, there may be mentioned, for example, 5 a binder (syrup, Gum Arabic, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone, etc.), an excipient (lactose, sugar, corn starch, potassium phosphate, sorbitol, glycine, etc.), a lubricant (magnesium stearate, talc, polyethylene glycol, silica, etc.), a disintegrator (potato starch, etc.) and a 10 wetting agent (anhydrous lauryl sodium sulfate, etc.), and the like.

Also, when these pharmaceutical preparations are administered orally, they may be a solid preparation such as tablets, granules, capsules, powders, or a liquid preparation 15 such as solution, suspension, and emulsion. On the other hand, when they are administered parenterally, for example, they can be administered as an injection solution or an infusion solution, using distilled water for injection, physiological saline, aqueous glucose solution, etc., or they 20 may be administered as a suppository, and the like.

A dose of the compound [I] or a pharmaceutically acceptable salt thereof of the present invention may vary depending on an administration method, an age, a body weight or a condition of a patient, etc., and, for example, in case 25 of oral administration, it is usually administered in a dose of 0.1 to 20 mg/kg per day, and particularly preferably 0.1 to 10 mg/kg per day, and in case of parental administration, usually in a dose of 0.01 to 10 mg/kg per day, particularly preferably 0.01 to 1 mg/kg per day.


30 [Method A]

The target compound [I] of the present invention can be prepared, for example, by reacting the compound of the formula [II]:



wherein Ring A represents an optionally substituted benzene ring, R¹ is an optionally substituted alkyl group, an optionally substituted hydroxyl group, a substituted thiol group, a substituted carbonyl group, a substituted sulfinyl group, a substituted sulfonyl group, or a group of the formula:

5



wherein R¹¹ and R¹² are the same or different and each is hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, or R¹¹ and R¹² are taken together, with an adjacent nitrogen atom, to form a heterocyclic group selected from piperidino group, azacycloheptyl group, pyrrolidino group, thiazolidyl group, morpholino group, triazolyl group, tetrazolyl group and purinyl group, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized,


10

15

20

25


with the compound of the formula [III]:



wherein Ring B represents an optionally substituted benzene ring, R³ represents hydrogen atom or an optionally substituted alkyl group, and R⁴ represents hydrogen atom or an optionally substituted alkyl group, in the presence of urea.


5 [Method B]

In the target compounds [I] of the present invention, the compound of the formula [I-a]:



10

wherein Ring A, Ring B, R², Z, R³ and R⁴ have the same meanings as defined above, can be prepared, for example, by reducing the compound of the formula [IV]:




15

wherein Ring A, Ring B, R², Z, R³ and R⁴ have the same meanings as defined above.


[Method C]

In the compounds of the present invention, the compound 20 of formula [I-b]:



wherein Ring A, Ring B, R^{11} , R^{12} , R^2 , Z, R^3 and R^4 have the same meanings as defined above,


can be prepared by reacting the compound of the formula [IV]:



5

wherein Ring A, Ring B, R^2 , Z, R^3 and R^4 have the same meanings as defined above,


with the compound of the formula [V]:



10 wherein X^1 represents hydrogen atom, hydroxyl group, a silicon atom, lithium atom or magnesium atom, R^{11} and R^{12} have the same meaning as defined above.


[Method D]

15 In the compounds of the present invention, the compound of the formula [I-c]:




wherein Ring A, Ring B, R^2 , Z, R^3 and R^4 have the same meanings as defined above, and R^{13} represents an optionally substituted carboxyl group,

can be prepared by reacting the compound of the formula [IV]:




wherein Ring A, Ring B, R², Z, R³ and R⁴ have the same meanings as defined above,

5 with the compound of the formula [VI]:



wherein X² represents a leaving group, and R¹³ has the same meaning as defined above,

and reducing the resulting compound of the formula [VII]:




10

wherein Ring A, Ring B, R¹³, Z, R², R³ and R⁴ have the same meanings as defined above.

[Method E]


In the compounds of the present invention, the
15 compound of the formula [I'']:



wherein Ring A, Ring B, R¹, R² and R⁴ have the same meanings as defined above,


can be prepared by reacting the compound of the formula

20 [II]:



wherein Ring A, R¹ and R² have the same meanings as defined above,

with the compound of the formula [III']:



5


wherein Ring B and R⁴ have the same meanings as defined above,

in the presence of an urea bond forming agent.

These [Method A] to [Method E] can be carried out as 10 described bellow.

[Method A]

The reaction of the compound [II] with the compound [III] can be carried out in a suitable solvent in the presence of an urea bond forming agent. The urea bond 15 forming agent is exemplified by the compounds shown by the formula:




wherein W¹ and W² are the same or different, and each represents a leaving group, and the like.


20 W¹ and W² are the same or different and each is exemplified by an imidazolyl group, a halogen atom, phenoxy group and the like. Specifically preferred are 1,1'-carbonyldiimidazole, a phosgene and the like, and carbonyldihalides such as 1,1'-carbonyldiimidazole, a 25 triphosgene or a phosgene etc. can be used. Further, any solvent can be used as long as it does not exert any bad

effect on the reaction, for example, acetonitrile, dichloromethane, tetrahydrofuran etc. can be used appropriately. This reaction can proceed, for example, at 0 °C to 80 °C, preferably at 0 °C to 50 °C.


5 Further, in this reaction, the compound [I] can be prepared also by reacting the compound [II] with the urea bond forming agent of the formula:




10 wherein W^1 and W^2 are the same or different and each represents a leaving group,
to give the resulting compound of the formula [VIII-a]:



wherein Ring A, R^1 , R^2 and W^2 have the same meanings as above,
15 subsequently leading the compound [VIII-a] to a reactive derivative thereof, and reacting the same with the compound [III], or alternatively, the compound [I] can be prepared by reacting the compound [III] and the urea bond forming agent of the formula:




20 wherein W^1 and W^2 have the same meanings as defined above,
to give the resulting compound of the formula [VIII-b]:



wherein Ring B, R³, R⁴ and W² have the same meanings as defined above,

subsequently leading the compound [VIII-b] to a reactive derivative thereof, and reacting the same with the compound 5 [II].

As the reactive derivative, there are mentioned a compound in which W² is lead to a group as shown by the formula:



10 in the compound [VIII-a] or the compound [VIII-b], and the like.

The reaction of the compound [II] or the compound [III] with the urea linkage forming agent can proceed, for example, at 0°C to 80°C, preferably at 0°C to 50°C. Further, 15 any solvent can be used as long as it does not exert any bad effect on the reaction, for example, acetonitrile, dichloromethane, tetrahydrofuran, etc. can be used appropriately.

The reaction to lead the compound [VIII-a] or the 20 compound [VIII-b] to a reactive derivative thereof can be carried out using a derivative-leading agent such as methyl iodide, for example, 0°C to 80°C, preferably at 0°C to 50°C. Further, any solvent can be used as long as it does not exert any bad effect on the reaction, for example, 25 acetonitrile, dichloromethane, tetrahydrofuran, etc. can be used appropriately.

The reaction of each reactive derivative with the compound [III] or the compound [II] can be carried out in the presence of a base, for example, at 0°C to 80°C, 30 preferably at 0°C to 50°C. Further, triethylamine etc. can be used as a base, and any solvent can be used as long as it does not exert any bad effect on the reaction, for example, acetonitrile, dichloromethane, tetrahydrofuran, etc. can be

used appropriately.

[Method B]

The reduction of the compound [IV] can be carried out in the presence of a reductive agent in suitable solvent. As 5 a reductive agent, sodium borohydride and the like is preferred, for example, sodium borohydride, aluminum hydride such as diisobutyl aluminum hydride etc. can be used. Further, any solvent can be used as long as it does not exert any bad effect on the reaction, for example, ethanol, 10 tetrahydrofuran, dichloromethane, etc. can be used appropriately. This reaction can be carried out, for example, at -70°C to under reflux, preferably, at -70°C to 20°C.

[Method C]

The reaction of the compound [IV] with the compound 15 [V] can be carried out in a suitable solvent by subjecting the compounds to a reductive amination reaction. This reductive amination reaction can be carried out in acidic condition by hydrogenation in the presence of a reductive agent such as sodium borohydride, triacetoxysodium 20 borohydride, sodium cyanoborohydride or a reduction catalyst such as palladium. As the group [X¹] in the compound [V], there are mentioned, for example, hydrogen atom, hydroxyl group, silicon atom, lithium atom or magnesium atom, and preferred are hydrogen atom and hydroxyl group. Any solvent 25 can be used as long as it does not exert any bad effect on the reaction, for example, dichloromethane, acetic acid, ethanol, methanol, etc. can be used appropriately. As a salt of the compound [V], hydrochloride, acetate, etc. can be used appropriately. The present reaction can proceed, for 30 example, at -10°C to 80°C, preferably at 0°C to 30°C.

[Method D]


The reaction of the compound [IV] with the compound [VI] can be carried out optionally in the presence of a base in a suitable solvent. As the leaving group [X²] of the 35 compound [VI], there are mentioned diethylphosphono group, triphenylphophinyl group, etc. As the base, there are

mentioned, for example, potassium-tert-butoxide, triethylamine, sodium hydroxide, etc., and preferred are potassium-tert-butoxide, triethylamine, and the like. Further, any solvent can be used as long as it does not 5 exert any bad effect on the reaction, for example, tetrahydrofuran, dichloromethane, etc. can be used appropriately. The present reaction can proceed, for example, at -30°C to 80°C, preferably at -20°C to 30°C.

Further, the reduction of the compound [VII] can be 10 carried out by a conventional method, by hydrogenation in the presence of a reduction catalyst such as palladium, etc. As the solvent, methanol, ethanol, etc. can be used appropriately. The present reaction can proceed, for example, at 0°C to 50°C.

15 [Method E]

The reaction of the compound [II] with the compound [III'] can be carried out in the presence of a urea bond forming agent in a suitable solvent. As the urea bond forming agent, those as shown by the formula:




wherein W^1 and W^2 are the same or different, and each represents a leaving group.

As W^1 and W^2 , being the same or different, there are mentioned imidazolyl group, a halogen atom or phenoxy group 25 and the like. Specifically, 1,1'-carbonyldiimidazole, phosgene are preferred and for example, carbonyldihalide such as 1,1'-carbonyldiimidazole, triphosgene, phosgene, etc. may be used. Further, any solvent can be used as long as it does not exert any bad effect on the reaction, for example, 30 acetonitrile, dichloromethane, tetrahydrofuran, etc. can be used appropriately. The present reaction can proceed, for example, at 0°C to 80°C, preferably at 0°C to 50°C.


Further, the compound [I''] can be prepared by reacting the compound [II] with the urea bond forming agent

of the formula:




wherein W^1 and W^2 are the same or different, and each represents a leaving group,

5 to give the compound of the formula [VIII-a]:




wherein Ring A, R^1 , R^2 and W^2 have the same meanings as defined above,

subsequently leading the compound [VIII-a] to a reactive
 10 derivative thereof, and reacting the same with the compound [III'], or alternatively, the compound [I''] can be prepared by reacting the compound [III'] with the urea bond forming agent of the formula:



15 wherein W^1 and W^2 have the same meanings as defined above,

to give the compound of the formula [VIII']:




wherein Ring B, R^4 and W^2 have the same meanings as
 20 defined above,

subsequently leading the compound [VIII'] to a reactive derivative thereof, and reacting the same with the compound [II].

As the reactive derivative, for example, the compound

in which W^2 is lead to the group as shown by the formula:



in the compound [VIII-a] or the compound [VIII'].

The reaction of the compound [II] or the compound [III'] with a urea bond forming agent can proceed, for example, at 0°C to 80°C, preferably at 0°C to 50°C. Further, any solvent can be used as long as it does not exert any bad effect on the reaction, for example, acetonitrile, dichloromethane, tetrahydrofuran, etc. can be used appropriately.

The reaction to lead the compound [VIII-a] or the compound [VIII'] to a reactive derivative thereof can be carried out using a derivative-leading agent such as methyl iodide, for example, 0°C to 80°C, preferably at 0°C to 50°C. Further, any solvent can be used as long as it does not exert any bad effect on the reaction, for example, acetonitrile, dichloromethane, tetrahydrofuran, etc. can be used appropriately.

The reaction of each reactive derivative with the compound [III] or the compound [II] can be carried out in the presence of a base, for example, at 0°C to 80°C, preferably at 0°C to 50°C. Further, triethylamine etc. can be used as a base, and any solvent can be used as long as it does not exert any bad effect on the reaction, for example, acetonitrile, dichloromethane, tetrahydrofuran, etc. can be used appropriately.

The compound [I] of the present invention can be also prepared by converting the group R^1 and group R^3 of the compound obtained in the above described method, to a desired substituent. Method for conversion of the substituents can be appropriately selected, depending on kinds of desired substituents, and the following (method a) to (method q) can be employed.

(method a)

The compound [I] in which R¹ is a group comprising a substituted hydroxyl group (for example, an optionally substituted alkoxy group, a substituted carbonyloxy group or 5 alkylsulfonyloxy group, etc.) in the formula [I] can be prepared by subjecting the corresponding compound having hydroxyl group as R¹ to alkylation, acylatoin or sulfonylation by a conventional method. For example, alkylation can proceed at -10°C to 80°C, acylatoin can 10 proceed at 5°C to 80°C, and sulfonylation can proceed at 5°C to 80°C.

(method b)

The compound [I] in which R¹ is a group comprising a substituted amino group in the formula [I] can be prepared by 15 substituting the corresponding compound having an amino group as R¹ with substituent(s) of the amino group by a conventional method (for example, an alkoxy carbonyl group such as tert-butoxycarbonyl, an arylalkoxycarbonyl group such as benzyloxycarbonyl group, etc., an alkanoyl group such as 20 formyl group, acetyl group, propionyl group, etc., an alkyl group such as methyl group, ethyl group, propyl group, etc., an alkylsulfonyl group such as methanesulfonyl group, ethanesulfonyl group, etc., an alkenylsulfonyl group such as vinylsulfonyl group, etc., a heterocyclic group such as 25 pyridyl group, etc., etc.). Alternatively, it can be prepared by using a carbamate synthesizing reagent such as N,N'-succinimidylcarbonate, etc., by reacting with, for example, an alkoxyalkylalcohol, etc. Substitution can be suitably carried out by a conventional method, depending on 30 the kinds of the substituent, by alkylation, acylation, sulfonylation, arylatoin, etc. Further, by substituting the hydrogen atom on the amino group, it can be made into a di-substituted compound. The present reaction can proceed at - 20°C to 50°C.

35 Further, in case that the compound [I] in which R¹ is a group comprising a substituted amino group has a urea bond,

it can be prepared by reacting the corresponding amine compound and a urea bond forming agent, according to the same manner as in [method A] or, a method described in Japanese Provisional Patent Publication No.10-195037.

5 Further, the compound [I] in which R¹ is a group comprising a substituted amino group in the formula [I] can be prepared by adding an amino group-containing compound to the corresponding compound having a carbon-carbon double bond at R¹. The present reaction can be carried out by refluxing 10 a solvent under heating, or in the absence of a catalyst.
(method c)

The compound [I] in which R¹ is a group comprising an amino group in the formula [I] can be prepared by removing a protective group from the corresponding compound having a 15 protected amino group at R¹. Removal of the protecting group can be carried out by a conventional method (for example, acid treatment, base treatment, catalytic reduction, etc.). In the present reaction, a reaction by acid treatment can proceed at 5°C to 120°C, a reaction by base treatment can 20 proceed at 5°C to 40°C, and a reaction by catalytic reduction can proceed at 10°C to 40°C.

Further, the compound [I] in which R¹ is a group comprising an amino group in the formula [I] can be prepared by reducing the corresponding compound having a nitro group 25 at R¹. Reduction can be carried out, in the presence of an acid, by reacting tin chloride, zinc, etc. For example, the present reaction can be carried out while refluxing the solvent under heating.

Further, the compound [I] in which R¹ is a group comprising an amino group in the formula [I] can be prepared by subjecting the corresponding compound having a carboxyl group at R¹ to Curtius rearrangement, etc. Curtius rearrangement can be carried out, for example, according to the method described in Advanced Organic Chemistry, vol.4, 35 page 1054. That is, it can be carried out by converting a carboxyl group into an acid chloride by thionyl chloride, etc.

and subsequently, subjecting the same to azidation by sodium azide, etc., followed by hydrolysis.

(method d)

The compound [I] in which R^1 is a group comprising hydroxyl group in the formula [I] can be prepared by removing a protective group from the corresponding compound having a protected hydroxyl group at R^1 by a conventional method. Removal of the protecting group can be carried out by acid treatment, base treatment, catalytic reduction, etc.

depending on the kinds of the protecting group. The present reaction can proceed, for example, at 0°C to 80°C, particularly preferably at 5°C to 50°C.

Further, the compound [I] in which R^1 is a group comprising hydroxyl group in the formula [I] can be prepared by reducing the corresponding compound having a formyl group at R^1 . Reduction can be carried out by reacting the compound in the presence of a reductive agent such as sodium borohydride, etc. The present reaction can proceed, for example, at -80°C to 80°C, particularly preferably at -70°C to 20°C.

Further, the compound [I] in which R^1 is a group comprising hydroxyl group in the formula [I] can be prepared by reducing the corresponding compound having an ester or a carboxyl group at R^1 . Reduction can be carried out by reacting the compound in the presence of a reductive agent such as lithium aluminum hydride, etc. The present reaction can proceed, for example, at -50°C to 200°C, particularly preferably at -20°C to 60°C.

(method e)

In case that R^1 in the formula [I] is hydroxyl group and it has an asymmetric center at the bonding portion, the configuration of the compound can be converted to the opposite configuration, for example, according to a method of Mitsunobu, et al. as described in *Synthesis*, pages 1 to 28, 1981. Specifically, conversion can be carried out by reacting the compound in the presence of triphenylphosphine,

benzoic acid and diethylazodicarboxylate, in a suitable solvent. The present reaction can proceed, for example, at 0 °C to 60 °C, particularly preferably at 5 °C to 40 °C.

(method f)

5 The compound [I] in which R¹ is a group comprising an optionally substituted thiol group in the formula [I] can be prepared by reacting the corresponding compound having hydroxyl group at R¹ with the corresponding compound comprising a thiol group, for example, according to a method 10 of Mitsunobu, et al. as described in *Synthesis*, pages 1 to 28, 1981. Specifically, reaction can be carried out by reacting the compound in the presence of triphenylphosphine, and diethylazodicarboxylate, in a suitable solvent. The present reaction can proceed, for example, while refluxing a solvent 15 under heating.

The compound [I] in which R¹ is a group comprising an optionally substituted thiol group in the formula [I] can be prepared by reacting the corresponding compound [I] having a halogen atom at R¹ with the corresponding compound comprising 20 a thiol group. The present reaction can proceed, for example, at -50 °C to 150 °C, particularly preferably at 10 °C to 100 °C.

Still further, the compound [I] in which R¹ is a group comprising an alkylthio group can be prepared by subjecting the corresponding compound [I] having a thiol group at R¹ or 25 the corresponding compound having a protective thiol group (for example, an acetylated thiol group) to alkylation. The present reaction can proceed in the presence of a base, for example, at -10 °C to 80 °C, particularly preferably at 5 °C to .50 °C.

30 (method g)

The compound [I] in which R¹ in the formula [I] is a group comprising a substituted amino group can be prepared by subjecting the corresponding compound [I] having hydroxyl group at R¹ to amination, for example, according to a method 35 of Mitsunobu, et al. as described in *Synthesis*, pages 1 to 28, 1981.

(method h)

The compound [I] in which R¹ in the formula [I] is a group comprising a free carboxyl group can be prepared by subjecting the corresponding compound [I] having an esterified carboxyl group at R¹ to deesterification, according to the conventional method (for example, by hydrolysis with a base such as sodium hydroxide, etc., acid treatment with hydrogen chloride, hydrogen bromide, etc., reduction under hydrogen atmosphere using palladium (black), palladium carbon, etc., depending on the kinds of the ester residue). In the deesterification reaction, for example, hydrolysis with a base can proceed, at 5°C to 70°C, acid treatment can proceed at 5°C to 80°C, reduction can proceed at 10°C to 40°C.

15 (method i)

The compound [I] in which R¹ in the formula [I] is a group comprising an amido bond can be prepared by reacting the corresponding compound [I] having a free carboxyl group at R¹ with the corresponding amine compound, or by reacting the corresponding compound [I] having a free amino group at R¹ with the corresponding carboxylic acid compound, in the presence or in the absence of a condensing agent. As the condensing agent, there are used 1,1'-carbonyldiimidazole, 1,3-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, isobutyl chloroformate or N-methylmorpholine, etc., which are normally used in a reaction to form an amide bond from a carboxylic acid and an amine. The present reaction can proceed, for example, at -20°C to 50°C.

30 (method j)

The compound [I] in which R¹ in the formula [I] is a group comprising a heterocyclic group whose nitrogen atom is substituted by an oxo group (a nitrogen atom is oxidized) (for example, N-oxomorpholino group, etc.) can be prepared by treating the corresponding compound [I] having a heterocyclic group at R¹ with an oxidizing agent (for example, 3-

chloroperbenzoic acid, hydrogen peroxide, peracetic acid, oxone, etc.). The present reaction can proceed, for example, at 5°C to 50°C.

(method k)

5 The compound [I] in which R¹ in the formula [I] is a group comprising a heterocyclic group whose nitrogen atom is oxidized, other than the compound of the above (method j) (for example, N-alkyl-4-morpholino group, etc.) can be prepared by reacting the corresponding compound [I] having a heterocyclic 10 group at R¹ with an alkyl halide. The present reaction can proceed, for example, at 20°C to 80°C.

(method l)

15 The compound [I] in which R³ in the formula [I] is an alkyl group can be prepared by subjecting the corresponding compound [I] in which R³ is hydrogen atom to alkylation by a conventional method. The alkyl group may be substituted. The present reaction can proceed, for example, at 20°C to 80°C.

(method m)

20 The compound [I] in which R¹ in the formula [I] is a group comprising a group whose sulfur atom is mono-substituted by an oxo group (for example, a sulfinyl group, etc.) can be prepared by treating the corresponding compound [I] having a thio group at R¹ with an oxidizing agent (for 25 example, 3-chloroperbenzoic acid, peracetic acid, sodium periodate, oxone, etc.). The present reaction can proceed, for example, at -80°C to 150°C, particularly preferably at 0°C to 40°C.

(method n)

30 The compound [I] in which R¹ in the formula [I] is a group comprising a group whose sulfur atom is di-substituted by oxo groups (for example, a sulfonyl group, etc.) can be prepared by treating the corresponding compound [I] having a thio group at R¹ with an oxidizing agent (for example, 3- 35 3-chloroperbenzoic acid, peracetic acid, sodium periodate, oxone, etc.). The present reaction can proceed, for example,

at -80°C to 150°C, particularly preferably at 0°C to 40°C.
(method o)

5 The compound [I] in which R¹ in the formula [I] is a group comprising an amino group can be prepared by subjecting the corresponding compound [I] having a carbonyl group at R¹ to reductive amination. The present reaction can be carried out in the same manner as in [Method C] mentioned above.

(method p)

10 The compound [I] in which R¹ in the formula [I] is a group comprising a sulfinic acid can be prepared by reacting the corresponding compound [I] having an alkylsulfinyl group at R¹, for example, according to a method described in *Synlett*, April, pages 375 to 377, 1997.


(method q)

15 The compound [I] in which R¹ in the formula [I] is a group comprising an imidazolidinyl group or a hexahydropyrimidinyl group can be prepared by subjecting the corresponding compound [I] having an aminoalkylamino group at R¹ to cyclization, for example, in the presence of a 20 condensing agent such as a 1,1'-carbonyldiimidazole, etc. The present reaction can proceed, for example, at -20°C to 50°C.

As the solvents to be used in the reactions described in the above (method a) to (method q), any solvent can be 25 used as long as it does not affect the reaction, for example, those can be used by appropriately selecting from dioxane, ethylene glycol dimethylether, dimethylacetamide, dimethylformamide, hexamethylphosphoramide, benzene, tetrahydrofuran, toluene, ethyl acetate, an alcohol, 30 dichloromethane, carbon tetrachloride, 1,3-dimethyl-2-imidazolidine, acetic acid, diethyl ether, methoxyethane, dimethylsulfoxide, acetonitrile, water and the mixture thereof.

Incidentally, the compound [IV] as the starting 35 material in the present invention is a novel compound, and it can be prepared, for example, as shown in the chemical

formula below:



wherein R^{51} represents an alkyl group, R^{61} represents a protecting group for an amino group, R^{52} represents an alkyl group which may form a bond at a terminal thereof, X^3 represents a leaving group, X^4 represents a leaving group, and Ring A, Ring B, R^3 and R^4 have the same meanings as defined above.

That is, pyridine compound [IX] and Grignard compound [X] are subjected to a condensation reaction, and further, an


amino group is protected, to give a compound [XI]. Subsequently, it is subjected to a reduction reaction, to give a compound [XII]. Further, a carbonyl group of the compound [XII] is protected by a ketal, to prepare a compound 5 [XIII], the protecting group for the amino group is removed, to give a compound [XIV]. Subsequently, the compound [XIV] and the compound [XV] are subjected to a condensation reaction, to give a compound [XVI], followed by reacting the same with a compound [XVII], or the compound [XIV] and the 10 compound [III] are subjected to a condensation reaction, to give a compound [XVIII], and by removing the protecting group thereof, to give a compound [IV].

The compound [IV] has an asymmetric carbon, therefore, optical isomers are present based on the asymmetric carbon. 15 By using an optical isomer of the above described compound [XIV], a desired optical isomer of the compound [IV] can be prepared.

The optical isomer of the compound [XIV] can be prepared by subjecting the racemic mixture of the compound 20 [XIV] to an optical resolution by a conventional method. The optical resolution can be carried out, for example, by reacting the compound [XIV] with N-acyl-optically active amino acid or N-sulfonyl-optically active amino acid, to give two kinds of diastereomeric salts, and by separating and 25 collecting one of the diastereomeric salts, using a difference in solubilities thereof.

The acyl group of N-acyl-optically active amino acid is exemplified by acetyl group, propionyl group, tosyl group or benzyloxycarbonyl group, and the optically active amino acid 30 is exemplified by L-phenylalanine, L-leucine, L-glutamine, L-methionine, L-valine, L-threonine, D-phenylalanine or D-phenylglycine.

Further, the compound [II] as the starting material in the present invention is a novel compound, and it can be 35 prepared, for example, as shown in the chemical formula below:




wherein Ring A, R^{11} , R^{12} , R^{61} and X^1 have the same meanings as defined above.

5 That is, the compound [XII] and the compound [V] are subjected to a reductive amination, to give a compound [XIX], and by removing the protecting group of the amino group thereof, a compound [II-a] is prepared. Reductive amination can be carried out in the same manner as in [Method C].

10 In preparing the above compound [IV], each of the intermediate compounds are not limited to those as shown in the reaction formula, and a salt thereof or a reactive derivative thereof may be suitably used, as long as it does not affect the reaction.

15 Further, in the starting material [II] of the present invention, the compound [II-b] can be prepared, for example, as shown in the chemical formula below:




$\text{[XX]} \quad \text{[XXI]} \quad \text{[XXII]} \quad \text{[II-b]}$


wherein R^{53} represents an alkyl group, X^3 represents a halogen atom and Ring A has the same meaning as defined above.

That is, pyridine compound [XX] and the compound [XXI] are condensed, and the resulting compound [XXII] is reduced, to give a compound [II-b].

Further, in the starting materials of the present invention, the compound of the formula [II-c]:



wherein a symbol has the same meaning as defined above, can be prepared as shown below.



5 wherein symbols have the same meanings as defined above.

That is, the compound [XII] is reduced, to give a compound [XXIII], and deprotection of the amino group of the obtained compound [XXIII] is carried out to give the compound [II-c].

10 Although there are optical isomers of the compound [II-c], in the similar method as in the above mentioned optical resolution for the compound [XIV], it can be prepared by optical resolution from a racemic mixture.

Further, in preparation of the compound or the starting materials of the present invention, when the starting materials or the intermediates have a functional group, suitable protecting groups can be introduced to each of the functional group, by a conventional method, besides the above described method, and if they are not necessary, these protecting groups can be suitably removed.

In the present specification, the alkyl group means, for example, a straight or branched alkyl group having 1 to 6 carbon atoms such as methyl group, ethyl group, propyl group, butyl group, isobutyl group, tert-butyl group, isopentyl group, etc., preferably those having 1 to 4 carbon atoms. The alkenyl group means, for example, a straight or branched alkenyl group having 2 to 7 carbon atoms such as vinyl group, aryl group, propenyl group, isopropenyl group, etc.,

preferably those having 1 to 4 carbon atoms. The alkoxy group means a straight or branched alkoxy group having 1 to 6 carbon atoms such as methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, etc., preferably those 5 having 1 to 4 carbon atoms. The alkanoyl group means a straight or branched alkanoyl group having 1 to 6 carbon atoms such as formyl group, acetyl group, propionyl group, butyryl group, valeryl group, tert-butyloxycarbonyl group, etc., preferably those having 1 to 4 carbon atoms. The cyclic 10 lower alkyl group means a cycloalkyl group having 3 to 8 carbon atoms such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, etc., preferably those having 3 to 6 carbon atoms. Further, the halogen atom is exemplified by chlorine 15 atom, bromine atom, fluorine atom and iodine atom.

Examples

In the following, the present invention will be explained in more detail by referring to Examples and 20 Reference Examples, but the present invention is not limited by these Examples.

Example 1

(1) In 30 ml of methanol was dissolved 1.43 g of 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine, and 114 mg of sodium 25 borohydride was added thereto. The mixture was stirred at room temperature for 3 hours. To the reaction mixture were added an aqueous ammonium chloride solution and ethyl acetate, and after stirring the mixture, layers were separated. The 30 organic layer was washed with water and brine and dried, and then, the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:acetone=4:1), to give 0.99 g of 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine as shown in 35 Table 1 below.

(2) 200 mg of the compound of the above (1) was further purified by silica gel column chromatography (hexane:ethyl acetate=4:1), to give 18 mg of (a) trans-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine and 125 mg of (b) cis-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine as shown in Table 1 below.

Example 2

10 In 10 ml of tetrahydrofuran was dissolved 200 mg of (2R)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine, and 60 mg of sodium borohydride was added thereto and the mixture was refluxed. While continuously refluxing the mixture, a mixed solvent of 1 ml of methanol and 5 ml of tetrahydrofuran was added thereto dropwise. After 5 hours, the reaction mixture was poured into water and layers were separated. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed 15 with water and saturated brine and dried, and then, the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=1:1→1:2), to give 33 mg of (a) (2R,4R)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine and 160 mg of (b) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine as shown in Table 2 below.

20 Example 3

25 (2R)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine was used and treated in the same manner as in Example 2 to give (a) (2R,4R)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine and (b) (2R,4S)-1-{N-

(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine as shown in Table 2 below.

Example 4

5 In 5 ml of dimethylformamide was dissolved 150 mg of 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, and 40 mg of sodium hydride (60%) was added thereto at 0°C. To this solution, 0.2 ml of methyl iodide was added at 0°C, and the
10 mixture was stirred at room temperature for 16 hours. After water and ethyl acetate were added to this solution, and the mixture was stirred, layers were separated. The organic layer was washed with water, dried over magnesium sulfate, and concentrated under reduced pressure. The concentrated
15 residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1), to give 72 mg of (a) cis-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methoxypiperidine and 36 mg of (b) trans-1-{N-(3,5-bistrifluoromethylbenzyl)-N-
20 methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methoxypiperidine as shown in Table 3 below.

Example 5

1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine and 2-picoly1 chloride hydrochloride were used and treated in the same manner as in Example 4 above, to give 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-pyridylmethoxy)piperidine as shown in Table 4 below.

30 Example 6

In 2 ml of a toluene solution containing 98 mg of 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine were added 57.6 mg of dimethylaminoethyl chloride hydrochloride, 12.5 mg of tetrabutylammonium bromide and 1 ml of 10M aqueous sodium hydroxide solution at room temperature. After stirring the

mixture at room temperature for 2 hours, stirring was further carried out at 60°C for 16 hours. After completion of the reaction, ethyl acetate and an aqueous sodium hydrogen carbonate solution were added to the reaction mixture and 5 layers were separated. The organic layer was further washed with water, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1). The obtained oily substance was treated with 4M hydrochloric 10 acid-ethyl acetate solution. The formed precipitates were collected by filtration and dried to give 53 mg of 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-4-(1-dimethylaminoethoxy)-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride as shown in Table 4 below.

15 Example 7

1-(2-chloroethyl)piperidine hydrochloride and 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine were treated in the same manner as in Example 6, to give 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-piperidylethoxy)piperidine hydrochloride as shown in Table 4 below.

Example 8

In 3 ml of dichloromethane was dissolved 100 mg of 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine, and added thereto were 0.03 ml of piperidine and 0.018 ml of acetic acid, and the mixture was stirred. 129.7 mg of sodium triacetoxy borohydride was added thereto and the mixture was stirred at 25 room temperature for 12 hours. The reaction mixture was poured into a saturated aqueous sodium bicarbonate solution, layers were separated and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with water and brine, dried and the solvent was 30 removed by distillation under reduced pressure.

Subsequently, the residue was purified by NH silica gel

column chromatography (hexane:ethyl acetate=4:1), to give trans-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-piperidinopiperidine and cis-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-piperidinopiperidine. Each of the obtained compounds was dissolved in 1 ml of chloroform, respectively, and 0.2 ml of 4M hydrochloric acid-ethyl acetate solution was added thereto. After stirring the mixture for a while, the mixture was concentrated under reduced pressure to give 58 mg of (a) trans-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-piperidinopiperidine hydrochloride and 16 mg of (b) cis-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-piperidinopiperidine hydrochloride as shown in Table 5 below.

Examples 9 to 44

The corresponding starting materials were used and treated in the same manner as in Example 8, to give compounds as shown in Tables 6 to 18 below.

Example 45

In 20 ml of acetic acid was dissolved 2.45 g of 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine, and 3.85 g of ammonium acetate and 5 g of sodium sulfate were added thereto. The mixture was stirred at room temperature for an hour. Subsequently, 1.18 g of sodium triacetoxy borohydride was added thereto and the mixture was stirred at room temperature for 24 hours. After the reaction was completed, a 2M aqueous sodium carbonate solution, chloroform and water were added thereto. The mixture was stirred for 0.5 hours, and layers were separated. The aqueous layer was extracted again by chloroform and combined organic layer was dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=10:1). The obtained oily substance was

treated with 4M hydrochloric acid-ethyl acetate solution, and concentrated under reduced pressure. Subsequently, the concentrate was triturated by isopropyl ether, to give 1.16 g of 4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride as shown in Table 19 below.

5 Example 46

(2R)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine was used and treated in the same manner as in Example 45, to give (2R)-4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride as shown in Table 19 below.

15 Example 47

In 20 ml of a dichloromethane solution containing 1.06 g of 4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine were added 0.42 ml of triethylamine and 660 mg of dibutyloxycarbonate, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane:ethyl acetate=4:1), to give 130 mg of (a) trans-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine and 120 mg of (b) cis-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine as shown in Table 20 below.

30 Example 48

100 mg of trans-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine was treated with 4M hydrochloric acid-ethyl acetate solution. Ether and hexane were added thereto and formed precipitates were collected by filtration, washed with hexane and vacuum dried, to give 56

mg of trans-4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride as shown in Table 21 below.

Example 49

5 cis-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine was used and treated in the same manner as in Example 48, to give cis-4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-10 2-methylphenyl)piperidine hydrochloride as shown in Table 21 below.

Example 50

In 1.2 ml of dichloromethane was dissolved 60 mg of 4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine, and added thereto were 0.02 ml of triethylamine and 0.013 ml of propionyl chloride under ice-cooling, and the mixture was stirred under ice-cooling for 20 minutes. The reaction mixture was poured into saturated brine and layers were separated. The aqueous layer was extracted with dichloromethane and the combined organic layers were washed with brine, dried and the solvent was removed by distillation. The residue was purified by thin-layer silica gel chromatography (chloroform:methanol=9:1), to give 40 mg of 25 (a) trans-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-propionylaminopiperidine and 27 mg of (b) cis-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-propionylaminopiperidine as shown in Table 30 22 below.

Examples 51 to 69

The corresponding starting materials were used and treated in the same manner as in Example 50 to give compounds as shown in Tables 23 to 33 below.

35 Example 70

In 4 ml of a dichloromethane solution containing 98 mg

of 4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine were added 0.056 ml of triethylamine and 0.028 ml of acetyl chloride successively at 0°C, and the mixture was stirred at 5 0°C for 0.5 hours. After the reaction was completed, an aqueous sodium hydrogen carbonate solution and chloroform were added thereto and the mixture was stirred and layers were separated. The aqueous layer was extracted again with chloroform, and the combined organic layers were dried over 10 magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:ethyl acetate=4:1) and vacuum dried to give 86 mg of 4-acetylamino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine in 15 powder form as shown in Table 34 below.

Example 71

4-Amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine and nicotinic chloride hydrochloride were used and treated in 20 the same manner as in Example 70, to give 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(3-pyridylcarbonylamino)piperidine as shown in Table 34 below.

Example 72

25 To 3 ml of a dimethylformamide solution containing 124 mg of 4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine were added 44 mg of N-tert-butoxycarbonyl glycine, 58 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 30 and 13.5 mg of 1-hydroxy-1H-benzotriazol, and the mixture was stirred at room temperature for 16 hours. After the reaction was completed, an aqueous sodium hydrogen carbonate solution and chloroform were added thereto and the mixture was stirred and layers were separated. The aqueous layer was extracted again with chloroform, and the combined organic layers were 35 dried over magnesium sulfate and concentrated under reduced

pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1), and treated with 4M hydrochloric acid-ethyl acetate solution. The mixture was concentrated under reduced pressure. The formed precipitates 5 were washed with isopropyl ether, collected by filtration and vacuum dried to give 83 mg of 4-aminoacetyl amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride as shown in Table 35 below.

10 Example 73

4-Amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine and N,N-dimethyl glycine were used and treated in the same manner as in Example 72, to give 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-4-dimethylaminoacetyl amino-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride as shown in Table 35 below.

Example 74

20 To 25 ml of an ethanol solution containing 320 mg of cis-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(4-nitrobenzoyl)aminopiperidine was added 480 mg of tin dichloride, and the mixture was refluxed for 4 hours. After 25 the reaction was completed, ethanol was removed by distillation under reduced pressure. Added thereto were diethyl ether and an aqueous 2M sodium hydroxide solution and layers were separated. The organic layer was washed again with 2M aqueous sodium hydroxide solution and further washed 30 with water. This organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1), and the obtained oily substance was treated with 4M hydrochloric acid-ethyl acetate solution. 35 The reaction mixture was concentrated under reduced pressure and triturated by isopropyl ether, to give 152 mg of cis-4-

(4-aminobenzoyl)amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride as shown in Table 36 below.

Example 75

5 To 60 ml of a tetrahydrofuran solution containing 3.91 g of N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methylamine was added 2.34 g of 1,1'-carbonyldiimidazole, and the mixture was stirred at 40°C overnight. After the solvent was removed by distillation, ethyl acetate was added. The 10 whole organic layers were washed with water and saturated brine, and dried. The white crystals obtained by removing the solvent by distillation under reduced pressure were collected by diisopropyl ether. The obtained white crystals were dissolved in 60 ml of acetonitrile, and 3.5 ml of methyl 15 iodide was added thereto. After the reaction proceeded at 60°C for 2 hours, the solvent was removed by distillation under reduced pressure. 224 mg of the residue was dissolved in 2 ml of dichloromethane, and under ice-cooling, 100 mg of cis-2-(4-fluoro-2-methylphenyl)-4-(propanoylamino)piperidine 20 and 0.11 ml of triethylamine were added thereto and the mixture was stirred at room temperature overnight. The reaction mixture was poured into water, and layers were separated. The aqueous layer was extracted with dichloromethane, and the combined organic layers were washed 25 with water and saturated brine and dried, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=1:3), to give 83.5 mg of (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-30 propanoylaminopiperidine as shown in Table 37 below.

Examples 76 to 84

The corresponding starting materials were used and treated in the same manner as in Example 75 to give compounds 35 as shown in Tables 37 to 39 below.

Example 85

To 1 ml of an ethyl acetate solution containing 212 mg of (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine was added 2 ml of 4M hydrochloric acid-ethyl acetate solution under ice-cooling, and the mixture was stirred under ice-cooling for 30 minutes. After the solvent was removed by distillation under reduced pressure, chloroform and 2M aqueous sodium hydroxide solution were added to the residue. Layers were separated and the aqueous layer was extracted with chloroform and the combined organic layers were dried and the solvent was removed by distillation under reduced pressure, to give 177 mg of (2R,4S)-4-amino-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 40 below.

Example 86

(2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine was used and treated in the same manner as in Example 85, to give (2R,4S)-4-amino-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 40 below.

Example 87

To 2 ml of a dichloromethane solution containing 253 mg of (2R,4S)-4-amino-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine and 0.139 ml of triethylamine was added 0.071 ml of methanesulfonyl chloride under ice-cooling, and the mixture was stirred for an hour. The reaction mixture was poured into water and layers were separated. The aqueous layer was extracted with chloroform, and the combined organic layers were washed and dried, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=1:1), to give 243 mg of

(2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-methanesulfonylamino-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 41 below.

Example 88

5 (2R,4S)-4-amino-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine and ethanesulfonyl chloride were used and treated in the same manner as in Example 87, to give (2R,4S)-1-[N-{1-(R)-(3,5-

10 bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-ethanesulfonylamino-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 41 below.

Example 89

To 1 ml of a dimethylformamide solution containing 58.4 mg of (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-methanesulfonylamino-2-(4-fluoro-2-methylphenyl)piperidine was added 4.6 mg of sodium hydride under ice-cooling. The mixture was stirred for 30 minutes and 0.010 ml of methyl iodide was added thereto and the mixture was further stirred for an hour. The reaction mixture was poured into water, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water and saturated brine and dried, and the solvent was removed by distillation under reduced pressure. Subsequently, the residue was purified with silica gel column chromatography (hexane:ethyl acetate=2:1), to give 36.7 mg of (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-(N-methanesulfonyl-N-methyl)amino-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 41 below.

Example 90

(2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-ethanesulfonylaminopiperidine was used and treated in the same manner as in Example 89, to give (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-

methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-methyl N-ethanesulfonyl)aminopiperidine as shown in Table 41 below.

Example 91

To 20 ml of a toluene solution containing 985 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine and 129 mg of tetrabutylammonium bromide and 10 ml of 10M aqueous sodium hydroxide solution was added 1.21 ml of 2-(2-bromoethoxy)tetrahydropyran at room temperature, and the temperature of the mixture was raised to 60°C to 70°C and the mixture was stirred overnight. Further added thereto was 2.42 ml of 2-(2-bromoethoxy)tetrahydropyran and the mixture was stirred overnight. The reaction mixture was poured into a saturated sodium bicarbonate solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine and dried, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=3:2), to give 1.12 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-(tetrahydropyran-2-yloxy)ethoxy)piperidine as shown in Table 42 below.

Example 92

To 30 ml of a methanol solution containing 1.04 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-(tetrahydropyran-2-yloxy)ethoxy)piperidine was added 64 mg of p-toluenesulfonic acid monohydrate, and the mixture was stirred for 20 minutes. The reaction mixture was concentrated under reduced pressure, and then, the residue was purified by silica gel column chromatography (chloroform:ethyl acetate=1:1), give 703 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethoxy)piperidine as shown in Table 42 below.

Example 93

To 2 ml of a tetrahydrofuran solution containing 53.6 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethoxy)piperidine, 13.8 mg of 4H-[1,2,4]-triazole and 24.4 mg of triphenylphosphine was added 0.092 ml of 40% diethylazodicarboxylate solution in toluene under ice-cooling. The temperature of the mixture was raised to room temperature and the mixture was stirred overnight. Further, the 10 temperature was raised to 50°C, 24.4 mg of triphenylphosphine was added thereto, and the mixture was stirred for 30 minutes. The reaction mixture was poured into water and extracted with ethyl acetate, and the organic layer was washed with saturated brine, dried and the solvent was removed by 15 distillation. The residue was purified by silica gel column chromatography (chloroform:ethyl acetate=1:1 and chloroform:methanol=19:1) to give 43.2 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-(1,2,4)triazolylethoxy)piperidine 20 as shown in Table 42 below.

Examples 94 and 95

The corresponding starting materials were treated in the same manner as in Example 93, to give compounds as shown in Table 42 below.

25 Example 96

To 2 ml of a dichloromethane solution containing 215 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethoxy)piperidine and 0.084 ml of triethylamine was 30 added 0.037 ml of methanesulfonyl chloride under ice-cooling, and the mixture was stirred for 30 minutes. The reaction mixture was poured into water and extracted with chloroform. The organic layer was washed with brine and dried, and the solvent was removed by distillation under reduced pressure. 35 The residue was purified by silica gel column chromatography (chloroform:ethyl acetate= 2:1), to give 189 mg of (2R,4S)-1-

(N-(3,5-bistrifluoromethylbenzyl)-N-methyl)aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-methanesulfonyloxyethoxy)piperidine as shown in Table 42 below.

5 Example 97

(1) To 1 ml of a dichloromethane solution containing 61.5 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl)aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-methane sulfonyloxyethoxy)piperidine and 0.028 ml of triethylamine 10 was added 0.013 ml of morpholine under ice-cooling, and the mixture was refluxed under heating overnight. Further added thereto was 1 ml of morpholine and the mixture was stirred for 8 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed 15 with saturated brine and dried, and the solvent was removed by distillation. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1) and NH silica gel column chromatography (hexane:ethyl acetate= 2:1), to give 36.3 mg of (2R,4S)-1-{N-(3,5- 20 bistrifluoromethylbenzyl)-N-methyl)aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-morpholinoethoxy)piperidine.

(2) In 1.0 ml of chloroform was dissolved 30.7 mg of the compound of the above (1), and 0.02 ml of 4M hydrochloric acid-ethyl acetate solution was added thereto. The mixture 25 was stirred for a while and concentrated under reduced pressure, to give 35.3 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl)aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-morpholinoethoxy)piperidine hydrochloride as shown in Table 42 below.

30 Example 98

(2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl)aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-methane sulfonyloxyethoxy)piperidine and diethylamine were used and treated in the same manner as in Example 97(1), to give 35 (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl)aminocarbonyl-4-(2-diethylaminoethoxy)-2-(4-fluoro-2-

methylphenyl)piperidine as shown in Table 42.

Example 99

In 2 ml of a dichloromethane was dissolved 200 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-5-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, and subsequently, 0.1 ml of ethyl isocyanate and 0.1 ml of triethylamine were added thereto and the mixture was stirred under heating at 60°C for 3 days. The reaction mixture was cooled down to room temperature, 10 water and chloroform were added thereto, and layers were separated. The aqueous layer was extracted again with chloroform, and the combined organic layers were dried over sodium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was purified by 15 silica gel column chromatography (hexane:ethyl acetate=1:1), to give 78 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-4-ethylaminocarbonyloxy-2-(4-fluoro 2-methylphenyl)piperidine as shown in Table 42 below.

Example 100

20 In 2 ml of a dichloromethane was dissolved 200 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, and subsequently, 0.1 ml of morpholin-4-carboxylic chloride and 0.1 ml of triethylamine were added 25 thereto and the mixture was stirred under heating at 60°C for 3 days. After the reaction mixture was cooled down to room temperature, water and chloroform were added thereto, and layers were separated. The aqueous layer was extracted again with chloroform, and the combined organic layers were 30 dried over sodium sulfate. After the solvent was removed by distillation under reduced pressure, the residue was purified by silica gel column chromatography (hexane:ethyl acetate=1:1), to give 68 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-35 2-methylphenyl)-4-morpholinocarbonyloxpiperidine as shown in Table 42 below.

Example 101

In 5 ml of tetrahydrofuran was dissolved 248 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-5 hydroxypiperidine, and subsequently, 81 mg of 1,1'-carbonyldiimidazole was added thereto and the mixture was stirred under heating at 60°C for 16 hours. The reaction mixture was cooled down to room temperature, water and chloroform were added and layers were separated. The aqueous 10 layer was extracted again with chloroform, and the combined organic layers were further washed with water. The organic layer was dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. The obtained concentrated residue was purified by NH silica gel column 15 chromatography (hexane:ethyl acetate= 1:1), to give 135 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-imidazolyl)carbonyloxypiperidine as shown in Table 42 below.

Example 102

20 (1) In 3 ml of acetonitrile was dissolved 298 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-imidazolyl)carbonyloxypiperidine, and subsequently, 0.06 ml of methyl iodide was added thereto and the mixture was 25 stirred under heating for an hour. The solution was cooled down to room temperature and the solvent was removed by distillation under reduced pressure. To the residue were added 2.5 ml of methylene chloride, 0.11 ml of 4-methylpiperazine and 0.14 ml of triethylamine and the mixture 30 was stirred at room temperature for 16 hours. To the reaction mixture was added an aqueous sodium hydrogen carbonate solution and chloroform and the mixture was stirred for 30 minutes. The layers were separated and the obtained organic layer was washed further with water, and dried over 35 magnesium sulfate. The solvent was removed by distillation under reduced pressure, and resultant residue was purified by

NH silica gel column chromatography (hexane:ethyl acetate=2:1), to give (2R,4S)- 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl- 2-(4-fluoro-2-methylphenyl)-4-(4-methylpiperazino)carbonyloxy-5-piperidine.

(2) The compound of the above (1) was treated with 4M hydrochloric acid-ethyl acetate solution, to give 78 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-4-(4-methylpiperazino)carbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride as shown in Table 43 below.

Examples 103 to 105

The corresponding starting materials were used and treated in the same manner as in Example 102 (1) and (2), to give the compounds as shown in Table 43 below.

Example 106

(1) In 100 ml of tetrahydrofuran were dissolved 5 g of cis-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, 10.5 g of triphenylphosphine and 4.88 g of benzoic acid, and subsequently, added thereto was 18.3 ml of a 40 % diethylazodicarboxylate-toluene solution under ice-cooling and the mixture was stirred at room temperature for 3 hours. To the reaction mixture were added water and ethyl acetate and the mixture was stirred for 30 minutes. The solution was separated by layers, and the obtained organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=4:1), to give 4.36 g of trans-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-4-benzyloxy-2-(4-fluoro-2-methylphenyl)piperidine.

(2) In 10 ml of methanol was dissolved 1.4 g of the compound of the above (1), and subsequently, added thereto was 325 mg of potassium carbonate and the mixture was stirred at room temperature for 16 hours. After the solution was

concentrated under reduced pressure for the solvent to be removed by distillation, water and ethyl acetate were added thereto and layers were separated. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=4:1), to give 0.68 g of trans-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine as shown in Table 44 below.

10 Example 107

In 10 ml of tetrahydrofuran were added 98 mg of trans-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, 70 mg of [1, 2,4] triazole and 262 mg of triphenylphosphine, and subsequently added thereto was 0.48 ml of a 40% diethylazodicarboxylate-toluene solution, and the mixture was stirred under reflux for 16 hours. After reaction is completed, an aqueous sodium bicarbonate solution and ethyl acetate were added thereto and the mixture was stirred for 30 minutes. The reaction mixture was separated by layers, and the obtained organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=9:1), to give 46 mg of cis-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1,2,4-triazolyl)piperidine as shown in Table 44 below.

Example 108

Cis-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine and 4,6-dihydroxy-2-mercaptopurimidine were used and treated in the same manner as in Example 107, to give a compound as shown in Table 45 below.

Example 109

35 (2R,4S)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-

fluoro-2-methylphenyl)-4-hydroxypiperidine was used and treated in the same manner as in Example 106 (1) and (2), to give (2R,4R)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine as shown in Table 46 below.

5 Examples 110 to 112

10 The corresponding starting materials were used and treated in the same manner as in Example 107, to give compounds as shown in Table 46 below.

Example 113

15 (1) 30 ml of tetrahydofuran solution containing 1.2 ml of triethylphosphonoacetate was ice cooled and slowly added thereto was sodium hydride. While keeping the same temperature, the mixture was stirred for 30 minutes and added dropwise thereto was 30 ml of a tetrahydofuran solution containing 3.02 g of (2R)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine. The mixture was 20 stirred at room temperature overnight. The reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with water and saturated brine and dried, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica 25 gel column chromatography (hexane:ethyl acetate=4:1), to give (2R)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-ethoxycarbonylmethylidene-2-(4-fluoro-2-methylphenyl)piperidine as a colorless liquid.

30 (2) The compound of the above (1) was dissolved in 50 ml of methanol, and added thereto was 500 mg of palladium-carbon, and the mixture was stirred under hydrogen atmosphere at room temperature overnight. The catalyst was removed and methanol was removed by distillation under reduced pressure, and the residue was purified by silica gel column 35 chromatography (hexane:ethyl acetate=4:1), to give 3.23 g of (2R)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-

methyl]aminocarbonyl-4-ethoxycarbonylmethyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 46 below.

Example 114

(1) In 20 ml of methanol was dissolved 3.23 g of (2R)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-4-ethoxycarbonylmethyl-2-(4-fluoro-2-methylphenyl)piperidine, and added thereto was 5.73 ml of a 2M aqueous sodium hydroxide solution. The mixture was stirred at room temperature overnight. After neutralizing the mixture by 2M hydrochloric acid, methanol was removed by distillation under reduced pressure, and an aqueous layer was extracted with ethyl acetate. The organic layer was washed with water and saturated brine and dried and the solvent was removed by distillation under reduced pressure, to give 2.97 g of (2R)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-4-carboxymethyl-2-(4-fluoro-2-methylphenyl)piperidine as yellow powder.

(2) 200 mg of the compound of the above (1) was dissolved in 2 ml of dimethylformamide, and added thereto were 84 mg of 1-ethyl 3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 65 mg of 1-hydroxy-1H-benzotriazole and 0.037 ml of morpholine and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate, and washed with a saturated aqueous citric acid solution, a saturated aqueous sodium bicarbonate solution and saturated brine. The organic layer was dried, and the solvent was removed by distillation to obtain the residue, and the residue was purified by NH silica gel column chromatography (hexane:ethyl acetate= 2: 1), to give 138 mg of (2R)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-morpholinocarbonylmethylpiperidine as shown in Table 46 below.

Examples 115 to 117

The corresponding starting materials were used and treated in the same manner as in Example 114 (2), to give compound as shown in Table 46 below.

Example 118

(1) In 10 ml of ethanol was dissolved 1.49 g of (2R)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine, and added thereto was 226 mg of hydroxylamine hydrochloride, 267mg of sodium acetate. The mixture was stirred overnight. Ethanol was removed by distillation under reduced pressure and water was added to the residue and extracted with ethyl acetate. The organic layer was washed with saturated brine and dried. The solvent was removed by distillation under reduced pressure to give a compound in a resin state.

(2) The compound of the above (1) was dissolved in 50 ml of methanol, and added thereto was 844 mg of nickel chloride. The mixture was ice cooled and slowly added thereto was 224 mg of sodium borohydride. After stirring the mixture overnight, it was concentrated under reduced pressure, and water and ethyl acetate were added thereto and the layers were separated. The organic layer was washed with saturated brine and dried. The solvent was removed by distillation under reduced pressure, to give 1.44 g of (2R)-4-amino-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 47 below.

Example 119

(2R)-1-[N-(3,5-bistrifluoromethylphenyl)methyl N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine was used and treated in the same manner as in Example 119 (1) and (2), to give (2R)-4-amino-1-[N-(3,5-bistrifluoromethylphenyl)methyl-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table47 below.

Example 120

(2R)-4-amino-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine was used and treated in the same manner as in Example 50, to give (a) (2R,4S)-1-[N-(1-

(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-pyrazinylcarbonylamino)piperidine and (b) (2R,4R)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-pyrazinylcarbonylamino)piperidine as shown in Table 47 below.

Example 121

In 2 ml of an acetonitrile solution containing 80 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-morpholinopiperidine was added 0.034 ml of methyl iodide and the mixture was stirred at 60°C overnight. The solvent was removed by distillation, and precipitated yellow powder was dried, to give 98 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-methyl-4-morpholinio)piperidine iodide as shown in Table 48 below.

Example 122

(2R,4S)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-morpholinopiperidine was used and treated in the same manner as in Example 121, to give (2R,4S)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-methyl-4-morpholinio)piperidine iodide as shown in Table 48 below.

Example 123

In 2 ml of a dichloromethane solution containing 80 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-morpholinopiperidine was added 34 mg of 3-chloroperbenzoic acid, and the mixture was stirred at room temperature overnight. The reaction mixture was poured into a saturated aqueous sodium bicarbonate solution, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with water and saturated brine and dried, and the solvent was removed by distillation under reduced

pressure. The precipitated white powder was dried, to give 79 mg of (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-oxo morpholino)piperidine as
5 shown in Table 48 below.

Example 124

(2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-morpholinopiperidine was used and
10 treated in the same manner as in Example 123, to give (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-oxo morpholino)piperidine as shown in Table 48 below.

Examples 125 to 127

15 The corresponding starting materials were used and treated in the same manner as in Example 8, to give compounds as shown in Table 49 below.

Examples 128 to 136

20 The corresponding starting materials were used and treated in the same manner as in Example 50, to give compounds as shown in Tables 49 to 51 below.

Example 137

In 2 ml of dichloromethane was dissolved 263 mg of (2R)-4-amino-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine, and at room temperature, were added thereto 52 μ l of 2-chloro ethylisocyanate and 167 μ l of triethylamine, and the mixture was stirred for 2 hours. To the solution was added a saturated sodium hydrogen carbonate solution, the dichloromethane layer was separated, and the aqueous layer was further extracted with chloroform. The combined organic layers were washed with saturated brine, dried and concentrated. The residue was purified by silica gel column chromatography (chloroform:methanol=9:1), to give 109 mg of (2R)-4-(2-chloroethyl)ureido-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-

2-methylphenyl)piperidine as shown in Table 51.

Example 138

In 20 ml of dimethylformamide were dissolved 2.65 g of (2R)-4-amino-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride and 1 g of 5-formylfuran-2-carboxylic acid, and added thereto were 1.92 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 0.6 g of 1-hydroxy-1H-benzotriazole and 1.4 ml of triethylamine. The mixture was stirred at room temperature for 3 hours. After the reaction was completed, an aqueous citric acid solution and ethyl acetate were added thereto and layers were separated. The organic layer was further washed with saturated brine, and the combined organic layers were dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=2:1), to give 289 mg of (a) (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-4-(5-formylfuran-2-yl)carbamoyl-2-(4-fluoro-2-methylphenyl)piperidine and 185 mg of (b) (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-4-(5-formylfuran-2-yl)carbamoyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 52 below.

Examples 140 to 168

The corresponding starting materials were used and treated in the same manner as in Example 138, to give compounds as shown in Tables 53 to 57 below.

Example 169

In 1 ml of tetrahydrofuran was dissolved 80 mg of (2R,4S)-4-amino-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine, and under ice-cooling, 25.7 mg of 1,1-carbonyldimidazole was added thereto and the mixture was stirred under ice-cooling for 30 minutes. To the solution, 19 μ l of 2-aminoethanol, 44 μ l of triethylamine were added under ice-cooling, and the mixture was stirred at

room temperature for 22 hours. The solvent was removed by distillation and to the residue, and added thereto were water and dichloromethane and layers were separated. The organic layer was washed with saturated brine, dried and concentrated.

5 To the residue was added isopropyl ether, and precipitated white crystals were collected by filtration, to give 74 mg of (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethyl)ureidopiperidine as shown in Table 57 below.

10 Examples 170 to 173

The corresponding starting materials were used and treated in the same manner as in Example 169, to give compounds as shown in Table 57 below.

Examples 174 to 177

15 The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds as shown in Table 58 below.

Example 178

20 In 10 ml of dichloromethane was dissolved 1.01 g of (2R,4S)-4-amino-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine and 0.558 ml of triethylamine, and under ice-cooling, added thereto was 0.314 ml of 2-chloroethanesulfonylchloride, and the mixture was 25 stirred for 4 hours. The solution was poured into water, layers were separated, and the aqueous layer was further extracted with dichloromethane. The combined organic layers were washed with saturated brine, dried and concentrated. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1), to give 725 mg of (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-ethylenesulfonylamino-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 58 below.

Example 179

35 (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-

fluoro-2-methylphenyl)-4-methylaminopiperidine was used and treated in the same manner as in Example 178, to give (2R,4S)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-4-(1-ethylenesulfonyl-1-methylamino)-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 58.

5 Examples 180 to 181

The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds as shown in Table 59 below.

10 Examples 183 to 184

The corresponding starting materials were used and treated in the same manner as in Example 89, to give compounds as shown in Table 59 below.

Example 185

15 (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine and 2-methoxyethyl chloride were used and treated in the same manner as in Example 91, to give (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-methoxyethoxy)piperidine as shown in Table 59 below.

20 Examples 186 to 189

The corresponding starting materials were used and treated in the same manner as in Example 91 and Example 92, to give compounds as shown in Tables 59 to 60 below.

Example 190

25 (2R,4S)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethoxy)piperidine and methanesulfonyl chloride were used and treated in the same manner as in Example 96, to give (2R,4S)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-methanesulfonyloxyethoxy)-piperidine as shown in Table 60 below.

30 Examples 191 to 196

The corresponding starting materials were used and treated in the same manner as in Example 97, to give compounds as shown in Tables 60 to 61 below.

Examples 197 to 198

5 The corresponding starting materials were used and treated in the same manner as in Example 101, to give compounds as shown in Table 62 below.

Examples 199 to 205

10 The corresponding starting materials were used and treated in the same manner as in Example 102 (1) or in Example 102 (1) and (2), to give compounds as shown in Table 63 below.

Example 206

15 (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-piperidinopiperidine were used and treated in the same manner as in Example 123, to give (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-oxopiperidino)piperidine as shown in 20 Table 65 below.

Example 207

25 In 4 ml of ethanol was dissolved 124 mg of (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-4-(5-formylfuran-2-yl)carbamoyl-2-(4-fluoro-2-methylphenyl)piperidine, and added thereto was 3.8 mg of sodium borohydride, and the mixture was stirred at room temperature for 2 hours. To the solution was added an aqueous sodium hydrogen carbonate solution, and the mixture was stirred for 10 minutes and concentrated, and ethanol was 30 removed by distillation. To the residue was added ethyl acetate and water, and layers were separated. The organic layer was dried and concentrated. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1), to give 68 mg of (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(5-hydroxymethylfuran-2-

yl)carbamoylpiperidine as shown in Table 65 below.

Example 208

In 4 ml of dichloroethane were dissolved 124 mg of (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-4-(5-formylfuran-2-yl)carbamoyl-2-(4-fluoro-2-methylphenyl)piperidine, 44 μ l of morpholine and 2.9 μ l of acetic acid, and added thereto 106 mg of sodium triacetoxyborohydride, and the mixture was stirred at room temperature for 3 hours. To the solution was added an aqueous sodium carbonate solution and chloroform, and the mixture was stirred for 10 minutes and layers were separated. The organic layer was dried over magnesium sulfate and concentrated. The residue was purified by NH silica gel column chromatography (n-hexane:ethyl acetate=1:1). The obtained oily substance was treated with 4M hydrochloric acid-ethyl acetate solution, to give 78 mg of (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(5-morpholinomethylfuran-2-yl)carbamoylpiperidine hydrochloride as shown in Table 65 below.

Example 209

In mixture of 3.3 ml of toluene and 0.4 ml of dichloromethane was dissolved 197 mg of (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, and added thereto was 78 mg of 1,1'-carbonyldiimidazole. The mixture was stirred at 60°C for 4 hours. Distilled water was added thereto and the mixture was extracted with chloroform, dried over magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in 3.7 ml of acetonitrile, and added thereto was 100 μ l of methyl iodide, and the mixture was stirred at 50°C for 3 hours. The solution was concentrated under reduced pressure, and to the residue were added 3.6 ml of toluene and 156 μ l of thiomorpholine, and the mixture was stirred at 70°C for 16 hours. Distilled water was added thereto and the mixture was extracted with chloroform, dried

over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1→1:2), to give 197 mg of (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-thiomorpholinocarbonyloxypiperidine as shown in Table 65 below.

5 Examples 210 to 212

The corresponding starting materials were used and treated in the same manner as in Example 209, to give 10 compounds as shown in Table 65 below.

Example 213

In 1.9 ml of dichloromethane was dissolved 62 mg of (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-thiomorpholinocarbonyloxypiperidine, and under ice-cooling, 22 mg of 3-chloroperbenzoic acid was added thereto and the mixture was stirred at 0°C for 30 minutes. The solution was extracted by adding a 0.1M aqueous sodium hydroxide solution and ethyl acetate. The organic layer was dried over 15 magnesium sulfate and concentrated. The residue was purified by thin-layer silica gel chromatography (chloroform:acetone=4:1), to give 63 mg of (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-oxothiomorpholino)carbonyloxypiperidine 20 as shown in Table 65 below.

Example 214

In 2.4 ml of dichloromethane was dissolved 79 mg of (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-thiomorpholinocarbonyloxypiperidine, and added thereto was 68 mg of 3-chloroperbenzoic acid, and the mixture was stirred at room temperature for 4 hours. The solution was extracted by adding a 0.1M aqueous sodium hydroxide solution and ethyl acetate. The organic layer was dried over magnesium sulfate 30 and concentrated. The residue was purified by thin-layer silica gel chromatography (chloroform:acetone=4:1), to give 35

76 mg of (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-4-(1,1-dioxothiomorpholino)carbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 65 below.

5 Example 215

In 1 ml of tetrahydrofuran was dissolved 78 mg of (2R,4S)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2,2,5-trimethyl [1,3] dioxolan-5-yl)carbamoylpiperidine, and under 10 ice-cooling, 0.5 ml of a 2M aqueous hydrochloric acid solution was added thereto. After 15 minutes, the temperature was raised to room temperature and the mixture was further stirred for 30 minutes. The mixture was poured into a saturated aqueous sodium hydrogen carbonate solution, 15 and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried and concentrated. The residue was purified by silica gel column chromatography (chloroform:ethyl acetate=2:1), to give 64 mg of (2R,4S)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1,1-di(hydroxymethyl)ethyl)carbamoylpiperidine as shown in Table 20 66 below.

Example 216

In 1 ml of dichloromethane was dissolved 50.5 mg of (2R,4S)-4-amino-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine, and under ice-cooling, 25.3 mg of methylisocyanate was added thereto. After the temperature of the mixture was raised to room temperature, 30 the mixture was stirred for 30 minutes. The solution was poured into water, the dichloromethane layer was separated and the aqueous layer was further extracted with chloroform. The combined organic layers were washed with saturated brine, dried and concentrated. The residue was purified by silica 35 gel column chromatography (chloroform:methanol=19:1), to give 47.9 mg of (2R,4S)-1-[N-(1-(R)-(3,5-

bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methylureidopiperidine as shown in Table 66 below.

Example 217

5 (2R,4S)-4-amino-1-[N-{1-(R)-(3,5-
bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-
fluoro-2-methylphenyl)piperidine and tert-butyl isocyanate
were used and treated in the same manner as in Example 216,
to give (2R,4S)-1-[N-{1-(R)-(3,5-
10 bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-
tert-butylureido-2-(4-fluoro-2-methylphenyl)piperidine as
shown in Table 66.

Example 218

In 1 ml of dichloromethane was dissolved 50.5 mg of
15 (2R,4S)-4-amino-1-[N-{1-(R)-(3,5-
bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-
fluoro-2-methylphenyl)piperidine, and under ice-cooling, 42
μl of triethylamine and 18μl of dimethylcarbamoyl chloride
were added thereto. After the temperature of the mixture was
20 raised to room temperature, the mixture was stirred overnight.
The solvent was poured into water, and the dichloromethane
layer was separated, and the aqueous layer was further
extracted with chloroform. The combined organic layers were
washed with saturated brine, dried and concentrated. The
25 residue was purified by silica gel column chromatography
(chloroform:methanol=39:1), to give 41.8 mg of (2R,4S)-1-[N-
{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-
methyl]aminocarbonyl-4-(3,3-dimethylureido)-2-(4-fluoro-2-
methylphenyl)piperidine as shown in Table 66 below.

30 Examples 219 to 224

The corresponding starting materials were used and
treated in the same manner as in Example 216, to give
compounds as shown in Table 67 below.

Example 225

35 (1) 80 mg of (2R,4S)-4-amino-1-[N-{1-(S)-(3,5-
bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-

fluoro-2-methylphenyl)piperidine was used and treated in the same manner as in Example 216, to give (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(4-methyl

5 piperazinocarbamoyl)piperidine.

(2) The compound of the above (1) was dissolved in 1 ml of ethyl acetate, and under ice-cooling, 0.5 ml of 4M hydrochloric acid-ethyl acetate solution was added thereto and the mixture was stirred for 30 minutes under ice-cooling.

10 The solvent was removed by distillation under reduced pressure and added thereto was diethyl ether. Precipitated white crystals were collected by filtration, to give 80 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(4-methyl

15 piperazinocarbamoyl)piperidine hydrochloride as shown in Table 67 below.

Example 226

In 2 ml of dichloromethane was dissolved 100 mg of (2R,4S)-4-amino-1-[N-(1-(S)-(3,5-

20 bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine, and under ice-cooling, 33 μ l of triethylamine and 19 μ l of methylchloroformate were added thereto and the mixture was stirred under ice-cooling for 30 minutes. The solution was poured into water and the

25 dichloromethane layer was separated, and the aqueous layer was further extracted with dichloromethane. The combined organic layers were washed with saturated brine, dried and concentrated. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1), to give 80 mg of

30 (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methoxycarbamoylpiperidine as shown in Table 66 below.

Examples 227 to 229

The corresponding starting materials were used and

35 treated in the same manner as in Example 226, to give compounds as shown in Table 68 below.

Example 230

In 1.2 ml of acetonitrile was dissolved 22 mg of 2-ethoxy-ethanol, and 94 mg of N,N'-disuccinimidylcarbonate and 0.1 ml of triethylamine were added thereto, and the mixture 5 was stirred at room temperature for 1.5 hours. The solvent was removed by distillation, and to the residue were added a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate, and extracted. The organic layer was washed with saturated brine, dried, and concentrated. The residue 10 was dissolved in 0.8 ml of dichloromethane, and added thereto were 80 mg of (2R,4S)-4-amino-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine and 33 μ l of triethylamine, and the mixture was stirred at room temperature for 30 15 minutes. To the solution were added a saturated aqueous sodium hydrogen carbonate solution and dichloromethane and extracted. The combined organic layers were washed with saturated brine, dried and concentrated. The residue was purified by thin-layer silica gel chromatography 20 (chloroform:methanol=19:1), to give 85 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-4-(2-ethoxyethoxy)carbamoyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 68 below.

Example 231

25 3-hydroxy-3-methylbutanol and (2R,4S)-4-amino-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine were used and treated in the same manner as in Example 230, to give (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(3-hydroxy-3-methylbutoxy)carbamoylpiperidine as shown in Table 68 below.

30 Example 232

(1) In 1 ml of tetrahydrofuran was dissolved 119 mg of 35 (2R,4S)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-

vinylsulfonylaminopiperidine. Added thereto was 26 μ l of morpholine at room temperature, and the mixture was refluxed under heating. Five hours later, 26 μ l of morpholine was added and the mixture was further refluxed under heating for 5 2.5 hours. The solution was concentrated and the residue was purified by silica gel column chromatography (chloroform:methanol=19:1), to give 129 mg of (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-morpholinoethyl)sulfonylaminopiperidine.

10 (2) In 1 ml of chloroform was dissolved 34.1 mg of the compound of the above (1), and added thereto 25 μ l of 4M hydrochloric acid-ethyl acetate solution. The mixture was concentrated, to give 33.1 mg of (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-morpholinoethyl)sulfonylaminopiperidine hydrochloride as shown in Table 69 below.

15 Examples 233 to 238
20 The corresponding starting materials were used and treated in the same manner as in Example 232 (1) and (2), to give compounds as shown in Table 69 below.

Example 239
25 In mixture of 1.6ml of dimethylformamide and 0.2 ml of dichloromethane was dissolved 101 mg of (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, and added thereto were 39 mg of (S)-(-)-2-pyrrolidone-5-carboxilic acid, 58 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 30 hydrochloride and 12 mg of 4-(dimethylamino)pyridine, and the mixture was stirred at room temperature for 6 hours, followed by stirring at 60°C for 4 days. To the solution was added a 5% aqueous citric acid solution, and the mixture was extracted with chloroform. The organic layer was washed with 35 a saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over magnesium sulfate and

concentrated. The residue was purified by silica gel column chromatography (chloroform:acetone=4:1→2:1), to give 64 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-4-{(2S)-5-oxopyrrolidin-2-yl}carbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 70 below.

Example 240

(1) In a mixture of 3.2ml of toluene and 0.4 ml of dichloromethane was dissolved 179 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, and added thereto was 69 mg of 1,1'-carbonyldiimidazole, and the mixture was stirred at 60°C for 3 hours. Distilled water was added thereto and the mixture was extracted with chloroform. The organic layer was dried over magnesium sulfate, and concentrated under reduced pressure. The residue was dissolved in 3.2 ml of acetonitrile, 88 µl of methyl iodide was added thereto, and the mixture was stirred at 50°C for 3 hours. After the solution was concentrated, 3.2 ml of toluene and 114 µl of thiazolidine were added and the mixture was stirred at 70°C for 16 hours. Distilled water was added thereto and the mixture was extracted with chloroform. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=1:1→1:2), to give 141 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1,3-tetrahydrothiazol-3-yl)carbonyloxy piperidine.

(2) In 2 ml of dichloroethane was dissolved 62 mg of the compound of the above (1), and under ice-cooling, 22 mg of 3-chloroperbenzoic acid was added thereto and the mixture was stirred at 0°C for an hour. To the mixture was added a saturated aqueous sodium hydrogen carbonate solution and extracted. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue

was purified by thin-layer silica gel chromatography (chloroform:acetone=4:1), to give 42 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-oxo-5 1,3-tetrahydrothiazol-3-yl)carbonyloxypiperidine as shown in Table 70 below.

Example 241

(1) In 1.9 ml of toluene was dissolved 101 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, and added thereto were 46 μ l of isocyanate acetic acid ethyl ester and one drop of acetic acid, and the mixture was stirred at 70°C for 16 hours. The solution was concentrated and the residue was purified by silica gel 10 column chromatography (hexane:ethyl acetate=2:1→1:1), to give 124 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-4-ethoxycarbonylmethylaminocarbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine.

(2) In a mixture of 1.35 ml of tetrahydrofuran and 0.15 ml of methanol was dissolved 106 mg of the compound of the above (1), and added thereto was 92 μ l of a 2M aqueous sodium hydroxide solution, and the mixture was stirred at room temperature for 1 hour. After the solution was 15 concentrated, a 10% aqueous citric acid solution was added thereto, and the precipitates were collected by filtration and washed with water, to give 92 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-4-carboxymethylaminocarbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 70 below.

Example 242

In 0.9 ml of dimethylformamide was dissolved 61 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-4-carboxymethylaminocarbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine, and added thereto were 9 μ l of morpholine, 15 mg of 1-hydroxybenzotriazole monohydrate 20 25 30

and 19 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and the mixture was stirred at room temperature for a day. To the solution was added distilled water and the mixture was extracted with chloroform, and the 5 organic layer was dried over magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1), to give 50 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4- 10 morpholinocarbonylmethylaminocarbonyloxypiperidine as shown in Table 70 below.

Example 243

In 1.9 ml of toluene was dissolved 101 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, and added thereto was 37 μ l of chlorosulfonylisocyanate, and the mixture was stirred at room temperature for 10 minutes. Added thereto was 207 μ l of diethylamine, and the mixture was stirred at room temperature 20 for an hour. To the solution was added distilled water, and the mixture was extracted with chloroform. The organic layer was dried over magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1), to give 116 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-4-diethylaminosulfonylaminocarbonyloxy- 25 2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 70 below.

Example 244

30 (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine and (S)-(-)-2-pyrrolidone-5-carboxylic acid were used and treated in the same manner as in Example 239, to give (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-4-((2S)-5-oxopyrrolidin-2- 35 yl)carbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine as shown

in Table 70 below.

Example 245

In 2 ml of toluene were dissolved 264 mg of (2R)-4-amino-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride, 80 mg of 2-bromopyridine, 12 mg of palladium acetate, 32 mg of 2,2'-bis(diphenylphosphino)-1,1'-bisnaphtyl and 48 mg of sodium tert-butoxide, and the mixture was stirred at 80°C for 16 hours. The solution was cooled down to room temperature, and added thereto were ethyl acetate and an aqueous sodium hydrogen carbonate solution and the mixture was extracted. The organic layer was dried over magnesium sulfate and concentrated. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=2:1), to give 68 mg of (a) (2R,4S)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-pyridylamino)piperidine and 56 mg of (b) (2R,4R)-1-[N-(3,5-bistrifluoromethylbenzyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-pyridylamino)piperidine as shown in Table 71 below.

Examples 246 to 247

The corresponding starting materials were used and treated in the same manner as in Example 245, to give compounds as shown in Tables 71 to 72 below.

25 Examples 248 to 249

The corresponding starting materials were used and treated in the same manner as in Example 75, to give compounds as shown in Table 72 below.

Example 250

30 (1) In 5 ml of tetrahydrofuran was dissolved 800 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)piperidine, and 5 ml of a 2M aqueous sodium hydroxide solution was added thereto and the mixture was stirred at room temperature for 3 days. To the reaction mixture was added an aqueous citric acid solution to make it

acidic, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried. This solution was concentrated, to give 700 mg of (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-carboxy-2-(4-fluoro-2-methylphenyl)piperidine.

5 (2) In dimethylformamide was dissolved 110 mg of the compound of the above (1), and added thereto were 96 mg of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 10 30 mg of 1-hydroxybenzotriazole, 0.1 ml of a 40% aqueous ammonium solution, and the mixture was stirred at room temperature for 3 hours. To the solution were added an aqueous citric acid solution and ethyl acetate, and the layers were separated. The organic layer was washed with 15 saturated brine, dried and concentrated. The residue was purified by silica gel column chromatography (chloroform:methanol=9:1), to give 87 mg of (2R,4S)-4-aminocarbonyl-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 73 below.

20 Examples 251 to 253

25 The corresponding starting materials were used and treated in the same manner as in Example 250 (1) and (2) or Example 250 (2), to give compounds as shown in Table 73 below.

Example 254

(1) In 40 ml of tetrahydrofuran was dissolved 2 g of (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, and added thereto were 1.59 g of carbon 30 tetrabromide and 1.26 g of triphenylphosphine, and the mixture was stirred at room temperature for 2 hours. To the solution was added 80 ml of diethyl ether, and after stirring the mixture, precipitated insoluble matters were removed by filtration. The organic layer was concentrated and the 35 residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=10:1), to give 1.26 g of (2R,4R)-1-[N-

{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-bromo-2-(4-fluoro-2-methylphenyl)piperidine.

(2) In 20 ml of dimethylformamide was dissolved 1.14 g of the compound of the above (1), and added thereto was 1.14 g of potassium thioacetate and the mixture was stirred at 80°C for 2 hours. After the solution was cooled down to room temperature, an aqueous citric acid solution and ethyl acetate were added thereto and layers were separated. The 10 organic layer was washed with saturated brine, dried and concentrated. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=6:1), to give 920 mg of (2R,4S)-4-acetylthio-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 74 below.

15 Examples 255 to 256

The corresponding starting materials were used and treated in the same manner as in Example 254 (1) and (2), to give compounds as shown in Table 74 below.

20 Example 257

In 10 ml of methanol was dissolved 880 mg of (2R,4S)-4-acetylthio-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine, and added thereto were methyl iodide and 5 ml of a 1M aqueous 25 sodium hydroxide solution, and the mixture was stirred at room temperature for 2 hours. To the solution was added an aqueous citric acid solution to neutralize the same, and methanol was removed by distillation. To the residue were added ethyl acetate and saturated brine and layers were 30 separated. The organic layer was dried and concentrated. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=6:1), to give 560 mg of (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methylthiopiperidine as shown in Table 74 below.

35 Examples 258 to 263

The corresponding starting materials were used and treated in the same manner as in Example 257, to give compounds as shown in Tables 74 to 75 below.

Examples 264 to 270

5 The corresponding starting materials were used and treated in the same manner as in Example 213, to give compounds as shown in Tables 76 to 77 below.

Examples 271 to 278

10 The corresponding starting materials were used and treated in the same manner as in Example 214, to give compounds as shown in Tables 78 to 79 below.

Examples 279 to 312

15 The corresponding starting materials were used and treated in the same manner as in Example 138, to give compounds as shown in Tables 80 to 87 below.

Example 313

20 To 4.2 ml of 4M hydrochloric acid in ethyl acetate was added 361 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}amino- carbonyl-4-[(2S,4R)-4-benzyloxy-1-tert- butyloxycarbonyl- pyrrolidin-2-ylcarbonyl]amino]-2-(4-fluoro-2-methylphenyl)- piperidine and the mixture was stirred for 1 hour at room temperature. After the evaporation in vacuo the residue was triturated with hexane and the solvent was removed by decantation. The residue was dissolved in 4 ml of methylenechloride and 158 ml of triethylamine and 36 ml of acetylchloride were added to the mixture under ice-cooling. After stirring for 1 hour under ice-cooling water was added to the mixture and the mixture was extracted with chloroform. The organic layer was dried over magnesium sulfate and evaporated in vacuo. The residue was purified by silica gel column chromatography (chroloform:methanol=49:1-19:1), to give 304 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}- aminocarbonyl-4-[(2S,4R)-4-benzyloxy-1-acetylpyrrolidin-2-ylcarbonyl]amino]-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 86.

Expmples 314 to 316

The corresponding starting materials were used and treated the same manner of Examples 313, to give the compounds as shown in Tables 86 and 87.

Examples 317 to 318

5 The corresponding starting materials were used and treated the same manner of Examples 113(2), to give the compounds as shown in Table 87.

Example 319

In 1.8 ml of toluene was dissolved 98 mg of (2R,4S)-4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}amino-carbonyl-2-(4-fluoro-2-methylphenyl)piperidine, and added thereto was 24 mg of succinic anhydride and 0.033 ml of triethylamine, and the mixture was refluxed for 18 hours. The mixture was cooled down at room temperature, and then was 10 added water. The mixture was extracted with ethyl acetate, the organic layer was dried and concentrated. The residue was purified by thin layer silica gel column chromatography (chloroform:methanol=19:1), to give 79 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-4-(2,5-dioxopyrrolino)-2-(4-fluoro-2-methylphenyl)piperidine as 15 20 shown in Table 87 below.

Examples 320 to 330

The corresponding starting materials were used and treated in the same manner as in Example 209, to give 25 compounds as shown in Tables 88 to 90 below.

Example 331

The corresponding starting materials were used and treated in the same manner as in Example 113, to give (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(ethoxycarbonylmethyl)-piperidine as shown in Table 91 below.

Example 332

In 20 ml of tetrahydrofuran was dissolved 2.03 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-ethoxycarbonylmethylpiperidine, and added thereto was 450 mg

of aluminum lithium hydride under ice-cooling, and the mixture was stirred for an hour. Slowly added thereto was 2 ml of water and after stirring the mixture for 10 minutes, 5 ml of a 1M aqueous sodium hydroxide solution was added and 5 the mixture was further stirred for 10 minutes. Formed white precipitates were removed, and diethyl ether and water were added to the filtrate, and layers were separated. The organic layer was further washed with water, dried, and concentrated under reduced pressure. The residue was 10 purified by silica gel column chromatography (hexane:ethyl acetate=4:1→3:2), to give 830 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethyl)piperidine as shown in Table 91 below.

15 Example 333

The corresponding starting material was used and treated in the same manner as in Example 245, to give (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-pirazine-2-ylamino)piperidine as shown in Table 91 below.

20 Example 334

In 2 ml of N,N-dimethylformamide was dissolved 114 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-pyrazin-2-ylamino)piperidine, and 10 mg of sodium hydride (40% oil mixture) was added thereto under ice-cooling, and 25 after stirring the mixture for 5 minutes, 0.013 ml of methyl iodide was added and the mixture was stirred at room temperature for 2 hours. To the solution were added water and ethyl acetate, and after stirring the mixture for 10 minutes, layers were separated. The organic layer was washed with brine, dried and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography(hexane:ethyl acetate=85:15→1:1), to give 98 30 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(N-

pyrazine-2-yl-N-methylamino)piperidine as shown in Table 91 below.

Example 335

In 40 ml of dichloromethane was dissolved 8.0 g of (2R)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine, and added thereto were 10 ml of an ethanol solution of methylamine (35%, about 8M), 2 ml of acetic acid and 4.24 g of sodium triacetoxy borohydride, and the mixture was stirred at room temperature for 16 hours. To the solution were added a 2M aqueous sodium carbonate solution and chloroform, and after stirring the mixture for 30 minutes, layers were separated. The aqueous layer was further extracted with chloroform, and the combined organic layers were dried and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography(hexane:ethyl acetate=2:1), to give a mixture of (a) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methylaminopiperidine and (b) (2R,4R)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methylaminopiperidine.

(2) The mixture obtained in the above (1) was dissolved in 40 ml of dichloromethane, and added thereto was 4.4 g of di-tert-butyldicarbonate, and the mixture was stirred at room temperature for 16 hours. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography(hexane:ethyl acetate=10:1), to give 4.2 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(tert-butoxycarbonyl-N-methylamino)piperidine.

(3) The compound of the above (2) was treated with 4M hydrochloric acid-ethyl acetate solution, and concentrated under reduced pressure. The residue was recrystallized by a mixed solution of hexane and ethyl acetate, to give 3.6 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-

methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methylaminopiperidine hydrochloride as shown in Table 91 below.

Example 336

5 (1) 2.12 g of (2R,4S)-4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-piperidine was used and treated in the same manner as in Example 248, to give 3.8 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)piperidine.

10 (2) The compound of the above (1) was treated in the same manner as in Example 250(1), to give 2.3 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}amino-4-carboxy-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 91 below.

15 Examples 337 to 340

The corresponding starting materials were used and treated in the same manner as in Example 250 (2), to give compounds as shown in Table 91 below.

Example 341

20 (1) 4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)piperidine and the corresponding starting material were used and treated in the same manner as in Example 248, and purified by silica gel column chromatography (hexane:ethyl acetate=4:1), to give (2R,4S)-25 1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-ethoxycarbonylpiperidine.

(2) The compound of the above (1) was used and treated in the same manner as in Example 250 (1), to give (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-carboxy-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 92 below.

Examples 342 to 349

35 (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-carboxy-2-(4-fluoro-2-methylphenyl)piperidine and the

corresponding starting materials were used and treated in the same manner as in Example 250 (2), to give compounds as shown in Table 92 below.

Example 350

5 In 12 ml of tetrahydrofuran was dissolved 1.62 g of (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-carboxy-2-(4-fluoro-2-methylphenyl)piperidine, and added dropwise thereto was 2 ml of dimethylsulfide complex of borane (about 10M), and the
10 mixture was stirred at room temperature for 16 hours. To the reaction mixture was added 10 ml of methanol and the mixture was stirred for 0.5 hours. After the reaction was completed, the mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography
15 (chloroform:methanol=9:1), to give 1.32 g of (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl- 2-(4-fluoro-2-methylphenyl)-4-hydroxymethylpiperidine as shown in Table 93 below.

Examples 351 to 352

20 (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxymethylpiperidine and the corresponding starting materials were used and treated in the same manner as in Example 209, to give compounds as shown in
25 Table 93 below.

Example 353

4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)piperidine and the corresponding starting material were used and treated in the same manner as in Example 341, to give compound
30 (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-carboxy-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 94 below.

Examples 354 to 365

35 (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-carboxy-2-(4-fluoro-2-methylphenyl)piperidine and the

corresponding starting materials were used and treated in the same manner as in Example 250 (2), to give compounds as shown in Tables 94 and 95 below.

Example 366

5 In 2 ml of dichloromethane was dissolved 132 mg of (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-carboxy-2-(4-fluoro-2-methylphenyl)piperidine, and added thereto were 0.027 ml of oxalic dichloride and one drop of N,N-dimethylformamide, and
10 the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure. To the residue were added 2.5 ml of tetrahydrofuran and 0.12 ml of 2-aminopyrazine and the mixture was stirred at room temperature for 16 hours. The reaction mixture was
15 concentrated under reduced pressure, and the residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=1:1), to give 63 mg of (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-pyrazylaminocarbonyl)piperidine
20 as shown in Table 96 below.

Example 367

25 (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-carboxy-2-(4-fluoro-2-methylphenyl)piperidine was used and
treated in the same manner as in Example 350, to give
(2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxymethylpiperidine as shown in Table 96 below.

Example 368

30 In a mixture of 20 ml of toluene and 20 ml of acetic acid anhydride was dissolved 1.07 g of the compound of Example 268, and added thereto 165 mg of sodium acetate and the mixture was stirred while being refluxed under heating for 16 hours. After the reaction mixture was cooled down to
35 room temperature, an aqueous sodium hydrogen carbonate solution was slowly added thereto until no foam was generated.

To the mixture were added water and ethyl acetate, and layers were separated. The aqueous layer was further extracted with ethyl acetate, and the combined organic layers were dried and concentrated under reduced pressure. The residue was

5 purified by silica gel column chromatography (hexane:ethyl acetate=1:1), to give 980 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-acetoxymethylthiopiperidine as shown in Table 97 below.

10 Example 369

(2R,4S)-4-acetoxymethylthio-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine was used and treated in the same manner as in Example 214, to give (2R,4S)-4-acetoxymethylsulfonyl-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 97 below.

Example 370

In 10ml of tetrahydrofuran and 5 ml of a 2M aqueous sodium hydroxide solution was dissolved 200 mg of (2R,4S)-4-acetoxymethylsulfonyl-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was neutralized by 2M hydrochloric acid, and the mixture was extracted with ethyl acetate twice. The combined organic layers were dried and concentrated under reduced pressure, to give 80 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxysulfinylpiperidine as shown in Table 97 below.

Example 371

In 2.5 ml of acetonitrile was dissolved 130 mg of the compound of Example 261, and added thereto was 0.5 ml of methyl iodide, and the mixture was stirred at 50°C for 2 hours. The reaction mixture was concentrated and the residue was washed with diethyl ether, to give 117 mg of (2R,4S)-[1-

{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine-4-yl]dimethylsulfonium iodide as shown in Table 97 below.

Example 372

5 In 100 ml of tetrahydrofuran was dissolved 10.7 g of (2R)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-hydroxypropyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine, and added thereto were 20 ml of pyridine and 20 ml of acetic acid anhydride, and the mixture was stirred
10 at room temperature for 5 hours. To the reaction mixture were added an aqueous sodium hydrogen carbonate solution and diethyl ether, and the mixture was stirred for an hour. Layers were separated and after the organic layer was washed with water twice, it was dried and concentrated under reduced
15 pressure. The residue was dissolved in 100 ml of ethanol, and added thereto was 1.5g of sodium borohydride under ice-cooling and the mixture was stirred for 0.5 hours. To the reaction mixture was added an aqueous ammonium chloride solution and after stirring the mixture for 30 minutes, the
20 solvent was removed by distillation under reduced pressure. To the residue was added water and the solution was extracted with chloroform twice. The combined organic layers were dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography
25 (chloroform:methanol=9:1), to give 9.6 g of (2R,4S)-1-{N-(3-acetoxypropyl)-N-(3,5-bistrifluoromethylbenzyl)}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine as shown in Table 98 below.

Examples 373 to 376

30 (2R,4S)-1-{N-(3-acetoxypropyl)-N-(3,5-bistrifluoromethylbenzyl)}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine and the corresponding starting materials were used and treated in the same manner as in Example 209, to give compounds as shown in Table 98
35 below.

Example 377

In 5 ml of methanol was dissolved 600 mg of (2R,4S)-1-{N-(3-acetoxypropyl)-N-(3,5-bistrifluoromethylbenzyl)}aminocarbonyl-4-ethylaminocarbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine, 5 and added thereto was 5 ml of a 2M aqueous sodium hydroxide solution, and the mixture was stirred at room temperature for 16 hours. To the reaction mixture was added a 2M aqueous hydrochloric acid solution to neutralize, and the mixture was extracted with chloroform twice. The combined organic layers 10 were dried, concentrated under reduced pressure and purified by silica gel column chromatography (chloroform:methanol=9:1), to give 550 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-(3-hydroxypropyl)}aminocarbonyl-4-ethylaminocarbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine 15 as shown in Table 99 below.

Examples 378 to 381

The corresponding starting materials were used and treated in the same manner as in Example 377 to give compounds as shown in Table 99 below.

20 Example 382

(2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-(3-hydroxypropyl)}aminocarbonyl-4-thiomorpholinocarbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine was used and treated in the same manner as in Example 213, to give (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-(3-hydroxypropyl)}aminocarbonyl-4-(1-oxothiomorpholino)carbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 99 below.

Example 383

(1) (2R,4S)-1-{N-acetoxypropyl-N-(3,5-bistrifluoromethylbenzyl)}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine was used and treated in the same manner as in Example 254 (1) and (2), to give (2R,4S)-1-{N-acetoxypropyl-N-(3,5-bistrifluoromethylbenzyl)}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-acetylthiopiperidine.

(2) The compound of the above (1) was used and treated

in the same manner as in Example 257, to give (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-hydroxypropyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-propylthio)piperidine.

(3) The compound of the above (2) was used and treated
5 in the same manner as in Example 213, to give (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-hydroxypropyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(propane-2-sulfinyl)piperidine as shown in Table 99 below.

Example 384

10 (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-hydroxypropyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-propylthio)piperidine was used and treated in the same manner as in Example 214, to give (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-hydroxypropyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(propane-2-sulfonyl)piperidine as
15 shown in Table 99 below.

Example 385

20 148 mg of (2R,4S)-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine and the corresponding starting material were used and treated in the same manner as in Reference Example 6, to give 36 mg of (2R,4S)-1-{N-(3,5-dimethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine as
25 shown in Table 100 below.

Example 386

30 The corresponding starting materials were used and treated in the same manner as in Example 385, to give (2R,4S)-1-{N-(3,5-dichlorobenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine as shown in Table 100 below.

Example 387

35 In 10 ml of tetrahydrofuran was dissolved 676 mg of (2R,4S)-2-(4-fluoro-2-methylphenyl)-4-(2-acetoxyethylaminocarbonyloxy)piperidine hydrochloride, and added thereto was 0.28 ml of triethylamine and the mixture

was stirred for 30 minutes. To the reaction mixture was added 330 mg of 1,1'-carbonyldiimidazole, and the mixture was stirred at 65°C for 2 hours. The solvent was removed by distillation under reduced pressure, and the residue was dissolved in 5 ml of dichloromethane. The mixture was washed with water and saturated brine and dried. The mixture was evaporated in vacuo, and the residue was dissolved in 5 ml of acetonitrile. To the solution was added 1 ml of methyl iodide, and the mixture was stirred at 60°C for 2 hours. The solvent was removed by distillation under reduced pressure. The residue was dissolved in 20 ml of tetrahydrofuran, and added thereto were 600 mg of N-(1-(3,5-bistrifluoromethylphenyl)-2-hydroxyethyl)-N-methylamine and 0.5 ml of triethylamine, and the mixture was stirred at 70°C for 3 hours. To the reaction mixture were added ethyl acetate and water, and layers were separated. The organic layer was dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1), to give 780 mg of a mixture of the compounds (a) (2R,4S)-4-(2-acetoxyethylaminocarbonyloxy)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)-2-hydroxyethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine and (b) (2R,4S)-4-(2-acetoxyethylaminocarbonyloxy)-1-[N-(1-(R)-(3,5-bistrifluoromethylphenyl)-2-hydroxyethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine, as shown in Table 101 below.

Example 388

In 2 ml of methanol was dissolved 122 mg of the compound of Example 387, and added thereto was 1 ml of a 2M aqueous sodium hydroxide solution, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was neutralized with a 6M aqueous hydrochloric acid solution, and the solvent was removed by distillation under reduced pressure. To the residue were added chloroform and water and layers were separated. The aqueous layer was further extracted with chloroform, and the combined organic

layers were dried and concentrated under reduced pressure. The residue was vacuum dried, to give 88 mg of a mixture of the compounds (a) (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)-2-hydroxyethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine and (b) (2R,4S)-1-[N-(1-(S)-(3,5-bistrifluoromethylphenyl)-2-hydroxyethyl)-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine as shown in Table 101 below.

Example 389

(1) In 50 ml of dichloromethane was dissolved 4.92 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine, and 2.43 g of carbodiimidazole was added to the solution at room temperature, and the mixture was stirred for 1.5 hours. To the reaction mixture was added water and layers were separated with dichloromethane. The organic layer was washed with saturated brine, dried and the solvent was removed by distillation under reduced pressure, to give 5.99 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-imidazolylcarbonyloxy)piperidine.

(2) In a toluene solution (12 ml) of N,N-dimethylformamide (5ml) was dissolved 1.17 g of the compound of the above (1), and added thereto was 0.925 ml of ethyl nipecotate at room temperature, and the mixture was stirred overnight. To the reaction mixture was added ethyl acetate, and the mixture was washed with water and saturated brine and dried. The solvent was removed by distillation under reduced pressure and the residue was purified by silica gel column chromatography (chloroform:methanol=39:1), to give 1.24 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-4-(4-ethoxycarbonylpiperidinocarbonyloxy)-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 102.

Example 390

In 15 ml of ethanol was dissolved 1.08 g of the compound of Example 389, and added thereto 4.8 ml of 1M potassium hydroxide-ethanol solution at room temperature.

5 After the temperature of the mixture was raised to 50°C, the mixture was stirred for 3 hours. To the reaction mixture was added a 2M aqueous hydrochloric acid solution and ethanol was removed by distillation under reduced pressure. Water and chloroform were added thereto and layers were separated with

10 chloroform. The organic layer was washed with saturated brine and dried, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=9:1), to give 1.05 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-

15 methyl}aminocarbonyl-4-(4-carboxypiperidinocarbonyloxy)-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 102 below.

Example 391

In 1 ml of dichloromethane were dissolved 64.8 mg of the compound of Example 390 and 18.6 mg of ethanalamine, and

20 added thereto at room temperature was 48.6 mg of carbodiimidazole, and the mixture was stirred at room temperature overnight. A saturated aqueous ammonium chloride solution was added thereto and the mixture was extracted with dichloromethane. The organic layer was dried

25 and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol= 19:1), to give 17.8 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-

30 methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{4-(2-hydroxyethylaminocarbonyl) piperidinocarbonyloxy}piperidine as shown in Table 102.

Examples 392 to 398

The compound of Example 390 and the corresponding starting materials were used and treated in the same manner

35 as in Example 391, to give compounds as shown in Tables 102 to 103 below.

Example 399

(1) In 12 ml of toluene was dissolved 1.17 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-imidazolylcarbonyloxy)piperidine, and added thereto at room temperature was 1.14 g of 4-amino-1-benzylpiperidine, and the mixture was stirred for 3 days. To the reaction mixture was added ethyl acetate, and the mixture was washed with water and saturated brine and dried. The solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1), to give 0.89 g of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-4-(1-benzylpiperidine-4-yl)aminocarbonyloxy-2-(4-fluoro-2-methylphenyl)piperidine.

(2) In 10 ml of methanol was dissolved 890 mg of the compound of the above (1), and added thereto were 400 mg of palladium carbon and one drop of concentrated hydrochloric acid, and the mixture was stirred in hydrogen atmosphere for 4.5 hours. After the reaction mixture was filtered and the filtrate was evaporated in vacuo, the residue was crystallized (ethyl acetate-hexane), to give 802 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(4-piperidinyl)aminocarbonyloxy)piperidine.

(3) In 2 ml of dichloromethane was dissolved 14.2 mg of 3-hydroxy-3-methylbutanoic acid, and added thereto at room temperature was 21.1 mg of carbodiimidazole, and the mixture was stirred at room temperature overnight. To the reaction mixture was added 61.9 mg of the compound of the above (2), and the mixture was further stirred overnight. To the reaction mixture was added water, and the mixture was extracted with chloroform. The organic layer was dried and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1), to give 57.5 mg of

(2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{1-(3-hydroxy-3-methylbutyryl)piperidine-4-yl}aminocarbonyloxy piperidine as shown in Table 104 below.

5 Examples 400 to 402

The compound of Example 399 (2) and the corresponding starting materials were treated in the same manner as in Example 399 (3), to give compounds as shown in Table 104 below.

10 Example 403

(2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-ethyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine obtained by treating the compound of Reference Example 11 (2) in the same manner as in Example 2 15 was treated in the same manner as in Example 209, to give a compound as shown in Table 105 below.

Example 404

The corresponding starting material was treated in the same manner as in Example 209, to give a compound as shown in 20 Table 105 below.

Example 405

The compound of Example 404 was treated in the same manner as in Example 213, to give a compound as shown in Table 105 below.

25 Example 406

The compound of Example 404 was treated in the same manner as in Example 214, to give a compound as shown in Table 105 below.

Examples 407 to 413

30 The corresponding starting materials were treated in the same manner as in Example 257, to give compounds as shown in Tables 106 to 107 below.

Example 414

In 50 ml of methanol was dissolved 1.17 g of (2R,4S)-4-acetylthio-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine,

and added thereto at room temperature was 1.17 g of tert-butyl 2-bromoethylcarbamate. Subsequently, 25 ml of a 1M aqueous sodium hydroxide solution was added dropwise thereto. The reaction mixture was stirred for 5 minutes, and the 5 solvent was removed by distillation under reduced pressure, and the mixture was extracted with dichloromethane, washed with saturated brine and dried. The solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl 10 acetate=2:1), to give 710 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-4-(2-tert-butoxycarbonylaminoethylthio)-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 107 below.

Example 415

15 (1) To 681 mg of the compound of Example 414 was added 2 ml of 4M hydrochloric acid-ethyl acetate solution under ice-cooling, and the mixture was stirred at room temperature for an hour. The solvent was removed by distillation, and a saturated aqueous sodium bicarbonate solution was added and 20 the mixture was extracted with chloroform. The organic layer was dried and the solvent was removed by distillation under reduced pressure, to give 612 mg of (2R,4S)-4-(2-aminoethylthio)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine 25 hydrochloride as shown in Table 107 below.

(2) In 1 ml of N,N-dimethylformamide were dissolved 55.2 mg of the compound of the above (1) and 9.1 mg of glycolic acid, and added thereto were 24.9 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 30 19.9 ml of N-hydroxybenzotriazole monohydrate, and the mixture was stirred at room temperature overnight. Ethyl acetate was added thereto and the mixture was washed with water and saturated brine, dried and the solvent was removed by distillation under reduced pressure. The residue was 35 purified by silica gel column chromatography (chloroform:methanol= 19:1), to give 28.8 mg of (2R,4S)-1-{N-

(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-(1-hydroxyacetylamino)ethylthio)piperidine as shown in Table 107 below.

5 Examples 416 to 419

The compound of Example 415 (1) and the corresponding starting materials were treated in the same manner as in Example 415 (2), to give compounds as shown in Table 108 below.

10 Example 420

In 1 ml of N,N-dimethylformamide was dissolved 55.2 mg of the compound of Example 415 (1), and 9.1 mg of carbodiimidazole was added thereto, and the mixture was stirred at room temperature for 3 hours. To the reaction mixture was added ethyl acetate, and the mixture was washed with water and brine and dried. The solvent was removed by distillation, and the residue was dissolved in 1 ml of acetonitrile, and 0.025 ml of methyl iodide was added thereto. The mixture was stirred at 50°C overnight. Subsequently, 0.025 ml of methyl iodide was further added and the mixture was stirred at the same temperature overnight. After removing N,N-dimethylformamide and methyl iodide by distillation under reduced pressure, 1 ml of toluene and 0.040 ml of morpholine were added, and the mixture was stirred at room temperature for 5 days. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The organic layer was dried and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol= 19:1), to give 38.0 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-morpholinocarbonylaminoethylthio)piperidine as shown in Table 108 below.

35 Example 421

The compound of Example 415 (1) and the corresponding

starting material were treated in the same manner as in Example 420, to give (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{2-(2-

5 hydroxymethylamino)carbonylaminoethylthio}piperidine as shown in Table 108 below.

Example 422

The corresponding starting materials were used and treated in the same manner as in Example 213, to give

10 (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{4-(2-methylsulfinylethylaminocarbonyl)piperidinocarbonyloxy}-piperidine as shown in Table 108 below.

Example 423

15 The corresponding starting materials were used and treated in the same manner as in Example 214, to give (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{4-(3-methylsulfonylpropylaminocarbonyl)piperidinocarbonyloxy}-piperidine as shown in Table 108 below.

20 Examples 424 to 425

The corresponding starting materials were used and treated in the same manner as in Example 209, to give compounds as shown in Table 109 below.

25 Example 426

In 1.5 ml of dichloromethane was dissolved 82.0 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-methylthioethylaminocarbonyloxy)piperidine, and added thereto

30 at room temperature 99.5 mg of m-chloroperbenzoic acid and the mixture was stirred for an hour. To the reaction mixture was added a saturated aqueous sodium hydrogen carbonate solution, and layers were separated with ethyl acetate. The organic layer was washed with saturated brine and dried, and

35 the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column

chromatography (chloroform:methanol=19:1), to give 48.6 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-methylsulfonylethylaminocarbonyloxy)piperidine as shown in

5 Table 109 below.

Example 427

(2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(3-methylthiopropylaminocarbonyloxy)piperidine was treated in 10 the same manner as in Example 426, to give (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(3-methylsulfonylpropylaminocarbonyloxy)piperidine as shown in Table 109 below.

15 Examples 428 to 431

The corresponding starting materials were treated in the same manner as in Example 169, to give compounds as shown in Table 110 below.

Examples 432 to 433

20 The corresponding starting materials were treated in the same manner as in Example 213, to give compounds as shown in Table 111 below.

Examples 434 to 435

25 The corresponding starting materials were treated in the same manner as in Example 214, to give compounds as shown in Table 111 below.

Example 436

30 In 2.8 ml of acetonitrile was dissolved 130 mg of imidazole-1-carboxylic acid N-(3,5-bistrifluoromethylbenzyl)-N-(2-methoxyethyl)amide, and added thereto was 411 μ l of methyl iodide, and the mixture was stirred at 50°C for 3 hours. The reaction mixture was concentrated under reduced pressure. The residue was suspended in 2.7 ml of dichloromethane, and added thereto were 89 mg of (2R,4S)-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine and 50 μ l of

triethylamine, and the mixture was stirred at room temperature for 20 hours. To the reaction mixture was added a 5% aqueous citric acid solution, and the mixture was extracted with chloroform. The organic layer was dried over 5 magnesium sulfate, and concentrated under reduced pressure. The residue was purified by thin-layer silica gel chromatography (chloroform:methanol=19:1), to give 63 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-(2-methoxyethyl)aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine as shown in Table 112 10 below.

Example 437

In 2.7 ml of dichloromethane was dissolved 94 mg of 2-(4-fluoro-2-methoxyphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine, and added thereto 15 were 163 mg of 3-[(3,5-bistrifluoromethylbenzyl)-methylcarbamoyl]-1-methyl-3H-imidazol-1-ium iodide and 50 μ l of triethylamine, and the mixture was stirred at room temperature for 18 hours. To the reaction mixture was added 20 distilled water and the mixture was extracted with chloroform. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by thin-layer silica gel chromatography (chloroform:methanol=19:1), to give 84 mg of 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro 25 2-methoxyphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine as shown in Table 112 below.

Example 438

In 5.2 ml of acetonitrile was dissolved 201 mg of 30 imidazole-1-carboxylic acid N-[(1S)-1-(3,5-bistrifluoromethylphenyl)ethyl]-N-methylamide, and added thereto was 137 μ l of methyl iodide. After the mixture was stirred at 50°C for 3 hours, the reaction mixture was concentrated under reduced pressure. The residue was 35 dissolved in 4.5 ml of dichloromethane, and added thereto was 132 mg of 4-(2-hydroxyethylcarbamoyloxy)-2-phenylpiperidine

and 84 μ l of triethylamine, and the mixture was stirred at room temperature for 18 hours. To the reaction mixture was added a 5% aqueous citric acid solution, and the mixture was extracted with chloroform, and the organic layer was dried 5 and concentrated under reduced pressure. The residue was purified by thin-layer silica gel chromatography (chloroform:acetone=4:1), to give 75 mg of (2R,4R)-1-[N-{(S)-1-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-4-(2-hydroxyethylaminocarbonyloxy)-2-phenylpiperidine as shown in Table 112 below.

Example 439

(1) In 3 ml of acetonitrile was dissolved 127 mg of 1-(3,5-bistrifluoromethylphenyl)ethyl imidazole-1-carboxylate, and added thereto was 448 μ l of methyl iodide. The mixture 15 was stirred at 50°C for 3 hours, and the reaction mixture was concentrated. The residue was suspended in 2.7 ml of dichloromethane, and added thereto were 102 mg of 2-[(2R,4S)-2-(4-fluoro-2-methylphenyl)piperidine-4-yloxycarbonylamino]ethyl acetate and 50 μ l of triethylamine, 20 and the mixture was stirred at room temperature for 18 hours. To the reaction mixture was added distilled water and the mixture was extracted with chloroform. The organic layer was dried and concentrated. The residue was purified by thin-layer silica gel chromatography (hexane:ethyl acetate=1:1), 25 to give 43 mg of (2R,4S)-4-(2-acetoxyethylaminocarbonyloxy)-1-{(S)-1-(3,5-bistrifluoromethylphenyl)ethyl}oxycarbonyl-2-(4-fluoro-2-methylphenyl)piperidine.

MS (m/z) : 623 [M⁺+1]

(2) In a mixture of 0.9 ml of tetrahydrofuran and 0.1 ml 30 of methanol was dissolved 43 mg of the compound of the above (1), and added thereto was 103 μ l of a 1M aqueous sodium hydroxide solution, and the mixture was stirred at room temperature for an hour. To the reaction mixture was added distilled water and the mixture was extracted with ethyl acetate. The organic layer was dried and concentrated. The residue was purified by thin-layer silica gel chromatography 35

(chloroform:methanol=19:1), to give 37 mg of (2R,4S)-1-{(S)-1-(3,5-bistrifluoromethylphenyl)ethyl}oxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine as shown in Table 112 5 below.

Example 440

In 2.4 ml of N,N-dimethylformamide was dissolved 50 mg of (2R,4S)-2-(4-fluoro-2-methyl)phenyl-4-hydroxypiperidine, and added thereto under nitrogen atmosphere at room 10 temperature were 0.044 ml of triethylamine and 99.3mg of N-(3,5-bistrifluoromethylbenzyl)-N-methylaminocarbonylchloride. The reaction mixture was stirred at room temperature for 21 hours. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate twice. The organic 15 layers were combined and washed with saturated brine, dried and concentrated. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1→1:2), to give 128 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-20 hydroxypiperidine as shown in Table 113 below.

Example 441

In 2.0 ml of dichloromethane was dissolved 560 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-25 hydroxypiperidine, and added thereto under nitrogen atmosphere under ice-cooling, 1.5 ml of dichloromethane solution containing 0.22 ml of pyridine and 0.314 ml of phenyl chloroformate. The reaction mixture was stirred at a temperature of 0°C to 5°C for 3.5 hours, and further stirred 30 at room temperature for 16 hours. The reaction mixture was poured into water and extracted by adding dichloromethane twice. The organic layers were combined and washed with a 1M aqueous hydrochloric acid solution twice, and was further washed with saturated brine. The organic layer was dried and 35 concentrated. The residue was dissolved in 11 ml of N,N-dimethylformamide, and added thereto under nitrogen

atmosphere and at room temperature was 0.274 ml of ethanolamine, and the mixture was stirred at 60°C for 26 hours. The reaction mixture was poured into water and extracted by adding ethyl acetate twice. The organic layers 5 were combined and washed with saturated brine, dried and concentrated. The residue was purified by silica gel column chromatography (chloroform:methanol=39:1), to give 493 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine as shown in Table 113 10 below.

Example 442

In 8 ml of dichloromethane was dissolved 1.0 g of (2R)-4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine, and added thereto were 0.31 ml of triethylamine and 466 mg of di-tert-butyloxycarbonate, and the mixture was stirred at room temperature for 16 hours. To the reaction mixture was added water and the mixture was extracted with 15 dichloromethane twice. The organic layers were combined and washed with saturated brine, dried and concentrated. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=4:1), to give 481 mg of (a) (2R,4R)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert- 20 butoxycarbonylaminopiperidine and 516 mg of (b) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine as shown in Table 113 below.

Example 443

In 3.5 ml of ethyl acetate was dissolved 700 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine, and added thereto under ice- 35 cooling was 3.5 ml of 4M hydrochloric acid-ethyl acetate solution, and the mixture was stirred under ice-cooling for

30 minutes. The solvent was removed by distillation, and added to the residue was ethyl acetate and subjected to filtration. To the collected materials were added chloroform and a 2M aqueous sodium hydroxide solution and layers were 5 separated. The aqueous layer was extracted with chloroform. The combined organic layers were dried and concentrated, to give 489 mg of (2R,4S)-4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 113 below.

10 Examples 444 to 449

The corresponding starting materials were used and treated in the same manner as in Example 138, to give compounds as shown in Table 114 below.

Examples 450 to 451

15 The corresponding starting materials were used and treated in the same manner as in Example 102 (1), to give compounds as shown in Table 114 below.

Examples 452 to 469

20 The corresponding starting materials were used and treated in the same manner as in Example 250 (2), to give compounds as shown in Tables 115 to 117 below.

Example 470

25 In 1 ml of dichloromethane was dissolved 52.8 mg of (2R,4S)-4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}amino- carbonyl-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride, and added thereto at room temperature was 0.017 ml of triethylamine and 24.3 mg of 1,1-carbodiimidazole, and the mixture was stirred for 30 minutes. The reaction mixture was added water and the mixture was extracted with 30 dichloromethane. The organic layers were washed with saturated brine, dried and concentrated. In 1 ml of acetonitrile was dissolved the residue, and added 0.025 ml of methyl iodide, and the mixture was stirred at 60°C over night. The reaction mixture was concentrated, and in 1ml of toluene-35 acetonitrile (7:3) solution was dissolved the residue, and added 24.4 mg of ethanolamine, and the mixture was stirred at

room temperature for 30 minutes. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The organic layer was dried and concentrated. The residue was purified by silica gel column chromatography

5 (chloroform:methanol=9:1), to give 53.1 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylamino)piperidine as shown in Table 118 below.

Examples 471 to 480

10 The corresponding starting materials were used and treated in the same manner as in Example 470, to give compounds as shown in Tables 118 to 119 below.

Example 481

15 In 10 ml of dichloromethane was dissolved 490 mg of (2R)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}amino-carbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine and 312 mg of 2-(2-aminoethylamino)ethanol, and added thereto at room temperature were 0.086 ml of acetic acid and 669 mg of sodium triacetoxyborohydride, and the mixture was stirred overnight.

20 To the reaction mixture was added water, and extracted with chloroform. The organic layer was washed with saturated brine, dried and concentrated, to give 581 mg of (2R,4RS)-1-{N-(3,5-bistrifluoro- methylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methyl- phenyl)-4-{2-(2-

25 hydroxyethylamino)ethylamino)piperidine

[(2R,4S):(2R,4R)=74:26]. In 2 ml of dichloromethane was dissolved 116 mg of (2R,4RS)-1-{N-(3,5-bistrifluoromethylbenzyl)-N- methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-{2-(2-

30 hydroxyethylamino)ethylamino)piperidine, and added thereto at room temperature was 39 mg of 1,1-carbodiimidazole, and the mixture was stirred for 40 minutes. To the reaction mixture was added water, and the mixture was extracted with chloroform. The organic layers were washed with saturated

35 brine, dried and concentrated. The residue was purified by silica gel column chromatography (chloroform:methanol=9:1),

to give (a) 75.5 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-[3-(2-hydroxyethyl)-2-oxoimidazolidine-1-yl]piperidine and give (b) 22.6 mg of (2R,4R)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-[3-(2-hydroxyethyl)-2-oxoimidazolidine-1-yl]piperidine as shown in Table 120 below.

5 Examples 482 to 486

10 The corresponding starting materials were used and treated in the same manner as in Example 481, to give compounds as shown in Tables 120 to 122 below.

Example 487

15 In 1 ml of dichloromethane was dissolved 12.4 ml of ethylene glycol, and added thereto at room temperature was 32.4 mg of 1,1-carbodiimidazole. The mixture was stirred at room temperature for 7.5 hours, and to the mixture were added 52.8 mg of (2R,4S)-4-amino-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine hydrochloride and 0.021 ml 20 of triethylamine. The mixture was stirred for 4 days, and the reaction mixture was concentrated. The residue was purified by silica gel column chromatography (chloroform:methanol=9:1), to give 16.4 mg of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-amino-carbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethyloxycarbonylamino)-25 piperidine as shown in Table 123 below.

Example 488

30 (1) In 3 ml of dichloromethane was dissolved 58mg of triphosgene, and added dropwise thereto under -60°C was 2 ml dichloromethane solution containing 138 mg of N-{2-methoxy-5-(5-trifluoromethyltetrazole-1-yl)benzyl}-N-methylamine and 0.201 ml of triethylamine, and then the mixture was warmed up at 0°C. The mixture was concentrated, and in 2 ml dichloromethane was dissolved the residue. To the mixture 35 was added dropwise 2ml of dichloromethane solution containing 135 mg of (2R,4S)-4-(2-acetyloxyethylaminocarbonyloxy)-2-(4-

fluoro-2-methylphenyl)-piperidine and 0.084 ml of triethylamine, and the mixture was stirred at room temperature for one day. To the reaction mixture was added water, and the mixture was extracted with chloroform. The 5 organic layer was dried over magnesium sulfate and concentrated. The residue was purified by thin layer silica gel column chromatography (chloroform:acetone=10:1), to give 44 mg of (2R,4S)-4-(2-acetyloxyethylaminocarbonyloxy)-1-[N-{2-methoxy-5-(5-trifluoromethyltetrazole-1-yl)benzyl}-N- 10 methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine. MS(m/z):652[M⁺+1]

(2) In 0.9 ml of the mixture solution (tetrahydrofuran:methanol=8:1) was dissolved 44 mg of (2R,4S)-4-(2-acetyloxyethylaminocarbonyloxy)-1-[N-{2-methoxy-5-(5-trifluoromethyltetrazole-1-yl)benzyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine, and added thereto was 0.101 ml of a 1 M aqueous sodium hydroxide solution, and the mixture was stirred at room temperature for 6 hours. To the reaction mixture was added water, and the mixture was 20 extracted with ethyl acetate. The organic layers were dried over magnesium sulfate and concentrated. The residue was purified by thin layer silica gel column chromatography (chloroform:methanol=19:1), to give 36 mg of (2R,4S)-1-[N-{2-methoxy-5-(5-trifluoromethyltetrazole-1-yl)benzyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine as shown in Table 124 25 below.

Reference Example 1

To Grignard reagent prepared from 14.2 g of magnesium, 30 93.1 g of 2-bromo-5-fluorotoluene and 500 ml of tetrahydrofuran was added dropwise 50 ml of 4-methoxypyridine at -20°C under nitrogen atmosphere. After completion of dripwise addition, the mixture was stirred at the same temperature for 20 minutes. Further, the reaction mixture 35 was cooled down to -50°C, and 85 ml of benzylchlorocarbonate was added dropwise, while keeping the temperature at -40°C or

below. After completion of dropwise addition, the temperature of the reaction mixture was slowly raised, 200 g of ice was added thereto at -15°C, and the mixture was stirred for 30 minutes. Further, 200 ml of a 5M aqueous 5 citric acid solution was added thereto and the mixture was stirred at room temperature for an hour. From the reaction mixture tetrahydrofuran was removed by distillation under reduced pressure. To the residue was added 200 ml of ethyl acetate and the mixture was extracted twice. The organic 10 layers were combined and washed with an aqueous sodium hydrogen carbonate solution and saturated brine, dried over magnesium sulfate, and the solvent was removed by distillation under reduced pressure. The residue was collected by filtration and washed with isopropyl ether, to 15 give 146.5 g of 1-benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxo-3,4-dihydro-2H-pyridine as shown in Table 125 below.

Reference Example 2

In 4600 ml of acetic acid was dissolved 190g of 1-benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxo-3,4-dihydro-2H-pyridine, and added thereto was 91 g of zinc powder and the mixture was stirred at room temperature for 24 hours. From the reaction mixture was removed insoluble matters by filtration, and the solvent was removed by 25 distillation under reduced pressure. To the residue was added 400 ml of ethyl acetate, and the mixture was washed with an aqueous sodium hydrogen carbonate solution and saturated brine, and dried over magnesium sulfate. The solvent was removed by distillation under reduced pressure, 30 and the residue was purified by silica gel column chromatography (ethyl acetate:hexane=2:1), to give 166g of 1-benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine as shown in Table 125 below.

Reference Example 3

35 To 132 g of 1-benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine were added 650 ml of methanol,

84ml of trimethoxymethane and 2 g of strongly acidic resin IR-120 (manufactured by Japan Organo Co., Ltd.), and the mixture was stirred at room temperature for 3 days. From the reaction mixture was removed insoluble matters by filtration, 5 and the solvent was removed by distillation under reduced pressure, to give 146 g of 1-benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine as shown in Table 125 below.

Reference Example 4

10 In 300ml of ethanol were added 30 g of 1-benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine and 3.0 g of 10% palladium-carbon, and the mixture was stirred under hydrogen atmosphere at room temperature for 3 hours. From the reaction mixture was 15 removed insoluble matters by filtration, and the solvent was removed by distillation under reduced pressure. To the residue was added 300 ml of ethyl acetate. Under ice-cooling 20 ml of 4M hydrochloric acid-ethyl acetate solution was slowly added dropwise. The crystals were collected by 20 filtration and washed with ethyl acetate. After drying, the crystals were added to a mixture of dichloromethane-an aqueous sodium carbonate solution, and the mixture was stirred. After the organic layer was separated, the aqueous layer was further extracted with dichloromethane. The 25 organic layers were combined and dried over sodium sulfate, the solvent was removed by distillation under reduced pressure, to give 16.7g of 2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine as shown in Table 125 below.

Reference Example 5

30 To 130 ml of ethyl acetate suspension of 10.1 g of 2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine and 3.18 g of L-N-acetylvaline was added 35 ml of methanol, and the mixture was heated to dissolve, and then, cooled down at room temperature. After 3.5 hours, precipitated crystals were 35 collected by filtration, and washed with 20 ml of ethyl acetate. The obtained crystals were dried under reduced

pressure. Subsequently, 50 ml of chloroform was added thereto, and the mixture was washed with 30 ml of a 2M aqueous sodium hydroxide solution and 30 ml of saturated brine, dried over magnesium sulfate and concentrated under reduced pressure. To the obtained residue was added ether, and precipitated crystals were further concentrated under reduced pressure, to give 2.94 g of (2R)-2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine (optical purity:97.0% ee) as shown in Table 125 below.

10 Reference Example 6

In 36 ml of tetrahydrofuran solution of 5.0 g of N-(3,5-bistrifluoromethylbenzyl)-N-methylamine was added 3.47 g of 1,1'-carbonyldiimidazole, and the mixture was stirred at 65°C for 20 minutes. The solvent was removed by distillation under reduced pressure and added thereto was dichloromethane. The whole organic layer was washed with saturated brine and dried, and the solvent was removed by distillation. The residue was dissolved in 26 ml of acetonitrile, and 4.84 ml of methyl iodide was added thereto and the mixture was stirred at 60°C for 2 hours. The solvent was removed by distillation under reduced pressure, and the residue was dissolved in 80 ml of dichloromethane. Under ice-cooling, 5.17g of 2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine and 3 ml of triethylamine were added thereto, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water and layers were separated. The aqueous layer was extracted with dichloromethane. The combined organic layers were washed with saturated brine and dried, and the solvent was removed by distillation. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=4:3), to give 9.7 g of 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine as shown in Table 126 below.

35 Reference Example 7

In 180 ml of tetrahydrofuran was dissolved 9.7 g of 1-

{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine, and under ice-cooling, 70 ml of a 1M aqueous sulfuric acid solution was added thereto, and the mixture was stirred at room

5 temperature for an hour. After adjusting pH of the mixture to 8 to 9 by a 1M aqueous sodium hydroxide solution, tetrahydrofuran was removed by distillation. To the residue were added water and ethyl acetate, and layers were separated. The aqueous layer was extracted with ethyl acetate. The

10 combined organic layers were washed with saturated brine and dried. The solvent was removed by distillation. To the obtained residue was added diisopropyl ether, and white crystals were collected by filtration, to give 7.86 g of 1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine as shown in Table

15 126 below.

Reference Example 8

In 60 ml of tetrahydrofuran solution of 3.91 g of N-(1-(S)-(3,5-bistrifluoromethylphenyl)ethyl)-N-methylamine was

20 added 2.34 g of 1,1'-carbonyldiimidazole, and the mixture was stirred at 40°C overnight. From the reaction mixture the solvent was removed by distillation, ethyl acetate was added thereto and the whole organic layer was washed with water and saturated brine, and dried. The solvent was removed by

25 distillation, and the obtained white crystals were collected by filtration with diisopropyl ether. The obtained white crystals were dissolved in 60 ml of acetonitrile and 3.4 ml of methyl iodide was added and the mixture was stirred at 60°C for 2 hours. The solvent was removed by distillation

30 under reduced pressure, and the residue was dissolved in 40 ml of dichloromethane. Under ice-cooling, added thereto were 3.47 g of 2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine and 3.82 ml of triethylamine and the mixture was stirred at room temperature overnight. The reaction mixture was poured

35 into water and layers were separated. The aqueous layer was extracted with dichloromethane. The combined organic layers

were washed with water and saturated brine and dried, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in 90 ml of tetrahydrofuran, and under ice-cooling, 30 ml of 1M aqueous sulfuric acid solution 5 was added thereto, and the mixture was stirred at room temperature for 5 hours. After adjusting pH of the mixture to 8 to 9 by a 1M aqueous sodium hydroxide solution, tetrahydrofuran was removed by distillation. To the residue were added water and ethyl acetate, and layers were separated. 10 The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water and saturated brine and dried, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1), to give 15 2.12 g of (2R)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine as shown in Table 126 below.

Reference Examples 9 to 11
20 The corresponding starting materials were used and treated in the same manner as in Reference Example 8, to give compounds as shown in Tables 126 to 127 below.

Reference Example 12
In 140 ml of ethanol was dissolved 16.7 g of 1-benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine, 25 and added thereto were 3.74 g of hydroxylamine hydrochloride and 4.41 g of sodium acetate, and the mixture was stirred at room temperature for 2 hours. Ethanol was removed under reduced pressure. To the residue were added water and ethyl acetate, and layers were separated. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with saturated brine and dried, and the solvent was removed under reduced pressure. The residue was dissolved in 500 ml of methanol, and 23.2 g of nickel 30 acetate hexahydrate was added thereto and after stirring the mixture, 3.7 g of sodium borohydride was slowly added under 35

ice-cooling, and the mixture was stirred under ice-cooling for 4 hours. Methanol was removed by distillation under reduced pressure, and to the residue were added an aqueous ammonia and dichloromethane, and the mixture was stirred at 5 room temperature for an hour. The reaction mixture was separated by layers, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with saturated brine and dried, and the solvent was removed by distillation. The residue was dissolved in 480 ml of 10 dichloromethane, and under ice-cooling added thereto were 8.2 ml of triethylamine and 5.1 ml of propionyl chloride, and the mixture was stirred under ice-cooling for an hour. The reaction mixture was poured into saturated brine and layers were separated. The aqueous layer was extracted with 15 dichloromethane. The combined organic layers were washed with saturated brine and dried, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=1:1), to give 6.43 g of (a) *trans*-1- 20 *benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-propanoylaminopiperidine* and 5.65 g of (b) *cis*-1-*benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-propanoylaminopiperidine* as shown in Table 127 below.

Reference Example 13

25 *1-Benzylloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine* and *isobutyroyl chloride* were used and treated in the same manner as in Reference Example 12, to give (a) *trans-1-benzylloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-isobutanoylaminopiperidine* and (b) *cis-1-benzylloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-isobutanoylaminopiperidine* as 30 shown in Table 128 below.

Reference Example 14

In 17 ml of ethanol was dissolved 1.73 g of *trans-1-benzylloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-propanoylaminopiperidine*, and added thereto was 280 mg of 35 palladium-carbon (moisture content of 50.9%), and the mixture

was stirred under hydrogen atmosphere at room temperature for 3 hours. The reaction mixture was filtered through Celite, and ethanol was removed by distillation. The residue was purified by NH silica gel column chromatography

5 (chloroform:hexane:ethyl acetate=5:5:2), to give 772 mg of trans-2-(4-fluoro-2-methylphenyl)-4-propanoylaminopiperidine as shown in Table 129 below.

Reference Examples 15 to 17

The corresponding starting materials were used and

10 treated in the same manner as in Reference Example 14, to give compounds as shown in Tables 129 to 130 below.

Reference Example 18

In 900 ml of ethanol was dissolved 110 g of 1-benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine,

15 and added thereto were 24.8 g of hydroxylamine hydrochloride and 29.3 g of sodium acetate, and the mixture was stirred at room temperature for 5 hours. Ethanol was removed by distillation, and to the residue were added water and ethyl acetate. Layers were separated and the aqueous layer was

20 extracted with ethyl acetate. The combined organic layers were washed with saturated brine and dried, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in 2.4 l of methanol, and 92.5 g of nickel chloride hexahydrate was added thereto. After

25 stirring the mixture, 18.4 g of sodium borohydride was slowly added under ice-cooling, and the mixture was stirred under ice-cooling for 4 hours. Methanol was removed by distillation, and to the residue were added aqueous ammonia and dichloromethane, and the mixture was stirred at room

30 temperature for an hour. The reaction mixture was separated by layers, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with saturated brine and dried, and the solvent was removed by distillation. The residue was dissolved in 1.2 l of

35 dichloromethane, and under ice-cooling added thereto were 45.2 ml of triethylamine, 74.5 ml of di-tert-butyldicarbonate,

and the mixture was stirred at room temperature for an hour. The reaction mixture was poured into saturated brine, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with saturated brine and 5 dried, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=4:1), to give 36.7 g of (a) trans-1-benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine and 37.9g 10 of (b) cis-1-benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine as shown in Table 131 below.

Reference Example 19

In 350 ml of ethanol was dissolved 37.0 g of cis-1-benzyloxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine, and 5.5 g of palladium-carbon (moisture content of 50.9%) was added thereto, and the mixture was stirred under hydrogen atmosphere at room temperature for 2 hours. The reaction mixture was filtered 20 through Celite, and ethanol was removed by distillation, to give 25.8 g of cis-2-(4-fluoro-2-methylphenyl)-4-tert-butoxycarbonylaminopiperidine as shown in Table 132 below.

Reference Example 20

To 1.34 g of 3-hydroxyl-2-hydroxymethyl-2-methylpropionic acid and 13 ml of acetonedimethylacetal was added 95 mg of p-toluenesulfonic acid monohydrate at room temperature, and the mixture was stirred for 6 hours. Further added thereto was 95 mg of p-toluenesulfonic acid monohydrate, and the mixture was stirred overnight. The 30 solution was concentrated and poured into water and extracted. The aqueous layer was extracted with chloroform. The combined organic layers were washed with saturated brine, dried, and concentrated. The residue was purified by silica gel column chromatography (chloroform:methanol=19:1), to give 35 333 mg of 2,2,5-trimethyl-[1,3]dioxolane-5-carboxylic acid as shown in Table 132 below.

Reference Example 21

In 400 ml of tetrahydrofuran was dissolved 31.5 g of 2-chloroisonicotinic acid, and 32.5 g of 1,1'-carbonyldiimidazole was added thereto. The mixture was 5 stirred under ice-cooling for an hour. To the solution was added 50 ml of ethanol, and the mixture was stirred at room temperature for 2 hours. The solution was concentrated, and extracted by adding ethyl acetate and water. The organic layer was dried over magnesium sulfate, and the residue was 10 vacuum dried, to give 35.6 g of ethyl 2-chloroisonicotinate as shown in Table 132 below.

Reference Example 22

In a mixed solvent of 250 ml of toluene and 50 ml of ethanol were dissolved 20 g of ethyl 2-chloroisonicotinate 15 and 20 g of 2-methyl-4-fluorophenylboronic acid, and 5.8 g of palladium tetrakis(triphenylphosphine) and 250 ml of a 2M aqueous sodium carbonate solution, and the mixture was stirred at 50 to 70°C for 2 hours. The solution was cooled down to room temperature and extracted by adding ethyl 20 acetate and water. The organic layer was further washed with water, and dried over magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=6:1), to give 24.8 g of 4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)pyridine as shown 25 in Table 132 below.

Reference Example 23

In 200 ml of ethanol were dissolved 5.2 g of 4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)pyridine and 1.5 g of platinum oxide, and 15 ml of concentrated hydrochloric 30 acid was added to the solution. The mixture was stirred under hydrogen atmosphere at room temperature for 5 hours. Added thereto was 200 ml of water and the mixture was stirred for 30 minutes, and then, insoluble matters were removed by filtration through Celite. The insoluble matters were washed 35 with ethanol and the filtrate and the liquid used for washing were combined and concentrated. To the residue were added

ethyl acetate and a saturated aqueous sodium hydrogen carbonate solution. After confirming that the aqueous solution was sufficiently alkaline, then extraction was carried out. The aqueous layer was extracted with ethyl acetate for 3 times, and the combined organic layers were dried over sodium sulfate and concentrated, to give 3.6 g of 2,4-cis-4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)piperidine as shown in Table 132 below.

Reference Example 24

(1) In a mixture of 50 ml of ethyl acetate and 50 ml of diethylether were dissolved under heating 7.4 g of 2,4-cis-4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)piperidine and 4.0 g of N-p-toluenesulfonyl-D-phenylalanine. The solvent was concentrated by heating, 30 ml of diisopropyl ether was added thereto and the mixture was stirred. Precipitated crystals were removed and mother liquor was washed with a concentrated aqueous ammonia solution, dried and concentrated under reduced pressure. To the residue was added 4.0 g of N-p-toluenesulfonyl-L-phenylalanine, and 50 ml of ethyl acetate and 30 ml of diisopropyl ether were added thereto and dissolved by heating, the mixture was stirred at room temperature for 16 hours. Precipitated crystals were collected by filtration, washed with diisopropyl ether, and dried, to give 4.0 g of N-p-toluenesulfonyl-L-phenylalanine salt of (2R,4S)-4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-piperidine.

(2) The compound of the above (1) was dissolved in an aqueous ammonia solution, and after confirming that the solution was sufficiently basic, it was extracted with chloroform twice. The combined organic layers were dried and concentrated under reduced pressure, to give 2.6 g of (2R,4S)-4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-piperidine (optical purity: 96% ee) as shown in Table 133 below.

Reference Example 25

(1) In 50 ml of N,N-dimethylformamide was dissolved 7.5

g of 3-aminopropanol, and 16 g of tert-butyldimethylsilyl chloride and 6.8 g of imidazole were added thereto, and the mixture was stirred at room temperature for 16 hours. To the reaction mixture was added 11 g of citric acid and after 5 stirring the mixture at room temperature for an hour, the mixture was concentrated under reduced pressure. To the residue were added a 2M aqueous sodium hydroxide solution and diethyl ether and layers were separated. The organic layer was dried and concentrated under reduced pressure. The 10 residue and 12.1 g of 3,5-bistrifluoromethylbenzaldehyde were dissolved in 300 ml of dichloromethane and 21.2 g of sodium triacetoxy borohydride and 2.9 ml of acetic acid were added and the mixture was stirred at room temperature for 3 hours. To the reaction mixture was added a 2M aqueous sodium 15 carbonate solution. The mixture was stirred for 30 minutes, and extracted with chloroform twice. The combined organic layers were dried, concentrated under reduced pressure, and purified by silica gel column chromatography(hexane:ethyl acetate=4:1), to give 20 g of 3-tert- 20 butyldimethylsiloxypropyl-3,5-bistrifluoromethylbenzylamine.

(2) 12.5 g of the compound of the above (1) and the compound of Reference Example 5 were used and treated in the same manner as in Reference Example 6, to give 19 g of (2R)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-(3-tert- 25 butyldimethylsiloxypropyl)aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine.

(3) 19.0 g of the compound of the above (2) was used and treated in the same manner as in Reference Example 7, to give 19 g of (2R)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-(3- 30 hydroxypropyl)aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine as shown in Table 133 below.

Reference Example 26

(1) In 40 ml of dichloromethane was dissolved 4.8 g of the compound of Reference Example 5, and 4.4 g of di-tert- 35 butyldicarbonate was added thereto and the mixture was stirred at room temperature for 16 hours. The reaction

mixture was concentrated under reduced pressure. The residue was dissolved in 100 ml of acetone, and 200 mg of an acidic resin (IR-120) was added thereto and the mixture was stirred at room temperature for 3 days. After removing the resin 5 from the reaction mixture, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=4:1), to give 3.9 g of (R)-1-tert-butoxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine.

10 (2) In 20 ml of ethanol was dissolved 3.9 g of the compound of the above (1), added thereto was 400 mg of sodium borohydride at -20°C, and the mixture was stirred for an hour. To the reaction mixture was added an aqueous ammonium chloride solution, and ethanol was removed by distillation. 15 To the residue were added ethyl acetate and water and layers were separated, and further washed with water. The organic layer was dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=4:1), to give 3.1 g of (2R,4S)-1-tert- 20 butoxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-hydroxypiperidine.

25 (3) 3.1 g of the compound of the above (2) and the corresponding starting material were used and treated in the same manner as in Example 209, to give 2.3 g of (2R,4S)-1-tert-butoxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine.

30 (4) In 20 ml of a 4M hydrochloric acid-ethyl acetate solution was dissolved 2.3 g of the compound of the above (3), and the solution was stirred at room temperature for an hour. The reaction mixture was concentrated under reduced pressure. The residue was dried, to give 1.5 g of (2R,4S)-2-(4-fluoro-2-methylphenyl)-4-(2-acetoxyethylaminocarbonyloxy)piperidine hydrochloride.

35 (5) In 25 ml of a 1M aqueous sodium hydroxide solution was dissolved 1.5 g of the compound of the above (4), and the solution was extracted with chloroform twice. The combined

organic layers were dried and concentrated under reduced pressure. The residue was dried, to give 1.5 g of (2R,4S)-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine as shown in Table 133
5 below.

Reference Example 27

In 250 ml of acetonitrile was dissolved 4.8 g of 3,5-bistrifluoromethylbenzaldehyde, added thereto were 6.6 g of trimethylsulfonium iodide, 3.2 g of ground potassium hydroxide and 0.5 ml of water, and the mixture was stirred at a temperature of 65°C to 70°C for 16 hours, in the presence of an alumina ball. After the reaction was completed, insoluble matters were removed, and ethyl acetate and water were added to the filtrate and layers were separated. The 10 organic layer was washed, dried and concentrated under reduced pressure. To the residue was added 50 ml of a 40% methylamine-methanol solution, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was 15 purified by NH silica gel column chromatography (hexane:ethyl acetate=1:2), to give 1.23 g of 1-(3,5-bistrifluoromethylphenyl)-2-hydroxyethylamine as shown in Table 133 below.

Reference Example 28

25 (1) In 43 ml of dichloromethane were dissolved 2.45 g of 3,5-bistrifluoromethylbenzaldehyde, 835 mg of 2-methoxyethylamine and 687 µl of acetic acid, added thereto was 3.12 g of sodium triacetoxy borohydride, and the mixture was stirred at room temperature for an hour under nitrogen 30 atmosphere. The reaction mixture was washed with a 0.5M aqueous sodium hydroxide solution, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate=19:1→9:1), to give 2.76 g of 3,5-bistrifluoromethylbenzyl-2-methoxyethylamine.

35 MS (m/z): 302 [M⁺+1]⁺

(2) In a mixed solution of 37 ml of toluene and 4 ml of methylene chloride was dissolved 2.76 g of 3,5-bistrifluoromethylbenzyl-2-methoxyethylamine, added thereto was 1.78 g of 1,1'-carbonyldiimidazole, and the mixture was 5 stirred at 60°C for 3 hours. To the reaction mixture was added distilled water, and extracted with chloroform. The organic layer was dried over magnesium sulfate, dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography

10 (chloroform:acetone=9:1→ 2:1), to give 3.45 g of imidazole-1-carboxylic acid 3,5-bistrifluoromethylbenzyl-2-methoxyethylamide as shown in Table 133 below.

Reference Example 29

(1) In 15 ml of N,N-dimethylformamide were dissolved 15 3.94 g of 2-bromo-5-fluorophenol and 1.62 ml of methyl iodide, slowly added thereto was 5.08 g of potassium carbonate under ice-cooling. The mixture was stirred at room temperature for 3 hours. After insoluble matters were removed by filtration, distilled water was added to the filtrate, and the mixture 20 was extracted with diethyl ether and washed with saturated brine. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography-(hexane:ethyl acetate=19:1→9:1), to give 4.10 g of 1-bromo-4-fluoro-2-methoxybenzene.

25 MS (m/z) : 204/206 (M⁺+1).

(2) To 7 ml of tetrahydrofuran were added 486 mg of magnesium and trace of iodine, and dropped thereto was a solution of 4.10 g of the compound of the above(1) in 16 ml 30 of tetrahydrofuran, to prepare Grignard reagent. To the solution, a solution of 1.96 g of 4-methoxypyridine in 7 ml of tetrahydrofuran was added dropwise under nitrogen atmosphere at -60°C or below. Subsequently, a solution of 3.75 g of benzyl chloroformate in 18 ml of tetrahydrofuran 35 was added dropwise, and the mixture was stirred for 3 hours. The temperature of the mixture was raised to room temperature,

and 40 ml of a 5% aqueous citric acid solution was added thereto. The mixture was extracted with ethyl acetate and washed with saturated brine. The organic layer was dried and concentrated. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1→1:2), to give 3.15 g of 1-benzyloxycarbonyl-2-(4-fluoro-2-methoxyphenyl)-4-oxo-3,4-dihydro-2H-pyridine.

5 MS (m/z) : 356 [M⁺+1]

(3) In a mixed solution of 79 ml of ethanol and 6 ml of tetrahydrofuran was dissolved 3.15 g of the compound of the above (2), and added thereto was 706 mg of sodium borohydride and the mixture was stirred at room temperature for 6 hours. The reaction mixture was concentrated and distilled water was added to the residue. The mixture was extracted with chloroform, and the organic layer was dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:acetone=19:1→9:1), to give 1.62 g of 1-benzyloxycarbonyl-2-(4-fluoro-2-methoxyphenyl)-4-hydroxypiperidine.

10 MS (m/z) : 360 [M⁺+1]

(4) In 20 ml of toluene was dissolved 1.62 g of the compound of the above (3), added thereto was 876 mg of 1,1'-carbonyldiimidazole and the mixture was stirred at 60°C for an hour. Added thereto was 1.09 ml of ethanolamine, and the mixture was stirred at 60°C for 6 hours. To the reaction mixture was added distilled water and the mixture was extracted with chloroform. The organic layer was dried and concentrated. The residue was purified by silica gel column chromatography (chloroform:acetone=4:1→1:1), to give 1.81 g of 1-benzyloxycarbonyl-2-(4-fluoro-2-methoxyphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine.

15 MS (m/z) : 447 [M⁺+1]

(5) In 20 ml of methanol was dissolved 1.81 g of the compound of the above (4), and added thereto was 90 mg of 10% palladium-carbon, and the mixture was stirred at room temperature for an hour under hydrogen atmosphere. After

insoluble matters were removed by filtration, the filtrate was concentrated. To the residue was added diethyl ether and precipitates were collected by filtration, to give 1.30 g of 2-(4-fluoro 2-methoxyphenyl)-4-(2-
5 hydroxyethylaminocarbonyloxy)piperidine as shown in Table 134 below.

Reference Example 30

(1) In 40 ml of tetrahydrofuran was dissolved 5.46 g of 4-methoxypyridine, and added dropwise thereto was 55 ml of a
10 1M phenylmagnesiumbromide-tetrahydrofuran solution under nitrogen atmosphere at -60°C of below. Subsequently, added dropwise thereto was a solution of 10.24 g of benzyl chloroformate in 50 ml of tetrahydrofuran, and the mixture was stirred for 3 hours. The temperature of the mixture was
15 raised to room temperature, and 120 ml of a 5% aqueous citric acid solution was added thereto. The mixture was extracted with ethyl acetate and washed with saturated brine. The organic layer was dried and concentrated. To the residue was added diisopropyl ether and the precipitates were collected
20 by filtration, to give 8.51 g of 1-benzyloxycarbonyl-4-oxo-2-phenyl-3,4-dihydro-2H-pyridine.

MS (m/z) : 308 [M⁺+1]

(2) In 260 ml of acetic acid was dissolved 8.48 g of the compound of the above (1), added thereto was 3.61 g of
25 zinc powder, and the mixture was stirred at room temperature for 18 hours. Subsequently, 1.8 g of zinc powder was added and after stirring the mixture at room temperature for 6 hours, 1.8 g of zinc powder was further added thereto and the mixture was stirred at 50°C for 3 days. After insoluble
30 matters were removed by filtration, the filtrate was concentrated under reduced pressure. The residue was extracted with ethyl acetate, and washed with a saturated aqueous sodium hydrogen carbonate solution and saturated brine. The organic layer was dried and concentrated, to give
35 8.54 g of 1-benzyloxycarbonyl-4-oxo-2-phenylpiperidine.

MS (m/z) : 310 [M⁺+1]

(3) In 15 ml of tetrahydrofuran was dissolved 619 mg of the compound of the above (2), and added dropwise thereto was 4 ml of a 1M diisobutylaluminium hydride solution in toluene under nitrogen atmosphere at -60°C or below. The mixture was 5 stirred for 10 minutes. To the reaction mixture was added 667 µl of a 6M aqueous hydrochloric acid solution, and the mixture was concentrated. To the residue was added distilled water and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried and 10 concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1→1:1), to give 553 mg of 1-benzyloxycarbonyl-4-hydroxy-2-phenylpiperidine.

MS (m/z) : 312 [M⁺+1]

(4) In a mixed solution of 14 ml of toluene and 1.6 ml of dichloromethane was added 511 mg of the compound of the above (3), and added thereto was 319 mg of 1,1'-carbonyldiimidazole, and the mixture was stirred at 60°C for 2 hours. Added thereto was 396 µl of ethanolamine, and the 20 mixture was stirred at 60°C for 3 hours. To the reaction mixture was added distilled water and the mixture was extracted with chloroform. The organic layer was dried and concentrated. The residue was purified by silica gel column chromatography (chloroform:acetone=9:1→2:1), to give 462 mg 25 of 1-benzyloxycarbonyl-4-(2-hydroxyethylaminocarbonyloxy)-2-phenylpiperidine.

MS (m/z) : 399 [M⁺+1]

(5) In 10 ml of methanol was dissolved 430 mg of the compound of the above (4), and added thereto was 30 mg of 10% 30 palladium-carbon, and the mixture was stirred at room temperature for 5 days under hydrogen atmosphere. Insoluble matters were removed by filtration and the filtrate was concentrated, to give 348 mg of 4-(2-hydroxyethylaminocarboxyloxy)-2-phenylpiperidine as shown in 35 Table 134 below.

Reference Example 31

(1) In 47 ml of ethanol was dissolved 2.61 g of 3,5-bistrifluoromethylacetophenone, added thereto was 478 mg of sodium borohydride, and the mixture was stirred at room temperature for 30 minutes. To the reaction mixture was 5 added a saturated aqueous ammonium chloride solution and the mixture was concentrated. The residue was extracted with ethyl acetate and washed with saturated brine. The organic layer was dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography 10 (hexane:ethyl acetate=9:1→4:1), to give 2.51 g of 1-(3,5-bistrifluoromethylphenyl)-ethanol.

MS (m/z): 258 [M⁺+1]

(2) In a mixed solution of 40 ml of toluene and 4 ml of acetonitrile was dissolved 2.49 g of the compound of the 15 above (1), added thereto was 1.72 g of 1,1'-carbonyldiimidazole, and the mixture was stirred at room temperature for 3 hours. To the reaction mixture was added water and the mixture was extracted with ethyl acetate and washed with saturated brine. The organic layer was dried and 20 concentrated under reduced pressure, to give 3.40 g of 1-(3,5-bistrifluoromethylphenyl)ethyl imidazole-1-carboxylate as shown in Table 134 below.

Reference Example 32

To 1.74 g of magnesium and 40 ml of tetrahydrofuran was 25 added trace of iodine, and under nitrogen atmosphere and at room temperature, 10.4 g of 2-bromo-5-fluorotoluene was added dropwise spending 40 minutes. The reaction mixture was refluxed under heating for an hour, to prepare Grignard reagent solution. To the prepared Grignard reagent solution 30 was added dropwise 5.46 g of 4-methoxypyridine spending 20 minutes, at -40°C under nitrogen atmosphere. After completion of dropwise addition, the mixture was stirred at a temperature from -40°C to - 30°C for 30 minutes. Subsequently, the reaction mixture was cooled down to -40°C, 35 and while keeping the temperature at -40°C or below, added dropwise thereto was a solution of 12 g of di-tert-

butyldicarbonate in 20 ml of tetrahydrofuran. After completion of dropwise addition, the temperature of the reaction mixture was slowly raised. At -15°C, ice was added thereto and the mixture was stirred for 20 minutes. Further 5 added thereto was an aqueous citric acid solution and the mixture was stirred at room temperature for 40 minutes. Tetrahydrofuran was removed by distillation and to the resultant residue was added ethyl acetate, and extracted twice. The combined organic layers were washed with 10 saturated brine, dried and concentrated under reduced pressure. To the residue was added diisopropyl ether, and the obtained crystals were collected by filtration with diisopropyl ether, to give 11.9 g of 1-tert-butoxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxo- 3,4-dihydro-2H-pyridine as 15 shown in Table 134 below.

Reference Example 33

To 6.0 ml of ethanol were added 916 mg of 1-tert-butoxycarbonyl-2-(4-fluoro-2-methylphenyl)-4-oxo-3,4-dihydro-2H-pyridine and 110 mg of 10% palladium-carbon (moisture 20 content of 50.5%), and the mixture was stirred at room temperature for 12 hours under hydrogen atmosphere. After insoluble matters were removed by filtration, the solvent was removed by distillation. The residue was dissolved in 15 ml of toluene and the solution was cooled down to -78°C. To the 25 solution was slowly added dropwise 1.8 ml of butyl lithium aluminum hydride (a 65% by weight toluene solution) under nitrogen atmosphere. After completion of dropwise addition, the mixture was stirred at a temperature from -78°C to -60°C for an hour. To the reaction mixture was added a 1M aqueous 30 sodium hydroxide solution, and the mixture was stirred for 10 minutes. Formed precipitates were separated by filtration through Celite, and extracted with ethyl acetate twice. The organic layers were combined and washed with saturated aqueous ammonia and saturated brine. The organic layer was 35 dried and concentrated under reduced pressure. After adding 7.5 ml of ethyl acetate to the residue, slowly added dropwise

thereto was 7.5 ml of 4M hydrochloric acid-ethyl acetate solution under ice-cooling. Crystals were collected by filtration and washed with ethyl acetate. After drying, the crystals were added to a mixture of ethyl acetate-a 1M 5 aqueous sodium hydroxide solution, and stirred. The organic layer was separated and the aqueous layer was extracted with ethyl acetate for 3 times. The organic layers were combined and dried over sodium sulfate. The solvent was removed by distillation under reduced pressure, to give 471 mg of 2-(4-10 fluoro-2-methyl)phenyl-4-hydroxypiperidine as shown in Table 134 below.

Reference Example 34

In 3.0 ml of dichloromethane was dissolved 831 ml of triphosgene, and added dropwise thereto were a solution of 15 1.08 g of N-(3,5-bistrifluoromethylbenzyl)-N-methylamine and 1.76 ml of triethylamine in 5.0 ml of dichloromethane, spending 10 minutes, under nitrogen atmosphere under ice-cooling. The reaction mixture was stirred at 0°C to 5°C for 30 minutes. The solvent was removed by distillation, and the 20 residue was dried. To the residue were added water and dichloromethane and the mixture was extracted twice with dichloromethane. The organic layers were combined and washed with saturated brine, and dried. Then, the solvent was removed by distillation. The residue was purified by silica 25 gel column chromatography (hexane→hexane:ethyl acetate=10:1), to give 760 mg of N-(3,5-bistrifluoromethylbenzyl)-N-methylaminocarbonyl chloride as shown in Table 134 below.

Reference Example 35

In 20 ml of methanol was dissolved 24.5 g of 3,5-30 bistrifluoromethylbenzaldehyde, and under ice-cooling, added thereto was 60 ml of ethylamine (a 2M tetrahydrofuran solution). Subsequently, 4.38 g of sodium borohydride was slowly added thereto, and the mixture was stirred at room temperature for 3 hours. To the reaction mixture was added 35 distilled water and concentrated under reduced pressure. The residue was extracted with dichloromethane, and the organic

layer was dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=4:1→chloroform:methanol=9:1), to give 6.35 g of N-(3,5-bistrifluoromethylbenzyl)-N-ethylamine as

5 shown in Table 135 below.

Reference Example 36

(1) To 20 ml of tetrahydrofuran were added 1.34 g of magnesium and trace of iodine, and added dropwise thereto was a solution of 9.50 g of 2-bromotoluene in 45 ml of

10 tetrahydrofuran, to prepare Grignard reagent. To the Grignard reagent was added dropwise a solution of 5.46 g of 4-methoxypyridine in 20 ml of tetrahydrofuran under nitrogen atmosphere at -60°C or below. Subsequently, a solution of 10.24 g of chlorobenzyl formate in 50 ml of tetrahydrofuran

15 was added dropwise thereto at -40°C and the mixture was stirred for 3 hours. The temperature of the mixture was raised to room temperature and added thereto was 120 ml of a 5% aqueous citric acid solution. The mixture was extracted with ethyl acetate and washed with saturated brine. The

20 organic layer was dried and concentrated under reduced pressure. The residue was crystallized with diisopropyl ether, and the crystals were collected by filtration, to give 11.15 g of 1-benzyloxycarbonyl-2-(2-methylphenyl)-4-oxo-3,4-dihydro-2H-pyridine.

25 MS (m/z): 322 [M⁺+1]

(2) In a mixed solution of 125 ml of ethanol and 35 ml of tetrahydrofuran was dissolved 11.15 g of 1-benzyloxycarbonyl-2-(2-methylphenyl)-4-oxo-3,4-dihydro-2H-pyridine, added thereto was 2.76 g of sodium borohydride, and

30 the mixture was stirred at room temperature for a day. Further added thereto was 1.38 g of sodium borohydride, and the mixture was stirred at room temperature for a day. The reaction mixture was concentrated under reduced pressure and to the residue was added distilled water. The mixture was

35 extracted with chloroform, and the organic layer was dried and concentrated under reduced pressure. The residue was

purified by silica gel column chromatography (chloroform:acetone=49:1→9:1), to give 6.18 g of 1-benzyloxycarbonyl-4-hydroxy-2-(2-methylphenyl)piperidine. MS (m/z) : 326 [M⁺1]

5 (3) In 21 ml of toluene was dissolved 1.63 g of 1-benzyloxycarbonyl-4-hydroxy-2-(2-methylphenyl)piperidine, added thereto was 973 mg of 1,1'-carbonyldiimidazole, and the mixture was stirred at 60°C for an hour. To the solution was added 1.21 ml of ethanolamine, and the mixture was stirred at 10 60°C for 6 hours. To the reaction mixture was added distilled water, and extracted with chloroform. The organic layer was dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:acetone=9:1→chloroform:methanol=19:1), to give 15 1.34 g of 1-benzyloxycarbonyl-4-(2-hydroxyethylaminocarbonyloxy)-2-(2-methylphenyl)piperidine. MS (m/z) : 413 [M⁺1]

20 (4) In 30 ml of methanol was dissolved 1.33 g of 1-benzyloxycarbonyl-4-(2-hydroxyethylaminocarbonyloxy)-2-(2-methylphenyl)piperidine, and added thereto was 70 mg of 10% palladium-carbon, and the mixture was stirred at room 25 temperature for 14 hours under hydrogen atmosphere. After insoluble matters were removed by filtration, the filtrate was concentrated, to give 880 mg of 4-(2-hydroxyethylaminocarbonyloxy)-2-(2-methylphenyl)piperidine as shown in Table 135 below.

Reference Example 37

30 (1) 25 g of 4-fluoro-1-bromobenzene was used and treated in the same manner as in Reference Example 1, to give 22.3 g of 1-benzyloxycarbonyl-2-(4-fluorophenyl)-4-oxo-3,4-dihydro-2H-pyridine.

35 (2) In 400 ml of ethanol was dissolved 20 g of the compound of the above (1), and added thereto was 7.6 g of sodium borohydride, and the mixture was stirred at - 20°C for 2 hours. After reaction was completed, slowly added thereto was an aqueous citric acid solution until no foam was

generated. The solvent was removed by distillation under reduced pressure, and layers were separated with addition of water and chloroform. The aqueous layer was further extracted with chloroform, and the combined organic layers 5 were dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:ethyl acetate=10:1), to give 6.3 g of a mixture of (a) (2R,4S)-1-benzyloxycarbonyl- 2-(4-fluorophenyl)-4- hydroxypiperidine and (b) (2S,4R)-1- benzyloxycarbonyl-2-(4- 10 fluorophenyl)-4-hydroxypiperidine.

(3) 6.2 g of the compound of the above (2) was used and treated in the same manner as in Example 209, to give 7.3 g of a mixture of (a) (2R,4S)-1-benzyloxycarbonyl-2-(4- fluorophenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine 15 and (b) (2S,4R)-1-benzyloxycarbonyl-2-(4-fluorophenyl)-4-(2- hydroxyethylaminocarbonyloxy)piperidine.

(4) 6.3 g of the compound of the above (3) was used and treated in the same manner as in Reference Example 4, to give 2.6 g of a mixture of (a) (2R,4S)-2-(4-fluorophenyl)-4-(2- 20 hydroxyethylaminocarbonyloxy)piperidine and (b) (2S,4R)-2-(4-fluorophenyl)-4-(2- hydroxyethylaminocarbonyloxy)piperidine as shown in Table 135 below.

Reference Example 38

25 In 5 ml of methanol was dissolved 0.639 g of N-tosyl-D- phenylalanine, and the solution was warmed up to 59°C and then added dropwise thereto was 1.3 ml of methanol solution containing 0.418 g of 2-(4-fluoro-2-methyl)phenyl-4- hydroxypiperidine. After the crystals were formed in 20 30 minutes from the beginning of the crystallization, the other methanol solution in 2-(4-fluoro-2-methyl)phenyl-4- hydroxypiperidine was added dropwise to the mixture in the period of 5 minutes. The mixture was cooled down from 59°C to 30°C in one hour, and then the crystals were formed for 35 1.5 hours. The obtained crystal was removed by filtration and washed by cooled-methanol, and dried by air at 60°C for

one night to give 0.325 g of (2R,4S)-2-(4-fluro-2-methyl)phenyl-4-hydroxypiperidine N-tosyl-D-phenylalanine salt. The obtained salt was added 0.62 ml of a 2 M aqueous hydrogen chloride solution, the mixture was extracted with 5 ethyl acetate. The water layer was added 0.3 ml of a 5 M aqueous sodium hydroxide and then extracted with ethyl acetate for four times. The organic layer was dried, concentrated under reduced pressure, to give 0.129 g of (2R,4S)-2-(4-fluro-2-methyl)phenyl-4-hydroxypiperidine as 10 shown in Table 136 below.

Reference Example 39

In 40 ml of dichloromethane was dissolved 2.72 g of 2-methoxy-5-(5-trifluoromethyltetrazole-1-yl)benzaldehyde, and added thereto was 2.5 ml of 8 M methylamine in ethanol 15 solution, 0.572 ml of acetic acid and 3.12 g of triacetoxy sodium borohydride, the mixture was stirred at room temperature for 6 hours. The reaction mixture was washed with saturated aqueous sodium hydrocarbonate solution, and the organic layers were dried and concentrate. The residue 20 was purified by silica gel column chromatography (chloroform:methanol=49:1 to 4:1), to give 2.2 g of N-(2-methoxy-5-(5-trifluoromethyltetrazole-1-yl)benzyl)-N-methylamine as shown in Table 136 below.

Table 1




Example No.	Structural Formula	MS
1 (1)		493 ($M^{+}+1$)
1 (2) (a)		493 ($M^{+}+1$)
1 (2) (b)		493 ($M^{+}+1$)

Table 2

Example No.	Structural Formula	MS
2 (a)		507 ($M^{+}+1$)
2 (b)		507 ($M^{+}+1$)
3 (a)		493 ($M^{+}+1$)
3 (b)		493 ($M^{+}+1$)

Table 3





Example No.	Structural Formula	MS
4 (a)	 <i>and</i> 	507 ($M^{+}+1$)
4 (b)	 <i>and</i> 	507 ($M^{+}+1$)

Table 4





			
Example No.	R¹	n	MS
5		0	584 (M¹+1)
6		1	564 (M¹+1)
7		1	604 (M¹+1)

Table 5





Example No.	Structural Formula	MS
8 (a)	 and 	560 ($M^{+}+1$)
8 (b)	 and 	560 ($M^{+}+1$)

Table 6



Example No.	Structural Formula	MS
9 (a)	 <p>and</p>	546 ($M^{+}+1$)
9 (b)	 <p>and</p>	546 ($M^{+}+1$)

Table 7





Example No.	Structural Formula	MS
10 (a)	  and	520 ($M^{+}+1$)
10 (b)	  and	520 ($M^{+}+1$)

Table 8



Example No.	Structural Formula	MS
11 (a)	 <p>and</p> <p>548 ($M^{+}+1$)</p>	
11 (b)	 <p>and</p> <p>548 ($M^{+}+1$)</p>	

Table 9





Example No.	Structural Formula	MS
12 (a)	  <p>and</p>	643 ($M^{+}+1$)
12 (b)	 <p>and</p> 	643 ($M^{+}+1$)

Table 10





Example No.	Structural Formula	MS
13 (a)	  and	574 ($M^{+}+1$)
13 (b)	  and	574 ($M^{+}+1$)

Table 11



Example No.	Structural Formula	MS
14 (a)	 <p>and</p>	562 ($M^{+}+1$)
14 (b)	 <p>and</p>	562 ($M^{+}+1$)

Table 12











Example No.	R ¹	MS
15 (a)		560 (M ⁺ +1)
15 (b)		560 (M ⁺ +1)
16 (a)		546 (M ⁺ +1)
16 (b)		546 (M ⁺ +1)
17 (a)		562 (M ⁺ +1)
17 (b)		562 (M ⁺ +1)
18 (a)		520 (M ⁺ +1)
18 (b)		520 (M ⁺ +1)
19 (a)		548 (M ⁺ +1)
19 (b)		548 (M ⁺ +1)

Table 13

Example No.	R ¹	MS
20 (a)		574 (M ⁺ +1)
20 (b)		574 (M ⁺ +1)
21 (a)		560 (M ⁺ +1)
21 (b)		560 (M ⁺ +1)
22 (a)		576 (M ⁺ +1)
22 (b)		576 (M ⁺ +1)

Table 14







Example No.	R^1	MS
23 (a)		534 ($M^{+}+1$)
23 (b)		534 ($M^{+}+1$)
24 (a)		562 ($M^{+}+1$)
24 (b)		562 ($M^{+}+1$)
25 (a)		588 ($M^{+}+1$)
25 (b)		588 ($M^{+}+1$)

Table 15

Example No.	R^1	MS
26 (a)		574 (M^++1)
26 (b)		574 (M^++1)
27 (a)		560 (M^++1)
27 (b)		560 (M^++1)
28 (a)		576 (M^++1)
28 (b)		576 (M^++1)
29 (a)		534 (M^++1)
29 (b)		534 (M^++1)
30 (a)		576 (M^++1)
30 (b)		576 (M^++1)

Table 16









Example No.	R^1	n	MS
31		1	534 (M^++1)
32		2	605 (M^++1)
33		1	564 (M^++1)
34		1	559 (M^++1)
35		2	577 (M^++1)
36		1	506 (M^++1)
37		1	562 (M^++1)
38		2	611 (M^++1)

Table 17





		
Example No.	R¹	MS
39		578 (M¹⁺¹)
40		604 (M¹⁺¹)
41		578 (M¹⁺¹)
42		605 (M¹⁺¹)

Table 18


		
Example No.	R¹	MS
43 (a)		574 (M¹+1)
43 (b)		574 (M¹+1)
44 (a)		560 (M¹+1)
44 (b)		560 (M¹+1)

Table 19



Example No.	Structural Formula	MS
45	 HCl	492 ($M^{+}+1$)
46	 HCl	492 ($M^{+}+1$)

Table 20





Example No.	Structural Formula	MS
47 (a)	 and 	592 ($M^{+}+1$)
47 (b)	 and 	592 ($M^{+}+1$)

Table 21



Example No.	Structural Formula	MS
48	 and	492 ($M^{+}+1$)
49	 and	492 ($M^{+}+1$)

Table 22



Example No.	Structural Formula	MS
50 (a)		548 ($M^{+}+1$)
50 (b)		548 ($M^{+}+1$)

Table 23



Example No.	Structural Formula	MS
51 (a)		562 ($M^{+}+1$)
51 (b)		562 ($M^{+}+1$)

Table 24



Example No.	Structural Formula	MS
52 (a)		576 ($M^{+}+1$)
52 (b)		576 ($M^{+}+1$)

Table 25





Example No.	Structural Formula	MS
53 (a)	 <p>and</p> 	550 ($M^{+}+1$)
53 (b)	 <p>and</p> 	550 ($M^{+}+1$)

Table 26




Example No.	Structural Formula	MS
54 (a)	 	564 ($M^{+}+1$)
54 (b)		564 ($M^{+}+1$)

Table 27



Example No.	Structural Formula	MS
55 (a)		596 ($M^{+}+1$)
55 (b)		596 ($M^{+}+1$)

Table 28





Example No.	Structural Formula	MS
56 (a)	 and 	641 ($M^{+}+1$)
56 (b)	 and 	641 ($M^{+}+1$)

Table 29

Example No.	R^1	MS
57 (a)		562 ($M^{+}+1$)
57 (b)		562 ($M^{+}+1$)
58 (a)		604 ($M^{+}+1$)
58 (b)		604 ($M^{+}+1$)
59 (a)		584 ($M^{+}+1$)
59 (b)		584 ($M^{+}+1$)
60 (a)		586 ($M^{+}+1$)
60 (b)		586 ($M^{+}+1$)

Table 30








Example No.	R^1	MS
61 (a)		602 ($M^{+}+1$)
61 (b)		602 ($M^{+}+1$)
62 (a)		584 ($M^{+}+1$)
62 (b)		584 ($M^{+}+1$)
63		588 ($M^{+}+1$)
64 (a)		602 ($M^{+}+1$)
64 (b)		602 ($M^{+}+1$)

Table 31




		
Example No.	R¹	MS
65 (a)		649 (M¹+1)
65 (b)		649 (M¹+1)

Table 32





Example No.	Structural Formula	MS
66	  <p>and</p>	646 ($M^{+}+1$)
67	  <p>and</p>	657 ($M^{+}+1$)

Table 33





Example No.	Structural Formula	MS
68	  <p>and</p>	597 ($M^{+}+1$)
69	 <p>and</p> 	703 ($M^{+}+1$)

Table 34




		
Example No.	R ¹	MS
70		534 (M ⁺ +1)
71		597 (M ⁺ +1)

Table 35




		
Example No.	R ¹	MS
72		549 (M ⁺ +1)
73		577 (M ⁺ +1)

Table 36



Example No.	Structural Formula	MS
74	  HCl	611 ($M^{+}+1$)

Table 37






		
Example No.	R¹	MS
75		562 (M¹+1)
76		562 (M¹+1)
77		576 (M¹+1)
78		576 (M¹+1)

Table 38

Example No.	R¹	MS
79 (a)		562 (M¹⁺¹)
79 (b)		562 (M¹⁺¹)
80 (a)		576 (M¹⁺¹)
80 (b)		576 (M¹⁺¹)

Table 39

Example No.	Structural Formula	MS
81		606 ($M^{+}+1$)
82		606 ($M^{+}+1$)
83		606 ($M^{+}+1$)
84		606 ($M^{+}+1$)

Table 40

Example No.	Structural Formula	MS
85		506 ($M^{+}+1$)
86		506 ($M^{+}+1$)

Table 41

Example No.	R^1	MS
87		584 ($M^{+}+1$)
88		598 ($M^{+}+1$)
89		598 ($M^{+}+1$)
90		612 ($M^{+}+1$)

Table 42












Example No.	R^1	MS
91		621 ($M^{+}+1$)
92		537 ($M^{+}+1$)
93		588 ($M^{+}+1$)
94		589 ($M^{+}+1$)
95		603 ($M^{+}+1$)
96		615 ($M^{+}+1$)
97 (2)		606 ($M^{+}+1$)
98		592 ($M^{+}+1$)
99		564 ($M^{+}+1$)
100		606 ($M^{+}+1$)
101		588 ($M^{+}+1$)

Table 43

Example No.	R¹	MS
102 (2)		619 (M¹⁺¹)
103		607 (M¹⁺¹)
104		647 (M¹⁺¹)
105		649 (M¹⁺¹)

Table 44




Example No.	Structural Formula	MS
106 (2)	 	493 ($M^{+}+1$)
107		544 ($M^{+}+1$)

Table 45


Example No.	Structural Formula	MS
108		619 ($M^{+}+1$)

Table 46







Example No.	R^1	MS
109		507 (M^++1)
110		558 (M^++1)
111		559 (M^++1)
112		624 (M^++1)
113 (2)		577 (M^++1)
114 (2)		618 (M^++1)
115		604 (M^++1)
116		633 (M^++1)
117		631 (M^++1)

Table 47

Example No.	Structural Formula	MS
118 (2)		506 (M^++1)
119		492 (M^++1)
120 (a)		612 (M^++1)
120 (b)		612 (M^++1)

Table 48

Example No.	Structural Formula	MS
121		590 ($M^{+}+1$)
122		590 ($M^{+}+1$)
123		592 ($M^{+}+1$)
124		592 ($M^{+}+1$)

Table 49





Example No.	Structural Formula	MS
125		506 (M^++1)
126		520 (M^++1)
127		520 (M^++1)
128		604 (M^++1)

Table 50

Example No.	Structural Formula	MS
129		548 (M^++1)
130		576 (M^++1)
131		614 (M^++1)
132		548 (M^++1)
133		590 (M^++1)

Table 51

Example No.	Structural Formula	MS
134		578 (M^++1)
135		576 (M^++1)
136		590 (M^++1)
137	 and 	597 (M^++1)

Table 52




		
Example No.	R¹	MS
138 (a)		614 (M¹+1)
138 (b)		614 (M¹+1)

Table 53









Example No.	R^1	MS
140		628 ($M^{+}+1$)
141		600 ($M^{+}+1$)
142		616 ($M^{+}+1$)
143		564 ($M^{+}+1$)
144		592 ($M^{+}+1$)
145		594 ($M^{+}+1$)
146		646 ($M^{+}+1$)
147		611 ($M^{+}+1$)

Table 54




		
Example No.	R ¹	MS
148		576 (M ⁺ +1)
149		630 (M ⁺ +1)

Table 55

Table 56

Example No.	R^1	MS
158		578 ($M^{+}+1$)
159		606 ($M^{+}+1$)
160		592 ($M^{+}+1$)
161		592 ($M^{+}+1$)
162		606 ($M^{+}+1$)
163		606 ($M^{+}+1$)
164		616 ($M^{+}+1$)
165		590 ($M^{+}+1$)

Table 57

Example No.	R^1	MS
166		592 ($M^{+}+1$)
167		578 ($M^{+}+1$)
168		677 ($M^{+}+1$)
169		593 ($M^{+}+1$)
170		621 ($M^{+}+1$)
171		607 ($M^{+}+1$)
172		607 ($M^{+}+1$)
173		607 ($M^{+}+1$)

Table 58








		
Example No.	R¹	MS
174		618 (M¹⁺¹)
175		614 (M¹⁺¹)
176		628 (M¹⁺¹)
177		613 (M¹⁺¹)
178		596 (M¹⁺¹)
179		610 (M¹⁺¹)

Table 59

Example No.	R^1	MS
180	$\begin{array}{c} \text{H}_3\text{C} \\ \text{S} \\ \text{O} \end{array} \text{H} \text{N} \text{O}$	584 (M^++1)
181	$\begin{array}{c} \text{H}_3\text{C} \\ \text{S} \\ \text{O} \end{array} \text{H} \text{N} \text{O}$	598 (M^++1)
183	$\begin{array}{c} \text{H}_3\text{C} \\ \text{S} \\ \text{O} \end{array} \text{CH}_3 \text{N} \text{O}$	584 (M^++1)
184	$\begin{array}{c} \text{H}_3\text{C} \\ \text{S} \\ \text{O} \end{array} \text{CH}_3 \text{N} \text{O}$	598 (M^++1)
185	$\text{H}_3\text{CO} \text{O}$	565 (M^++1)
186	$\text{HO} \text{O}$	551 (M^++1)
187	$\text{HO} \text{O}$	565 (M^++1)

Table 60

Example No.	R ¹	MS
188		551 (M ⁺ +1)
189		565 (M ⁺ +1)
190		629 (M ⁺ +1)
191		620 (M ⁺ +1)
192		606 (M ⁺ +1)

Table 61






		
Example No.	R¹	MS
193		620 (M¹+1)
194		606 (M¹+1)
195		578 (M¹+1)
196		604 (M¹+1)

Table 62


 Chemical structure of a piperidine derivative. It features a piperidine ring substituted with an imidazole ring at the 4-position, an acetoxy group at the 5-position, and a 4-(trifluoromethyl)phenyl group at the 2-position. The 2-position of the piperidine ring is also substituted with a 4-(trifluoromethyl)phenyl group and an R ₄ group. The 3-position of the piperidine ring is substituted with a 4-fluorophenyl group.		
Example No.	R ⁴	MS
197	 A methyl group (CH ₃) with a wedge bond.	601 (M ⁺ +1)
198	 A methyl group (CH ₃) with a dash bond.	601 (M ⁺ +1)

Table 63






		
Example No.	R ¹	MS
199		634 (M ⁺ +1)
200		633 (M ⁺ +1)
201		608 (M ⁺ +1)
202		594 (M ⁺ +1)

Table 64




Example No.	R^1	MS
203		594 (M^++1)
204		662 (M^++1)
205		633 (M^++1)

Table 65

Example No.	R^1	MS
206		578 ($M^{+}+1$)
207		616 ($M^{+}+1$)
208		685 ($M^{+}+1$)
209		622 ($M^{+}+1$)
210		580 ($M^{+}+1$)
211		594 ($M^{+}+1$)
212		594 ($M^{+}+1$)
213		638 ($M^{+}+1$)
214		654 ($M^{+}+1$)

Table 66









Example No.	R^1	MS
215	 	622 ($M^{+}+1$)
216	 	563 ($M^{+}+1$)
217	 	605 ($M^{+}+1$)
218	 	577 ($M^{+}+1$)

Table 67









Example No.	R^1	MS
219		577 (M^++1)
220		591 (M^++1)
221		605 (M^++1)
222		577 (M^++1)
223		619 (M^++1)
224		603 (M^++1)
225		632 (M^++1)
226		564 (M^++1)

Table 68

Example No.	R^1	MS
227	$CH_3OCH_2OCH_2N^+H$	564 ($M^{+}+1$)
228	$C_2H_5OCH_2N^+H$	578 ($M^{+}+1$)
229	$ClCH_2OCH_2N^+H$	598 ($M^{+}+1$)
230	$C_2H_5OCH_2OCH_2N^+H$	622 ($M^{+}+1$)
231	$CH_3CH(OH)CH_2OCH_2N^+H$	636 ($M^{+}+1$)




Table 69









 $n\text{HCl}$			
Example No.	R¹	n	MS
232		1	683 (M⁺+1)
233		2	696 (M⁺+1)
234		1	681 (M⁺+1)
235		1	669 (M⁺+1)
236		1	697 (M⁺+1)
237		1	683 (M⁺+1)
238		1	685 (M⁺+1)

Table 70







		
Example No.	R ¹	MS
239		618 (M ⁺ +1)
240		638 (M ⁺ +1)
241		608 (M ⁺ +1)
242		677 (M ⁺ +1)
243		685 (M ⁺ +1)

Table 71

Example No.	R ¹	MS
244		604 (M ⁺ +1)
245 (a)		569 (M ⁺ +1)
245 (b)		569 (M ⁺ +1)
246		583 (M ⁺ +1)

Table 72

Example No.	Structural Formula	MS
247		660 ($M^{+}+1$)
248		549 ($M^{+}+1$)
249 (a)		563 ($M^{+}+1$)
249 (b)		563 ($M^{+}+1$)

Table 73

Example No.	Structural Formula	MS
249 (c)		563 (M ⁺ +1)
250 (2)		534 (M ⁺ +1)
251		578 (M ⁺ +1)
252		534 (M ⁺ +1)
253		578 (M ⁺ +1)

Table 74

Example No.	Structural Formula	MS
254 (2)		565 (M^++1)
255		565 (M^++1)
256		551 (M^++1)
257		537 (M^++1)
258		567 (M^++1)
259		581 (M^++1)

Table 75

Example No.	Structural Formula	MS
260		567 ($M^{+}+1$)
261		523 ($M^{+}+1$)
262		553 ($M^{+}+1$)
263		567 ($M^{+}+1$)

Table 76

Example No.	Structural Formula	MS
264		610 ($M^{+}+1$)
265		553 ($M^{+}+1$)
266		583 ($M^{+}+1$)
267		583 ($M^{+}+1$)
268		539 ($M^{+}+1$)

Table 77



Example No.	Structural Formula	MS
269		569 ($M^{+}+1$)
270		597 ($M^{+}+1$)

Table 78

Example No.	Structural Formula	MS
271		626 ($M^{+}+1$)
272		569 ($M^{+}+1$)
273		599 ($M^{+}+1$)
274		613 ($M^{+}+1$)
275		599 ($M^{+}+1$)

Table 79




Example No.	Structural Formula	MS
276		555 ($M^{+}+1$)
277		585 ($M^{+}+1$)
278		613 ($M^{+}+1$)

Table 80


Example No.	Structural Formula	MS
279		604 ($M^{+}+1$)

Table 81

Example No.	R ¹	MS
280		564 (M ⁺ +1)
281		592 (M ⁺ +1)

Table 82

Example No.	R^1	MS
282		550 ($M^{+}+1$)
283		564 ($M^{+}+1$)
284		564 ($M^{+}+1$)
285		578 ($M^{+}+1$)
286		578 ($M^{+}+1$)
287		603 ($M^{+}+1$)
288		591 ($M^{+}+1$)
289		605 ($M^{+}+1$)

Table 83









		
Example No.	R^1	MS
290		605 (M^++1)
291		619 (M^++1)
292		645 (M^++1)
293		552 (M^++1)
294		617 (M^++1)
295		646 (M^++1)
296		663 (M^++1)

Table 84







Example No.	R^1	MS
297		706 ($M^{+}+1$)
298		795 ($M^{+}+1$)
299		668 ($M^{+}+1$)
300		566 ($M^{+}+1$)
301		605 ($M^{+}+1$)
302		619 ($M^{+}+1$)

Table 85

Example No.	R^1	MS
303		619 (M^++1)
304		633 (M^++1)
305		659 (M^++1)
306		617 (M^++1)
307		631 (M^++1)
308		660 (M^++1)
309		677 (M^++1)

Table 86

Example No.	R^1	MS
310		564 ($M^{+}+1$)
311		564 ($M^{+}+1$)
312		603 ($M^{+}+1$)
313		737 ($M^{+}+1$)
314		605 ($M^{+}+1$)
315		648 ($M^{+}+1$)

Table 87




Table 88

Example No.	R^1	MS
320		607 (M^++1)
321		621 (M^++1)
322		621 (M^++1)
323		594 (M^++1)
324		608 (M^++1)
325		624 (M^++1)
326		580 (M^++1)

Table 89




Example No.	Structural Formula	MS
327		510 ($M^{+}+1$)
328	 	576 ($M^{+}+1$)

Table 90














Example No.	Structural Formula	MS
329	 	576 ($M^{+}+1$)
330	 	548 ($M^{+}+1$)

Table 91

Example No.	R^1	MS
331		563 ($M^{+}+1$)
332		521 ($M^{+}+1$)
333		570 ($M^{+}+1$)
334		584 ($M^{+}+1$)
335 (3)		506 ($M^{+}+1$)
336 (2)		521 ($M^{+}+1$)
337		578 ($M^{+}+1$)
338		604 ($M^{+}+1$)
339		631 ($M^{+}+1$)
340		602 ($M^{+}+1$)












Table 92

Example No.	R^1	MS
341 (2)		535 (M^++1)
342		548 (M^++1)
343		592 (M^++1)
344		592 (M^++1)
345		604 (M^++1)
346		620 (M^++1)
347		618 (M^++1)
348		645 (M^++1)
349		622 (M^++1)

250

Table 93










		
Example No.	R¹	MS
350		521 (M¹+1)
351		608 (M¹+1)
352		622 (M¹+1)

Table 94

Example No.	R^1	MS
353		535 ($M^{+}+1$)
354		592 ($M^{+}+1$)
355		592 ($M^{+}+1$)
356		606 ($M^{+}+1$)
357		592 ($M^{+}+1$)
358		618 ($M^{+}+1$)
359		645 ($M^{+}+1$)




Table 95

Example No.	R^1	MS
360		695 (M^++1)
361		616 (M^++1)
362		681 (M^++1)
363		681 (M^++1)
364		622 (M^++1)
365		618 (M^++1)

Table 96

Example No.	R ¹	MS
366		612 (M ⁺ +1)
367		521 (M ⁺ +1)

Table 97

Example No.	R ¹	MS
368		581 (M ⁺ +1)
369		613 (M ⁺ +1)
370		553 (M-1)
371		537 (M-I)

Table 98

Example No.	R ¹	MS
372		579 (M ⁺ +1)
373		636 (M ⁺ +1)
374		692 (M ⁺ +1)
375		708 (M ⁺ +1)
376		650 (M ⁺ +1)

Table 99

Example No.	R ¹	MS
377		608 (M ⁺ +1)
378		537 (M ⁺ +1)
379		594 (M ⁺ +1)
380		650 (M ⁺ +1)
381		666 (M ⁺ +1)
382		682 (M ⁺ +1)
383 (3)		611 (M ⁺ +1)
384		627 (M ⁺ +1)

Table 100



Example No.	Ring B	MS
385		472 (M^++1)
386		512 (M^++1)

Table 101





Example No.	Structural Formula	MS
387	 	652 ($M^{+}+1$)
388	 	610 ($M^{+}+1$)

Table 102

Example No.	R^1	MS
389 (2)		676 ($M^{+}+1$)
390		648 ($M^{+}+1$)
391		691 ($M^{+}+1$)
392		705 ($M^{+}+1$)
393		705 ($M^{+}+1$)
394		705 ($M^{+}+1$)

Table 103

Example No.	R^1	MS
395		719 ($M^{+}+1$)
396		733 ($M^{+}+1$)
397		735 ($M^{+}+1$)
398		721 ($M^{+}+1$)

Table 104





Example No.	R^1	MS
399	 <p>Chemical structure of Example 399: A piperazine derivative substituted with a 4-(4,4,4-trifluorobenzyl)amino group and an R^1 group.</p>	719 ($M^{+}+1$)
400	 <p>Chemical structure of Example 400: A piperazine derivative substituted with a 4-(2-hydroxy-2-methylpropyl)amino group.</p>	705 ($M^{+}+1$)
401	 <p>Chemical structure of Example 401: A piperazine derivative substituted with a 4-(2-hydroxy-2-methylbutyl)amino group.</p>	705 ($M^{+}+1$)
402	 <p>Chemical structure of Example 402: A piperazine derivative substituted with a 4-(2-hydroxy-2-methylpentyl)amino group.</p>	705 ($M^{+}+1$)

Table 105






		
Example No.	R ¹	MS
403		594 (M ⁺ +1)
404		636 (M ⁺ +1)
405		652 (M ⁺ +1)
406		668 (M ⁺ +1)

Table 106


Example No.	Structural Formula	MS
407		565 (M ⁺ +1)

Table 107









Example No.	R^1	MS
408		567 ($M^{+}+1$)
409		567 ($M^{+}+1$)
410		567 ($M^{+}+1$)
411		580 ($M^{+}+1$)
412		594 ($M^{+}+1$)
413		594 ($M^{+}+1$)
414		652 ($M^{+}+1$)
415 (2)		610 ($M^{+}+1$)

Table 108

Table 109

Example No.	R^1	MS
424	$H_3CS\sim N^{\text{H}}(O)C(=O)R^1$	610 (M^++1)
425	$H_3CS\sim\sim N^{\text{H}}(O)C(=O)R^1$	624 (M^++1)
426	$H_3C\sim S(=O)O\sim N^{\text{H}}(O)C(=O)R^1$	642 (M^++1)
427	$H_3C\sim S(=O)O\sim\sim N^{\text{H}}(O)C(=O)R^1$	656 (M^++1)

Table 110






		
Example No.	R ¹	MS
428		646 (M ⁺ +1)
429		621 (M ⁺ +1)
430		660 (M ⁺ +1)
431		635 (M ⁺ +1)

Table 111





Example No.	R^1	MS
432		637 ($M^{+}+1$)
433		651 ($M^{+}+1$)
434		653 ($M^{+}+1$)
435		667 ($M^{+}+1$)

Table 112

Example No.	Structural Formula	MS
436		624 ($M^{+}+1$)
437		596 ($M^{+}+1$)
438		562 ($M^{+}+1$)
439		548 ($M^{+}+1$)

Table 113

Example No.	R¹	MS
440		493 (M¹+1)
441		580 (M¹+1)
442 (a)		592 (M¹+1)
442 (b)		592 (M¹+1)
443		492 (M¹+1)

Table 114









Example No.	R ¹	MS
444		597 (M ⁺ +1)
445		613 (M ⁺ +1)
446		611 (M ⁺ +1)
447		611 (M ⁺ +1)
448		627 (M ⁺ +1)
449		625 (M ⁺ +1)
450		594 (M ⁺ +1)
451		594 (M ⁺ +1)

Table 115









Example No.	R^1	MS
452		592 ($M^{+}+1$)
453		592 ($M^{+}+1$)
454		612 ($M^{+}+1$)
455		626 ($M^{+}+1$)
456		606 ($M^{+}+1$)
457		631 ($M^{+}+1$)
458		611 ($M^{+}+1$)
459		626 ($M^{+}+1$)

Table 116









		
Example No.	R^1	MS
460		627 (M^++1)
461		655 (M^++1)
462		617 (M^++1)
463		578 (M^++1)
464		604 (M^++1)
465		618 (M^++1)
466		573 (M^++1)

Table 117

Example No.	Structural Formula	MS
467		578 (M^++1)
468		620 (M^++1)
469		592 (M^++1)

Table 118

Example No.	R^1	MS
470		579 (M^++1)
471		593 (M^++1)
472		593 (M^++1)
473		593 (M^++1)
474		593 (M^++1)
475		593 (M^++1)
476		593 (M^++1)

Table 119






		
Example No.	R¹	MS
477		607 (M⁺+1)
478		607 (M⁺+1)
479		607 (M⁺+1)
480		607 (M⁺+1)

Table 120

Example No.	R^1	MS
481(a)		605 (M^++1)
481(b)		605 (M^++1)
482		619 (M^++1)

Table 121

Example No.	R^1	MS
483		619 (M^++1)
484		633 (M^++1)

Table 122

Example No.	R^1	MS
485		619 (M^++1)
486		633 (M^++1)

Table 123

Example No.	Structural Formula	MS
487		580 (M^++1)

Table 124


Example No.	Structural Formula	MS
488(2)		610 (M ⁺⁺¹)

Table 125

Reference Example No.	Structural Formula	MS
1		340 (M ⁺ +1)
2		342 (M ⁺ +1)
3		388 (M ⁺ +1)
4		254 (M ⁺ +1)
5		254 (M ⁺ +1)

Table 126

Reference Example No.	Structural Formula	MS
6		505 (M ⁺ +1)
7		491 (M ⁺ +1)
8		505 (M ⁺ +1)
9		505 (M ⁺ +1)
10		505 (M ⁺ +1)
11 (1)		491 (M ⁺ +1)

Table 127




Reference Example No.	Structural Formula	MS
11 (2)		505 ($M^{+}+1$)
12 (a)		399 ($M^{+}+1$)
12 (b)		399 ($M^{+}+1$)

Table 128





Reference Example No.	Structural Formula	MS
13 (a)	 <p>and</p> 	413 (M ⁺ +1)
13 (b)	 <p>and</p> 	413 (M ⁺ +1)

Table 129



Reference Example No.	Structural Formula	MS
14		265 ($M^{+}+1$)
15		265 ($M^{+}+1$)

Table 130

Reference Example No.	Structural Formula	MS
16		279 ($M^{+}+1$)
17		279 ($M^{+}+1$)

Table 131





Reference Example No.	Structural Formula	MS
18 (a)	 <p>and</p> 	443 ($M^{+}+1$)
18 (b)	 <p>and</p> 	443 ($M^{+}+1$)

Table 132







Reference Example No.	Structural Formula	MS
19	 <p>and</p>	309 ($M^{+}+1$)
20		173 ($M^{+}+1$)
21		186 ($M^{+}+1$)
22		260 ($M^{+}+1$)
23	 <p>and</p> 	266 ($M^{+}+1$)

Table 133

Reference Example No.	Structural Formula	MS
24 (2)		266 (M ⁺ +1)
25 (3)		535 (M ⁺ +1)
26 (5)		297 (M ⁺ +1)
27		288 (M ⁺ +1)
28 (2)		396 (M ⁺ +1)

Table 134

Reference Example No.	Structural Formula	MS
29 (5)		313 (M ⁺ +1)
30 (5)		265 (M ⁺ +1)
31 (2)		353 (M ⁺ +1)
32		306 (M ⁺ +1)
33		210 (M ⁺ +1)
34		319 (M ⁺ +1)

Table 135






Reference Example No.	Structural Formula	MS
35		272 (M ⁺ +1)
36 (4)		279 (M ⁺ +1)
37 (4)		283 (M ⁺ +1)

Table 136


Reference Example No.	Structural Formula	MS
38		210 (M^++1)
39		288 (M^++1)

Industrial Applicability

The compound of the present invention or a salt thereof has an excellent tachykinin receptor antagonistic action. Further, the compound of the present invention or a salt thereof is excellent in terms of safety, absorption, transportability into brain, metabolic stability, concentration in blood and sustainability, so that it has excellent pharmaceutical effects.


CLAIMS

1. A piperidine compound represented by the formula [I]:



5 wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R^1 represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, a substituted thiol group, a substituted carbonyl group, a substituted sulfinyl group, a substituted sulfonyl group, or a group represented by the formula:

10 15 20 25



wherein R^{11} and R^{12} are the same or different and each is hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group, a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, or R^{11} and R^{12} are taken together, with an adjacent nitrogen atom, to form a heterocyclic group selected from piperidino group, azacycloheptyl group, pyrrolidino group, imidazolidinyl group, hexahdropyrimidinyl group, thiazolidyl group, morpholino group, triazolyl group, tetrazolyl group and purinyl group, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained

in the heterocyclic group is optionally oxidized, R² represents hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, Z represents oxygen atom or a group represented by -N(R³)-, wherein R³ represents hydrogen atom or an optionally substituted alkyl group and R⁴ represents hydrogen atom or an optionally substituted alkyl group,

5 10 or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1, wherein R¹ is an optionally substituted alkyl group.

3. The compound according to Claim 1, wherein R¹ is an optionally substituted hydroxyl group.

15 4. The compound according to Claim 1, wherein R¹ is a substituted thiol group.


5. The compound according to Claim 1, wherein R¹ is a substituted carbonyl group.

6. The compound according to Claim 1, wherein R¹ is a

20 substituted sulfinyl group.

7. The compound according to Claim 1, wherein R¹ is a substituted sulfonyl group.

8. The compound according to Claim 1, wherein R¹ is a group represented by the formula:



25 wherein R¹¹ and R¹² are the same or different and each is hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, or R¹¹ and R¹² are taken together, with an

30

adjacent nitrogen atom, to form a heterocyclic group selected from piperidino group, azacycloheptyl group, pyrrolidino group, imidazolidinyl group, hexahdropyrimidinyl group, thiazolidyl group, morpholino group, triazolyl group, tetrazolyl group and purinyl group, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized.

5 9. A compound selected from the following (a) to (q):

10 (a) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxy-2-methylpropionylamino)piperidine,

(b) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((S)-3-15 hydroxybutyrylamino)piperidine,

(c) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethyl-aminocarbonyloxy)piperidine,

(d) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(3-20 hydroxy-3-methylbutyrylamino)piperidine,

(e) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((R)-3-hydroxybutyrylamino)piperidine,

(f) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxy-2-methylpropanesulfonyl)piperidine,

(g) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxy-2-30 methylpropanesulfinyl)piperidine,

(h) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((S)-2-hydroxypropanesulfonyl)piperidine,

(i) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-35 aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((S)-3-hydroxybutyrylamino)piperidine,

(j) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((R)-3-hydroxybutyrylamino)piperidine,

5 (k) (2R,4S)-4-(4-acetyl piperazinocarbonyl)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)piperidine,

(l) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-oxothiomorpholinocarbonyloxy)piperidine,

10 (m) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethanesulfonyl)piperidine,

(n) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-amino- carbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-methyl-15 ethanesulfonyl)piperidine,

(o) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(4-hydroxypiperidinocarbonyl)piperidine,

(p) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-20 aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-methanesulfonyl-piperidine,


(q) (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}-aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-((R)-2-hydroxypropionyl)piperidine,

25 (r) (2R,4S)-1-[N-{1-(S)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyacetyl amino)piperidine, and

(s) (2R,4S)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methyl]aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(1-30 methylethylthio)piperidine,

or a pharmaceutically acceptable salt thereof.


10. A method for preparing a piperidine compound of the formula [I']:



5

wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R¹ represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, a substituted thiol group, a substituted carbonyl group, a substituted sulfinyl group, a substituted sulfonyl group, or a group represented by the formula:

10



15


20

25

wherein R¹¹ and R¹² are the same or different and each is hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, or R¹¹ and R¹² are taken together, with an adjacent nitrogen atom, to form a heterocyclic group selected from piperidino group, azacycloheptyl group, pyrrolidino group, imidazolidinyl group, hexahdropyrimidinyl group, thiazolidyl group, morpholino group, triazolyl group, tetrazolyl group and purinyl group, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, R² represents hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group,


an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, R³ represents hydrogen atom or an optionally substituted alkyl group and R⁴ represents hydrogen atom or an optionally substituted alkyl group,

5 or a pharmaceutically acceptable salt thereof, comprising reacting a compound of the formula [II]:



wherein Ring A, R¹ and R² have the same meanings as
10 defined above,


with a compound of the formula [III]:



wherein Ring B, R³ and R⁴ have the same meanings as
defined above,


15 in the presence of a urea bond forming agent, and if desired, converting into a pharmaceutically acceptable salt thereof.

11. A method for preparing a piperidine compound of the formula [I-a]:




20 wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R² represents hydrogen atom, an optionally substituted hydroxyl group, an optionally

substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, Z represents oxygen atom or a group represented by $-N(R^3)-$, wherein R^3 represents hydrogen atom or an 5 optionally substituted alkyl group and R^4 represents hydrogen atom or an optionally substituted alkyl group, or a pharmaceutically acceptable salt thereof, comprising reducing a compound of the formula [IV]:




10 wherein Ring A, Ring B, R^2 , Z and R^4 have the same meaning as defined above, and if desired, converting into a pharmaceutically acceptable salt thereof.

12. A method for preparing a piperidine compound of the 15 formula [I-b]:



wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R^2 represents hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, Z represents oxygen atom or a group represented by $-N(R^3)-$, wherein R^3 represents hydrogen atom or an 20 optionally substituted alkyl group, R^4 represents hydrogen atom or an optionally substituted alkyl group, R^4 represents hydrogen atom or an 25 optionally substituted alkyl group, R^4 represents hydrogen atom or an optionally substituted alkyl group,


R¹¹ and R¹² are the same or different and each is a hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, or R¹¹ and R¹² are taken together, with an adjacent nitrogen atom, to form a heterocyclic group selected from piperidino group, azacycloheptyl group, pyrrolidino group, imidazolidinyl group, hexahdropyrimidinyl group, thiazolidyl group, morpholino group, triazolyl group, tetrazolyl group and purinyl group, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, or a pharmaceutically acceptable salt thereof, comprising reacting a compound of the formula [IV]:



20

wherein Ring A, Ring B, R², Z, R³ and R⁴ have the same meanings as defined above,


with a compound of the formula [V]:




25

wherein R¹¹ and R¹² have the same meanings as defined above, and X¹ represents hydrogen atom, hydroxyl group, silicon atom, lithium atom or magnesium atom, and if desired, converting into a pharmaceutically acceptable salt thereof.


13. A method for preparing a piperidine compound of the formula [I-c]:



wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R¹³ represents an optionally substituted carboxyl group, R² represents hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, Z represents oxygen atom or a group represented by -N(R³)-, wherein R³ represents hydrogen atom or an optionally substituted alkyl group, R⁴ represents hydrogen atom or an optionally substituted alkyl group,
 5 or a pharmaceutically acceptable salt thereof, comprising
 reacting a compound of the formula [IV]:




wherein Ring A, Ring B, R², Z, R³ and R⁴ have the same meanings as defined above,
 20 with a compound of the formula [VI]:



Wherein X² represents a leaving group and R¹³ has the same meaning as defined above,


reducing the resulting compound of the formula [VII]:




wherein Ring A, Ring B, R^{13} , R^2 , Z, R^3 and R^4 have the same meanings as defined above,

and if desired, converting into a pharmaceutically acceptable
5 salt thereof.

14. A method for preparing a piperidine compound of the formula [I'']:




wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R^1 represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, a substituted thiol group, a substituted carbonyl group, a substituted sulfinyl group, a substituted sulfonyl group, or a group
10 represented by the formula:




wherein R^{11} and R^{12} are the same or different and each is hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group or a heterocyclic group containing 1 to 4 atom(s) selected from nitrogen atom, oxygen atom and sulfur atom as a hetero atom, wherein the heterocyclic group is optionally substituted, and the nitrogen atom
20

contained in the heterocyclic group is optionally oxidized, or R¹¹ and R¹² are taken together, with an adjacent nitrogen atom, to form a heterocyclic group selected from piperidino group, azacycloheptyl group, 5 pyrrolidino group, imidazolidinyl group, hexahdropyrimidinyl group, thiazolidyl group, morpholino group, triazolyl group, tetrazolyl group and purinyl group, wherein the heterocyclic group is optionally substituted, and the nitrogen atom contained in the heterocyclic group is optionally oxidized, 10 R² represents hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, and R⁴ represents hydrogen atom or an optionally substituted alkyl group, 15 or a pharmaceutically acceptable salt thereof, comprising reacting a compound of the formula [II]:



wherein Ring A, R¹ and R² have the same meanings as 20 defined above,

with a compound of the formula [III']:



wherein Ring B and R⁴ have the same meanings as defined above, 25 in the presence of a urea bond forming agent, and if desired, converting into a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising the compound according to any one of Claims 1 to 9, in a clinically

effective dose and a pharmaceutically acceptable carrier.

16. The compound according to any one of Claims 1 to 9 for a use as a clinically effective ingredient.

17. Use of the compound according to any one of Claims 1 to 5 9, for preparation of a medicament for treatment and prophylaxis of a disease selected from inflammation, allergic diseases, pain, migraine, neuralgia, itchiness, cough, central nervous system diseases, digestive organs disease nausea, emesis, urinary disorder, circulatory disease and 10 immune disorder.

18. A method for treating and preventing a disease selected from inflammation, allergic diseases, pain, migraine, neuralgia, itchiness, cough, central nervous system diseases, digestive organs disease nausea, emesis, urinary disorder, 15 circulatory disease and immune disorder, comprising administering the compound according to any one of Claims 1 to 9 in a clinically effective dose to a mammal.

19. The method according to Claim 18, wherein the disease is urinary disorder.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/06720

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl' C07D211/46, 211/58, 211/62, 211/54, 211/74, 401/04, 401/12, 401/14, 405/12, 409/12, 417/04, 417/12, 473/34, A61K31/451, 31/454, 31/4545, 31/4709, 31/497, 31/513,
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl' C07D211/46, 211/58, 211/62, 211/54, 211/74, 401/04, 401/12, 401/14, 405/12, 409/12, 417/04, 417/12, 473/34, A61K31/451, 31/454, 31/4545, 31/4709, 31/497, 31/513,

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

REGISTRY (STN), CAPLUS (STN), CAOLD (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5310743 A (CIBA-GEIGY CORP.) 1994.05.10 see whole document & JP 7-196649 A & EP 532456 A1 & CA 2075684 A	1,2,5,8, 15-17
Y	& AU 9220965 A1 & IL 102769 A1 & NO 9203123 A & ZA 9206013 A & HU 67088 A & CN 1089261 A	9,12
A	& US 5541195 A & US 5646144 A & FI 9604117 A & NO 9703117 A	3,4,6,7, 10,11,13,14
Y	WO 02/32867 A1 (GLAXO GROUP LIMITED) 2002.04.25 see whole document	1,2,5,8,9, 12,15-17
A	& AU 2001095723 A & EP 1326832 A1	3,4,6,7, 10,11,13,14



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

04.08.03

Date of mailing of the international search report

19.08.03

Name and mailing address of the ISA/JP

Japan Patent Office

3-4-3, Kasumigaseki, Chiyoda-ku, Tokyo 100-8915, Japan

Authorized officer

AKI NAKAKI

Telephone No. +81-3-3581-1101 Ext. 3492



4P 9282

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/06720

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97/24324 A1 (JANSSEN PHARMACEUTICA N.V.) 1997.07.10 see whole document	1,2,5,8,9, 12,15-17
A	& JP 2000-502690 A & EP 855999 B1 & AU 1308497 A & CA 2238818 A & US 6169097 B1 & US 6346540 B1 & ZA 9610885 A & NO 982404 A & IL 124640 A & PL 327441 A & CZ 9801864 A & SK 83198 A & BR 9612334 A & NZ 325843 A & HU 9904125 A	3,4,6,7, 10,11,13, 14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP03/06720

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **18, 19**
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 18 and 19 are directed to a method for treatment of the human body by therapy.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/06720

A. CLASSIFICATION OF SUBJECT MATTER (Continued)

A61K31/52,31/5377,31/541,31/55,31/4525,31/4535,31/453,31/506,A61P1/00,1/08,9/00,11/14,
13/00,17/04,25/00,25/04,25/06,29/00,37/00,37/08,43/00

B. FIELDS SEARCHED (Continued)

A61K31/52,31/5377,31/541,31/55,31/4525,31/4535,31/453,31/506,A61P1/00,1/08,9/00,11/14,
13/00,17/04,25/00,25/04,25/06,29/00,37/00,37/08,43/00